Thionucleoside derivative or salt thereof, and pharmaceutical composition

ABSTRACT

Disclosed are a compound and a pharmaceutical composition that exhibit an excellent drug efficacy against a tumor, in particular a tumor which has acquired resistance to gemcitabine. Specifically, provided is a thionucleoside derivative represented by General Formula [1] 
     
       
         
         
             
             
         
       
         
         
           
             (in the formula, R 1  represents a hydroxyl group which may be protected, a C 1-20  alkoxy group which may be substituted, or the like; R 2  represents a C 1-20  alkoxy group which may be substituted, a C 3-8  cycloalkoxy group which may be substituted, or the like; and R 3  represents a hydrogen atom or the like); or a salt thereof. Further, provided is a pharmaceutical composition containing such a thionucleoside derivative or a salt thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of PCT/JP2015/80885 filed onNov. 2, 2015 and claims priorities under 35 U.S.C. §119 of JP PatentApplication No. 2014-222527 filed on Oct. 31, 2014.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a thionucleoside derivative or a saltthereof which is useful as a tumor treatment agent and a pharmaceuticalcomposition.

2. Description of the Related Art

It has been known that 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine (hereinafter, also referred to as compound A), which is athionucleoside, has an excellent antitumor action and is useful in thetreatment of malignant tumors (for example, lung cancer, esophagealcancer, stomach cancer, colon cancer, rectal cancer, pancreatic cancer,breast cancer, renal cancer, bladder cancer, uterine cancer,osteosarcoma, and melanoma) and the like (WO1997/038001A).

On the other hand, it has been known that gemcitabine(2′,2′-difluoro-2′-deoxycytidine), which is a nucleoside, is effectiveagainst cancerous tumors such as the large intestine, lung, pancreas,breast, bladder and ovarian tumors (Cancer Research, Vol. 50, pp 4417 to4422, 1990 and Anti-Cancer Drugs, Vol. 6, pp 7 to 13, 1995). Gemcitabinehas become a standard chemotherapy of pancreatic cancer after receivingthe FDA approval in 1996 and has also recently received an approval foruse in the treatment of non-small cell lung cancer, ovarian cancer,bladder cancer, and breast cancer.

In this regard, congenital or acquired resistance to nucleosideanalogues (for example, gemcitabine, 5-fluorouracil, cytarabine, andfludarabine) is a common problem in cancer therapy and is considered asan important cause of a low patient survival rate. Like other nucleosideanalogues, gemcitabine is also faced with many problems of congenital oracquired drug resistance (Journal of Medicinal Chemistry, Vol. 57, pp1531 to 1542, 2014). It has been reported that acquisition of theresistance to gemcitabine by tumor cells results in a decreased overallsurvival time of cancer patients (Neoplasia, Vol. 12, pp 807 to 817,2010).

To overcome the resistance to gemcitabine, the development of new drugsbased on resistance mechanisms has been carried out and for example, acompound obtained by adding an amide phosphite ester to gemcitabine isknown (Journal of Medicinal Chemistry, Vol. 57, pp 1531 to 1542, 2014).

SUMMARY OF THE INVENTION

An object of the present invention is to provide a compound and apharmaceutical composition which exhibit an excellent drug efficacyagainst a tumor, in particular a tumor that has acquired resistance togemcitabine.

As a result of extensive studies, the present inventors have found thata certain derivative of compound A exhibits an excellent drug efficacyagainst a tumor, in particular a tumor which has acquired resistance togemcitabine. The present invention has been completed based on such afinding.

The present invention provides the following.

-   -   (1) A thionucleoside derivative represented by General Formula        [1]:

-   -   in the formula, R¹ represents a hydroxyl group which may be        protected, a C₁₋₂₀ alkoxy group which may be substituted, a C₃₋₈        cycloalkoxy group which may be substituted, an aryloxy group        which may be substituted, a heterocyclic oxy group which may be        substituted, or an amino group which may be substituted; R²        represents a C₁₋₂₀ alkoxy group which may be substituted, a C₃₋₈        cycloalkoxy group which may be substituted, an aryloxy group        which may be substituted, a heterocyclic oxy group which may be        substituted, or an amino group which may be substituted; or R¹        and R², together with the phosphorus atom to which they are        bonded, may form a 5- to 10-membered        nitrogen.phosphorus-containing heterocyclic ring which may be        substituted, a 5- to 10-membered oxygen.phosphorus-containing        heterocyclic ring which may be substituted, or a 5- to        10-membered nitrogen.oxygen.phosphorus-containing heterocyclic        ring; and R³ represents a hydrogen atom; or R² and R³, together        with the phosphorus atom to which R² is bonded, an oxygen atom,        methylene, two carbon atoms constituting the tetrahydrothiophene        ring and the oxygen atom to which R³ is bonded, may form a 6 to        10-membered oxygen.phosphorus-containing heterocyclic ring which        may be substituted; or a salt thereof.    -   (2) The thionucleoside derivative according to (1), in which R¹        is a hydroxyl group which may be protected, a C₁₋₆ alkoxy group        which may be substituted with one or more substituents selected        from Substituent group A, an aryloxy group which may be        substituted with one or more substituents selected from        Substituent group A, a heterocyclic oxy group which may be        substituted with one or more substituents selected from        Substituent group A, or an amino group which may be substituted        with one or more substituents selected from Substituent group A;        or the salt thereof.    -   (3) The thionucleoside derivative according to (1) or (2), in        which R² is a C₁₋₆ alkoxy group which may be substituted with        one or more substituents selected from Substituent group A, an        aryloxy group which may be substituted with one or more        substituents selected from Substituent group A, or an amino        group which may be substituted with one or more substituents        selected from Substituent group A; or the salt thereof    -   (4) The thionucleoside derivative according to any one of (1) to        (3), in which R¹ is a hydroxyl group which may be protected, a        C₁₋₆ alkoxy group which may be substituted with one or more        substituents selected from Substituent group A, an aryloxy group        which may be substituted with one or more substituents selected        from Substituent group A, a heterocyclic oxy group which may be        substituted with one or more substituents selected from        Substituent group A, or an amino group which may be substituted        with one or more substituents selected from Substituent group A;        and R² is a C₁₋₆ alkoxy group which may be substituted with one        or more substituents selected from Substituent group A, an        aryloxy group which may be substituted with one or more        substituents selected from Substituent group A, or an amino        group which may be substituted with one or more substituents        selected from Substituent group A; or the salt thereof.    -   (5) The thionucleoside derivative according to any one of (1) to        (4), in which R¹ is an aryloxy group which may be substituted        with one or more substituents selected from Substituent group A,        and R² is an amino group which may be substituted with one or        more substituents selected from Substituent group A, or    -   R¹ is a C₁₋₆ alkoxy group which may be substituted with one or        more substituents selected from Substituent group A, and R² is a        C₁₋₆ alkoxy group which may be substituted with one or more        substituents selected from Substituent group A; or the salt        thereof    -   (6) The thionucleoside derivative according to (1), in which the        thionucleoside derivative is a compound selected from:

-   (2S)-benzyl    2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate,

-   (2S)-methyl    2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)    (4-chlorophenoxy)phosphoryl)amino)propanoate,

-   (2S)-cyclobutyl    2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate,

-   (2S)-methyl    2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(4-bromophenoxy)phosphoryl)amino)propanoate,

-   (2S)-methyl    2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(4-iodophenoxy)phosphoryl)amino)propanoate,

-   ((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyl    bis(S-pivaloyl-2-mercaptoethan-1-yl) phosphate,

-   ((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyl    bis(S-isobutyryl-2-mercaptoethan-1-yl) phosphate,

-   ((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyl    bis(S-propionyl-2-mercaptoethan-1-yl) phosphate,

-   (((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(2-(pivaloylthio)ethoxy)phosphoryl)oxy)methyl    pivalate,

-   S-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(((isopropoxycarbonyl)oxy)methoxy)phosphoryl)oxy)ethyl)    2,2-dimethylpropanethioate,

-   ((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyl    bis(pivaloyloxymethyl) phosphate,

-   ((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyl    bis(2-((2-(benzyloxy)ethyl)disulfanyl)ethyl) phosphate,

-   ((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyl    bis(2-((2-pivaloyloxyethyl)disulfanyl)ethyl) phosphate,

-   ((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyl    bis(2-((2-isobutyroyloxyethyl)disulfanyl)ethyl) phosphate,

-   S-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)oxy)ethyl)    2,2-dimethylpropanethioate,

-   4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-((((RS)-2-oxido-4H-benzo[d][1,3,2]dioxaphosphinin-2-yl)oxy)methyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one,

-   (2S)-benzyl    2-(((2RS,4aR,6R,7S,7aS)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-7-fluoro-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-2-yl)amino)propanoate,    and

-   (2S)-isopropyl    2-(((2RS,4aR,6R,7S,7aS)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-7-fluoro-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-2-yl)amino)propanoate;    or the salt thereof.    -   (7) A pharmaceutical composition comprising the thionucleoside        derivative or the salt thereof according to any one of (1) to        (6).    -   (8) The pharmaceutical composition according to (7), for use in        the treatment of a tumor.    -   (9) The pharmaceutical composition according to (7), for use in        the treatment of lung cancer, esophageal cancer, stomach cancer,        colon cancer, rectal cancer, pancreatic cancer, breast cancer,        renal cancer, bladder cancer, uterine cancer, osteosarcoma,        melanoma, leukemia, multiple myeloma, or malignant lymphoma.

The present invention also provides the following.

-   -   (a) A thionucleoside derivative represented by the above defined        General Formula [1] or a salt thereof, for use as a medicine.    -   (b) A thionucleoside derivative represented by General Formula        [1] or a salt thereof, for use in the treatment of a tumor.    -   (c) A thionucleoside derivative represented by General Formula        [1] or a salt thereof, for use in the treatment of lung cancer,        esophageal cancer, stomach cancer, colon cancer, rectal cancer,        pancreatic cancer, breast cancer, renal cancer, bladder cancer,        uterine cancer, osteosarcoma, melanoma, leukemia, multiple        myeloma, or malignant lymphoma.    -   (d) A pharmaceutical composition comprising a pharmacologically        acceptable additive in conjunction with a thionucleoside        derivative represented by General Formula [1] or a salt thereof    -   (e) Use of a thionucleoside derivative represented by General        Formula [1] or a salt thereof, in the manufacture of a medicine        for use in the treatment of a tumor.    -   (f) Use of a thionucleoside derivative represented by General        Formula [1] or a salt thereof, in the manufacture of a medicine        for use in the treatment of lung cancer, esophageal cancer,        stomach cancer, colon cancer, rectal cancer, pancreatic cancer,        breast cancer, renal cancer, bladder cancer, uterine cancer,        osteosarcoma, melanoma, leukemia, multiple myeloma, or malignant        lymphoma.    -   (g) A method for the treatment of a tumor, comprising the step        of administering a therapeutically effective amount of a        thionucleoside derivative represented by General Formula [1] or        a salt thereof to a subject (a mammal including a human) in need        of such a treatment.    -   (h) A method for the treatment of lung cancer, esophageal        cancer, stomach cancer, colon cancer, rectal cancer, pancreatic        cancer, breast cancer, renal cancer, bladder cancer, uterine        cancer, osteosarcoma, melanoma, leukemia, multiple myeloma, or        malignant lymphoma, comprising the step of administering a        therapeutically effective amount of a thionucleoside derivative        represented by General Formula [1] or a salt thereof to a        subject (a mammal including a human) in need of such a        treatment.

The thionucleoside derivative or the salt thereof of the presentinvention is useful as a tumor treatment agent. The thionucleosidederivative or the salt thereof of the present invention is useful as atumor treatment agent, in particular, for a tumor which has acquiredresistance to gemcitabine.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Hereinafter, the present invention will be described in detail.

In the present invention, unless otherwise indicated, the individualterms have the following meanings.

The halogen atom refers to a fluorine atom, a chlorine atom, a bromineatom, or an iodine atom.

The C₁₋₆ alkyl group refers to a linear or branched C₁₋₆ alkyl groupsuch as a methyl group, an ethyl group, a propyl group, an isopropylgroup, a butyl group, a sec-butyl group, an isobutyl group, a tert-butylgroup, a pentyl group, an isopentyl group, a 2-methylbutyl group, a2-pentyl group, a 3-pentyl group, or a hexyl group.

The C₁₋₂₀ alkyl group refers to a linear or branched C₁₋₂₀ alkyl groupsuch as a methyl group, an ethyl group, a propyl group, an isopropylgroup, a butyl group, a sec-butyl group, an isobutyl group, a tert-butylgroup, a pentyl group, an isopentyl group, a 2-methylbutyl group, a2-pentyl group, a 3-pentyl group, a hexyl group, a 4-methylpentyl group,a 3-methylpentyl group, a 2-methylpentyl group, a 1-methylpentyl group,a 3,3-dimethylbutyl group, a 2,2-dimethylbutyl group, a1,1-dimethylbutyl group, a 1,2-dimethylbutyl group, a 1,3-dimethylbutylgroup, a 2,3-dimethylbutyl group, a 2-ethylbutyl group, a heptyl group,a 1-methylhexyl group, a 2-methylhexyl group, a 3-methylhexyl group, a4-methylhexyl group, a 5-methylhexyl group, a 1-propylbutyl group, a4,4-dimethylpentyl group, an octyl group, a 1-methylheptyl group, a2-methylheptyl group, a 3-methylheptyl group, a 4-methylheptyl group, a5-methylheptyl group, a 6-methylheptyl group, a 1-propylpentyl group, a2-ethylhexyl group, a 5,5-dimethylhexyl group, a nonyl group, a decylgroup, an undecyl group, a dodecyl group, a tridecyl group, a tetradecylgroup, a pentadecyl group, a hexadecyl group, a heptadecyl group, anoctadecyl group, a nonadecyl group, or an eicosanyl group.

The C₁₋₆ alkylsulfonyl group refers to a C₁₋₆ alkylsulfonyl group suchas a methylsulfonyl group, an ethylsulfonyl group, or a propylsulfonylgroup.

The C₁₋₆ alkylsulfonyloxy group refers to a C₁₋₆ alkylsulfonyloxy groupsuch as a methylsulfonyloxy group or an ethylsulfonyloxy group.

The C₁₋₆ alkyldisulfanyl group refers to a linear or branched C₁₋₆alkyldisulfanyl group such as a methyldisulfanyl group, anethyldisulfanyl group, a propyldisulfanyl group, an isopropyldisulfanylgroup, a butyldisulfanyl group, a sec-butyldisulfanyl group, anisobutyldisulfanyl group, a tert-butyldisulfanyl group, apentyldisulfanyl group, an isopentyldisulfanyl group, a2-methylbutyldisulfanyl group, a 2-pentyldisulfanyl group, a3-pentyldisulfanyl group, or a hexyldisulfanyl group.

The C₂₋₆ alkenyl group refers to a linear or branched C₂₋₆ alkenyl groupsuch as a vinyl group, an allyl group, a propenyl group, an isopropenylgroup, a butenyl group, an isobutenyl group, a 1,3-butadienyl group, apentenyl group, or a hexenyl group.

The C₂₋₆ alkynyl group refers to a linear or branched C₂₋₆ alkynyl groupsuch as an ethynyl group, a propynyl group, a butynyl group, a pentynylgroup, or a hexynyl group.

The C₃₋₈ cycloalkyl group refers to a C₃₋₈ cycloalkyl group such as acyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexylgroup, or a cycloheptyl group.

The C₃₋₈ cycloalkyldisulfanyl group refers to a C₃₋₈cycloalkyldisulfanyl group such as a cyclopropyldisulfanyl group, acyclobutyldisulfanyl group, cyclopentyldisulfanyl group, acyclohexyldisulfanyl group, or a cycloheptyldisulfanyl group.

The C₁₋₆ alkoxy group refers to a linear or branched C₁₋₆ alkyloxy groupsuch as a methoxy group, an ethoxy group, a propoxy group, an isopropoxygroup, a butoxy group, an isobutoxy group, a sec-butoxy group, atert-butoxy group, a pentyloxy group, or a hexyloxy group.

The C₁₋₂₀ alkoxy group refers to a linear or branched C₁₋₂₀ alkyloxygroup such as a methoxy group, an ethoxy group, a propoxy group, anisopropoxy group, a butoxy group, an isobutoxy group, a sec-butoxygroup, a tert-butoxy group, a pentyloxy group, a hexyloxy group, aheptyloxy group, an octyloxy group, a nonyloxy group, a decyloxy group,an undecyloxy group, a dodecyloxy group, a tridecyloxy group, atetradecyloxy group, a pentadecyloxy group, a hexadecyloxy group, aheptadecyloxy group, an octadecyloxy group, a nonadecyloxy group, or aneicosanyloxy.

The C₁₋₆ alkoxy C₁₋₆ alkyl group refers to a C₁₋₆ alkyloxy C₁₋₆ alkylgroup such as a methoxymethyl group or a 1-ethoxyethyl group.

The C₁₋₆ alkoxycarbonyl group refers to a linear or branched C₁₋₆alkyloxycarbonyl group such as a methoxycarbonyl group, anethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonylgroup, a butoxycarbonyl group, an isobutoxycarbonyl group, asec-butoxycarbonyl group, a tert-butoxycarbonyl group, apentyloxycarbonyl group, or a hexyloxycarbonyl group.

The C₁₋₂₀ alkoxycarbonyl group refers to a linear or branched C₁₋₂₀alkyloxycarbonyl group such as a methoxycarbonyl group, anethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonylgroup, a butoxycarbonyl group, an isobutoxycarbonyl group, asec-butoxycarbonyl group, a tert-butoxycarbonyl group, apentyloxycarbonyl group, a hexyloxycarbonyl group, a heptyloxycarbonylgroup, an octyloxycarbonyl group, a nonyloxycarbonyl group, adecyloxycarbonyl group, an undecyloxycarbonyl group, adodecyloxycarbonyl group, a tridecyloxycarbonyl group, atetradecyloxycarbonyl group, a pentadecyloxycarbonyl group, ahexadecyloxycarbonyl group, a heptadecyloxycarbonyl group, anoctadecyloxycarbonyl group, a nonadecyloxycarbonyl group, or aneicosanyloxycarbonyl group.

The C₁₋₆ alkoxycarbonyloxy group refers to a linear or branched C₁₋₆alkyloxycarbonyloxy group such as a methoxycarbonyloxy group, anethoxycarbonyloxy group, a propoxycarbonyloxy group, anisopropoxycarbonyloxy group, a butoxycarbonyloxy group, anisobutoxycarbonyloxy group, a sec-butoxycarbonyloxy group, atert-butoxycarbonyloxy group, a pentyloxycarbonyloxy group, or ahexyloxycarbonyloxy group.

The C₃₋₈ cycloalkoxy group refers to a C₃₋₈ cycloalkyloxy group such asa cyclopropoxy group, a cyclobutoxy group, a cyclopentyloxy group, acyclohexyloxy group, or a cycloheptyloxy group.

The C₃₋₈ cycloalkoxycarbonyl group refers to a C₃₋₈ cycloalkoxycarbonylgroup such as a cyclopropoxycarbonyl group, a cyclobutoxycarbonyl group,a cyclopentyloxycarbonyl group, a cyclohexyloxycarbonyl group, acycloheptyloxycarbonyl group, or a cyclooctyloxycarbonyl group.

The aryl group refers to a phenyl group or a naphthyl group.

The aryloxy group refers to a phenoxy group, a naphthalen-1-yloxy group,or a naphthalen-2-yloxy group.

The arylsulfonyl group refers to a benzenesulfonylgroup, ap-toluenesulfonyl group, or a naphthalenesulfonyl group.

The arylsulfonyloxy group refers to a benzenesulfonyloxy group or ap-toluenesulfonyloxy group.

The aryldisulfanyl group refers to a phenyldisulfanyl group or anaphthyldisulfanyl group.

The ar-C₁₋₆ alkyl group refers to an ar-C₁₋₆ alkyl group such as abenzyl group, a diphenylmethyl group, a trityl group, a phenethyl group,a 2-phenylpropyl group, a 3-phenylpropyl group, or a naphthylmethylgroup.

The ar-C₁₋₆ alkoxy group refers to an ar-C₁₋₆ alkyloxy group such as abenzyloxy group, a diphenylmethoxy group, a trityloxy group, aphenethyloxy group, a 2-phenylpropoxy group, a 3-phenylpropoxy group, ora naphthylmethoxy group.

The ar-C₁₋₆ alkoxy C₁₋₆ alkyl group refers to an ar-C₁₋₆ alkyloxy C₁₋₆alkyl group such as a benzyloxymethyl group or a phenethyloxymethylgroup.

The ar-C₁₋₆ alkoxycarbonyl group refers to an ar-C₁₋₆ alkyloxycarbonylgroup such as a benzyloxycarbonyl group or a phenethyloxycarbonyl group.

The monocyclic nitrogen-containing heterocyclic group refers to amonocyclic nitrogen-containing heterocyclic group which contains only anitrogen atom as a heteroatom forming the following ring, such as anaziridinyl group, an azetidinyl group, a pyrrolidinyl group, apyrrolinyl group, a pyrrolyl group, a piperidyl group, atetrahydropyridyl group, a dihydropyridyl group, a pyridyl group, ahomopiperidinyl group, an octahydroazocinyl group, an imidazolidinylgroup, an imidazolinyl group, an imidazolyl group, a pyrazolidinylgroup, a pyrazolinyl group, a pyrazolyl group, a piperazinyl group, apyrazinyl group, a pyridazinyl group, a pyrimidinyl group, ahomopiperazinyl group, a triazolyl group, or a tetrazolyl group.

The monocyclic oxygen-containing heterocyclic group refers to amonocyclic oxygen-containing heterocyclic group which contains only anoxygen atom as a heteroatom forming the following ring, such as anoxetanyl group, a tetrahydrofuranyl group, a furanyl group, atetrahydropyranyl group, a pyranyl group, a 1,3-dioxanyl group, or a1,4-dioxanyl group.

The monocyclic sulfur-containing heterocyclic group refers to a thienylgroup.

The monocyclic nitrogen.oxygen-containing heterocyclic group refers to amonocyclic nitrogen.oxygen-containing heterocyclic group which containsonly a nitrogen atom and an oxygen atom as heteroatoms forming thefollowing ring, such as an oxazolyl group, an isoxazolyl group, anoxadiazolyl group, a morpholinyl group, or an oxazepanyl group.

The monocyclic nitrogen.sulfur-containing heterocyclic group refers to amonocyclic nitrogen.sulfur-containing heterocyclic group which containsonly a nitrogen atom and a sulfur atom as heteroatoms forming thefollowing ring, such as a thiazolyl group, an isothiazolyl group, athiadiazolyl group, a thiomorpholinyl group, a 1-oxidothiomorpholinylgroup, or a 1,1-dioxidothiomorpholinyl group.

The monocyclic heterocyclic group refers to a monocyclicnitrogen-containing heterocyclic group, a monocyclic oxygen-containingheterocyclic group, a monocyclic sulfur-containing heterocyclic group, amonocyclic nitrogen.oxygen-containing heterocyclic group, or amonocyclic nitrogen.sulfur-containing heterocyclic group.

The bicyclic nitrogen-containing heterocyclic group refers to a bicyclicnitrogen-containing heterocyclic group which contains only a nitrogenatom as a heteroatom forming the following ring, such as an indolinylgroup, an indolyl group, an isoindolinyl group, an isoindolyl group, abenzimidazolyl group, an indazolyl group, a benzotriazolyl group, apyrazolopyridinyl group, a quinolyl group, a tetrahydroquinolinyl group,a quinolyl group, a tetrahydroisoquinolinyl group, an isoquinolinylgroup, a quinolizinyl group, a cinnolinyl group, a phthalazinyl group, aquinazolinyl group, a dihydroquinoxalinyl group, a quinoxalinyl group, anaphthyridinyl group, a purinyl group, a pteridinyl group, or aquinuclidinyl group.

The bicyclic oxygen-containing heterocyclic group refers to a bicyclicoxygen-containing heterocyclic group which contains only an oxygen atomas a heteroatom forming the following ring, such as a2,3-dihydrobenzofuranyl group, a benzofuranyl group, an isobenzofuranylgroup, a chromanyl group, a chromenyl group, an isochromanyl group, a1,3-benzodioxolyl group, a 1,3-benzodioxanyl group, or a1,4-benzodioxanyl group.

The bicyclic sulfur-containing heterocyclic group refers to a bicyclicsulfur-containing heterocyclic group which contains only a sulfur atomas a heteroatom forming the following ring, such as a2,3-dihydrobenzothienyl group or a benzothienyl group.

The bicyclic nitrogen.oxygen-containing heterocyclic group refers to abicyclic nitrogen.oxygen-containing heterocyclic group which containsonly a nitrogen atom and an oxygen atom as heteroatoms forming thefollowing ring, such as a benzoxazolyl group, a benzisoxazolyl group, abenzoxadiazolyl group, a benzomorpholinyl group, a dihydropyranopyridylgroup, a dioxolopyridyl group, a furopyridinyl group, adihydrodioxynopyridyl group, or a dihydropyridooxazinyl group.

The bicyclic nitrogen.sulfur-containing heterocyclic group refers to abicyclic nitrogen.sulfur-containing heterocyclic group which contains anitrogen atom and a sulfur atom as heteroatoms forming the followingring, such as a benzothiazolyl group, a benzoisothiazolyl group, or abenzothiadiazolyl group.

The bicyclic heterocyclic group refers to a bicyclic nitrogen-containingheterocyclic group, a bicyclic oxygen-containing heterocyclic group, abicyclic sulfur-containing heterocyclic group, a bicyclicnitrogen.oxygen-containing heterocyclic group, or a bicyclicnitrogen.sulfur-containing heterocyclic group.

The spiro heterocyclic group refers to a Spiro heterocyclic group whichcontains a nitrogen atom, an oxygen atom, or a sulfur atom as aheteroatom forming the following ring, such as a2-oxa-6-azaspiro[3.3]heptyl group, a 1,4-dioxaspiro[4.5]decyl group, a1-oxa-8-azaspiro[4.5]decyl group, or a 1-thia-8-azaspiro[4.5]decylgroup.

The bridged heterocyclic group refers to a bridged heterocyclic groupwhich contains a nitrogen atom, an oxygen atom, or a sulfur atom as aheteroatom forming the following ring, such as a3-oxa-8-azabicyclo[3.2.1]octyl group, an 8-oxa-3-azabicyclo[3.2.1]octylgroup, or a quinuclidinyl group.

The heterocyclic group refers to a monocyclic heterocyclic group, abicyclic heterocyclic group, a spiro heterocyclic group, or a bridgedheterocyclic group.

The heterocyclic oxy group refers to a substituent in which an oxygenatom is bonded to a heterocyclic group such as pyrrolidinyloxy,piperidinyloxy, tetrahydrofuranyloxy, tetrahydropyranyloxy, ortetrahydrothiopyranyloxy.

The 5- to 10-membered nitrogen.phosphorus-containing heterocyclic ringrefers to a 5- to 10-membered nitrogen.phosphorus-containingheterocyclic ring which contains only a nitrogen atom and a phosphorusatom as heteroatoms forming the following ring, such as1,3,2-diazaphospholidine, 1,3,2-diazaphosphinane,1,3,2-diazaphosphepane, or 1,3,2-diazaphosphocane and which may befused.

The 5- to 10-membered oxygen.phosphorus-containing heterocyclic ringrefers to a 5- to 10-membered oxygen.phosphorus-containing heterocyclicring which contains only an oxygen atom and a phosphorus atom asheteroatoms forming the following ring, such as 1,3,2-dioxaphospholane,1,3,2-dioxaphosphinane, 1,3,2-dioxaphosphepane, 1,3,2-dioxaphosphocane,benzo[d][1,3,2]dioxaphosphor, or 4H-benzo[d][1,3,2]dioxaphosphinine andwhich may be fused.

The 5- to 10-membered nitrogen.oxygen.phosphorus-containing heterocyclicring refers to a 5- to 10-membered nitrogen.oxygen.phosphorus-containingheterocyclic ring which contains only a nitrogen atom, an oxygen atom,and a phosphorus atom as heteroatoms forming the following ring, such as1,3,2-oxazaphospholidine, 2,3-dihydrobenzo[d][1,3,2]oxazaphosphor,1,3,2-oxazaphosphinane, or3,4-dihydro-4H-benzo[e][1,3,2]oxazaphosphinine and which may be fused.

The 6 to 10-membered oxygen.phosphorus-containing heterocyclic ringrefers to a 6 to 10-membered oxygen.phosphorus-containing heterocyclicring which contains only an oxygen atom and a phosphorus atom asheteroatoms forming the following ring, such as 1,3,2-dioxaphosphinane,1,3,2-dioxaphosphepane, or 1,3,2-dioxaphosphocane and which may befused.

The C₂₋₆ alkanoyl group refers to a linear or branched C₂₋₆ alkanoylgroup such as an acetyl group, a propionyl group, a valeryl group, anisovaleryl group, or a pivaloyl group.

The C₃₋₈ cycloalkylcarbonyl group refers to a C₃₋₈ cycloalkylcarbonylgroup such as a cyclopropylcarbonyl group, a cyclobutylcarbonyl group, acyclopentylcarbonyl group, a cyclohexylcarbonyl group, or acycloheptylcarbonyl group.

The aroyl group refers to a benzoyl group, a naphthoyl group, or thelike.

The heterocyclic carbonyl group refers to a heterocyclic carbonyl groupsuch as pyrrolylcarbonyl, pyridylcarbonyl, furanylcarbonyl, orthienylcarbonyl.

The acyl group refers to a formyl group, a succinyl group, a glutarylgroup, a maleoyl group, a phthaloyl group, a C₂₋₆ alkanoyl group, a C₃₋₈cycloalkylcarbonyl group, an aroyl group, or a heterocyclic carbonylgroup.

The C₂₋₆ alkanoyloxy group refers to a linear or branched C₂₋₆alkanoyloxy group such as an acetyloxy group, a propionyloxy group, avaleryloxy group, an isovaleryloxy group, or a pivaloyloxy group.

The C₃₋₈ cycloalkylcarbonyloxy group refers to a C₃₋₈cycloalkylcarbonyloxy group such as a cyclopropylcarbonyloxy group, acyclobutylcarbonyloxy group, a cyclopentylcarbonyloxy group, acyclohexylcarbonyloxy group, or a cycloheptylcarbonyloxy group.

The aroyloxy group refers to a benzoyloxy group, a naphthoyloxy group,or the like.

The heterocyclic carbonyloxy group refers to a heterocyclic carbonyloxygroup such as pyrrolylcarbonyloxy, pyridylcarbonyloxy,furanylcarbonyloxy, or thienylcarbonyloxy.

The acyloxy group refers to a C₂₋₆ alkanoyloxy group, a C₃₋₈cycloalkylcarbonyloxy group, an aroyloxy group, or a heterocycliccarbonyloxy group.

The C₂₋₆ alkanoylthio group refers to a linear or branched C₂₋₆alkanoylthio group such as an acetylthio group, a propionylthio group, avalerylthio group, an isovalerylthio group, or a pivaloylthio group.

The C₃₋₈ cycloalkylcarbonylthio group refers to a C₃₋₈cycloalkylcarbonylthio group such as a cyclopropylcarbonylthio group, acyclobutylcarbonylthio group, a cyclopentylcarbonylthio group, acyclohexylcarbonylthio group, or a cycloheptylcarbonylthio group.

The aroylthio group refers to a benzoylthio group, a naphthoylthiogroup, or the like.

The heterocyclic carbonylthio group refers to a heterocycliccarbonylthio group such as pyrrolylcarbonylthio, pyridylcarbonylthio,furanylcarbonylthio, or thienylcarbonylthio.

The acylthio group refers to a C₂₋₆ alkanoylthio group, a C₃₋₈cycloalkylcarbonylthio group, an aroylthio group, or a heterocycliccarbonylthio group.

The silyl group refers to trimethylsilyl, triethylsilyl, a tributylsilylgroup, or tert-butylmethylsilyl.

The leaving group refers to a halogen atom, a C₁₋₆ alkylsulfonyloxygroup, an aryloxy group, or an arylsulfonyloxy group. The C₁₋₆alkylsulfonyloxy group, aryloxy group, and arylsulfonyloxy group may besubstituted with one or more substituents selected from a halogen atom,a nitro group, a C₁₋₆ alkyl group, and a C₁₋₆ alkoxy group.

The hydroxyl protecting group is any conventional group which can beused as a protecting group for a hydroxyl group, and examples thereofinclude the groups described in, for example, T. W. Greene et al.,Protective Groups in Organic Synthesis 4th edition, pp. 16 to 299, 2007,John Wiley & Sons, Inc. Specific examples of the hydroxyl protectinggroup include a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, an ar-C₁₋₆ alkylgroup, a C₁₋₆ alkoxy C₁₋₆ alkyl group, an ar-C₁₋₆ alkoxy C₁₋₆ alkylgroup, an acyl group, a C₁₋₆ alkoxycarbonyl group, an ar-C₁₋₆alkoxycarbonyl group, a C₁₋₆ alkylsulfonyl group, an arylsulfonyl group,a silyl group, a tetrahydrofuranyl group, and a tetrahydropyranyl group.

Aliphatic hydrocarbons refer to pentane, hexane, heptane, cyclohexane,methylcyclohexane, and ethylcyclohexane.

Halogenated hydrocarbons refer to dichloromethane, chloroform, anddichloroethane.

Ethers refer to diethyl ether, diisopropyl ether, dioxane,tetrahydrofuran, anisole, ethylene glycol dimethyl ether, diethyleneglycol dimethyl ether, and diethylene glycol diethyl ether.

Ketones refer to acetone, 2-butanone, 4-methyl-2-pentanone, and methylisobutyl ketone.

Esters refer to methyl acetate, ethyl acetate, propyl acetate, and butylacetate.

Amides refer to N,N-dimethylformamide, N,N-dimethylacetamide, andN-methylpyrrolidone.

Nitriles refer to acetonitrile and propionitrile.

Sulfoxides refer to dimethyl sulfoxide and sulfolane.

Aromatic hydrocarbons refer to benzene, toluene, and xylene.

The inorganic base refers to sodium hydroxide, potassium hydroxide,sodium methoxide, sodium ethoxide, tert-butoxy sodium, tert-butoxypotassium, sodium hydrogen carbonate, sodium carbonate, potassiumcarbonate, tripotassium phosphate, potassium acetate, cesium fluoride,cesium carbonate, or tert-butyl magnesium chloride.

The organic base refers to triethylamine, N,N-diisopropylethylamine,1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), pyridine,4-dimethylaminopyridine, N-methylmorpholine, or imidazole.

Individual substituent groups have the following meanings.

<Substituent group A> a halogen atom; a hydroxyl group which may beprotected; a cyano group; a nitro group; a carbamoyl group; an oxogroup; a C₁₋₆ alkyl group which may be substituted with one or moresubstituents selected from Substituent group B; a C₁₋₆ alkyldisulfanylgroup which may be substituted with one or more substituents selectedfrom Substituent group B; a C₂₋₆ alkenyl group which may be substitutedwith one or more substituents selected from Substituent group B; a C₂₋₆alkynyl group which may be substituted with one or more substituentsselected from Substituent group B; a C₃₋₈ cycloalkyl group which may besubstituted with one or more substituents selected from Substituentgroup B; a C₃₋₈ cycloalkyldisulfanyl group which may be substituted withone or more substituents selected from Substituent group B; a C₁₋₆alkoxy group which may be substituted with one or more substituentsselected from Substituent group B; a C₁₋₆ alkoxycarbonyloxy group whichmay be substituted with one or more substituents selected fromSubstituent group B; a C₃₋₈ cycloalkoxycarbonyl group which may besubstituted with one or more substituents selected from Substituentgroup B; an aryl group which may be substituted with one or moresubstituents selected from Substituent group B; an aryldisulfanyl groupwhich may be substituted with one or more substituents selected fromSubstituent group B; a heterocyclic group which may be substituted withone or more substituents selected from Substituent group B; aheterocyclic oxy group which may be substituted with one or moresubstituents selected from Substituent group B; an acyloxy group whichmay be substituted with one or more substituents selected fromSubstituent group B; an acylthio group which may be substituted with oneor more substituents selected from Substituent group B; anaminocarbonyloxy group which may be substituted with one or moresubstituents selected from Substituent group B; and an aminocarbonylthiogroup which may be substituted with one or more substituents selectedfrom Substituent group B.

<Substituent group B> a halogen atom; a hydroxyl group; a cyano group; anitro group; a carboxyl group; a carbamoyl group; a hydroxymethyl group;a C₁₋₆ alkyl group; a C₂₋₆ alkenyl group; a C₂₋₆ alkynyl group; a C₃₋₈cycloalkyl group; a C₁₋₆ alkoxy group; a C₁₋₆ alkoxycarbonyl group; aC₃₋₈ cycloalkoxycarbonyl group; an ar-C₁₋₆ alkoxycarbonyl group; an arylgroup; an aryloxy group; a heterocyclic oxy group which may besubstituted with one or more substituents selected from a hydroxyl groupand a hydroxymethyl group; an ar-C₁₋₆ alkoxy group; and an acyloxygroup.

Examples of salts of the thionucleoside derivative represented byGeneral Formula [1] include salts in basic groups such as an aminogroup, and salts in acidic groups such as a hydroxyl group and acarboxyl group, which are commonly known.

Examples of salts in basic groups include salts with mineral acids suchas hydrochloric acid, hydrobromic acid, nitric acid, and sulfuric acid;salts with organic carboxylic acids such as formic acid, acetic acid,citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid,malic acid, tartaric acid, aspartic acid, trichloroacetic acid, andtrifluoroacetic acid; and salts with sulfonic acids such asmethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid,mesitylene sulfonic acid, and naphthalene sulfonic acid.

Examples of salts in acidic groups include salts with alkali metals suchas sodium and potassium; salts with alkaline earth metals such ascalcium and magnesium; ammonium salts; and salts withnitrogen-containing organic bases such as trimethylamine, triethylamine,tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine,N-methylmorpholine, diethylamine, dicyclohexylamine, procaine,dibenzylamine, N-benzyl-β-phenethylamine, 1-ephenamine, andN,N′-dibenzylethylenediamine.

Among the salts mentioned above, preferred salts includepharmacologically acceptable salts.

The preventing refers to inhibition of disease onset, reduction ofdisease onset risk, delay of disease onset, or the like.

The treating refers to improvement of, inhibition of progression of, orthe like of a target disease or condition.

The treatment refers to preventing, treating, or the like of a varietyof diseases.

The treatment agent refers to a substance which is provided for thepurpose of preventing or treating a variety of diseases.

The benign tumor refers to a tumor in which a tumor cell and a sequencethereof take a form close to a normal cell from which the tumor cell andthe sequence thereof are derived, and which is free of invasiveness ormetastatic properties.

The malignant tumor refers to a tumor in which the morphology andsequence of a tumor cell are different from a normal cell from whichsuch a tumor cell is derived, and which exhibits invasiveness ormetastatic properties.

The tumor refers to a benign tumor or a malignant tumor.

The thionucleoside derivative or the salt thereof of the presentinvention can be used in the treatment of a tumor.

The thionucleoside derivative or the salt thereof of the presentinvention is preferably used in the treatment of, for example, lungcancer, esophageal cancer, stomach cancer, colon cancer, rectal cancer,pancreatic cancer, breast cancer, renal cancer, bladder cancer, uterinecancer, osteosarcoma, melanoma, leukemia, multiple myeloma, or malignantlymphoma.

In another embodiment, the thionucleoside derivative or the salt thereofof the present invention is preferably used in the treatment of a tumorwhich has acquired resistance to gemcitabine.

The thionucleoside derivative of the present invention is represented byGeneral Formula [1]

(in the formula, R¹, R², and R³ have the same meanings as above).

R¹

R¹ is a hydroxyl group which may be protected, a C₁₋₂₀ alkoxy groupwhich may be substituted, a C₃₋₈ cycloalkoxy group which may besubstituted, an aryloxy group which may be substituted, a heterocyclicoxy group which may be substituted, or an amino group which may besubstituted.

R¹ is preferably a hydroxyl group which may be protected, a C₁₋₆ alkoxygroup which may be substituted with one or more substituents selectedfrom Substituent group A, an aryloxy group which may be substituted withone or more substituents selected from Substituent group A, aheterocyclic oxy group which may be substituted with one or moresubstituents selected from Substituent group A, or an amino group whichmay be substituted with one or more substituents selected fromSubstituent group A, more preferably a C₁₋₆ alkoxy group which may besubstituted with one or more substituents selected from Substituentgroup A, an aryloxy group which may be substituted with one or moresubstituents selected from Substituent group A, or an amino group whichmay be substituted with one or more substituents selected fromSubstituent group A, and still more preferably a C₁₋₆ alkoxy group whichmay be substituted with one or more substituents selected fromSubstituent group A or an aryloxy group which may be substituted withone or more substituents selected from Substituent group A.

The substituent of the C₁₋₆ alkoxy group which may be substituted withone or more substituents selected from Substituent group A in thedefinition of R¹ is preferably a C₁₋₆ alkyldisulfanyl group which may besubstituted with one or more substituents selected from Substituentgroup B, a C₁₋₆ alkoxycarbonyloxy group which may be substituted withone or more substituents selected from Substituent group B, an acyloxygroup which may be substituted with one or more substituents selectedfrom Substituent group B, or an acylthio group which may be substitutedwith one or more substituents selected from Substituent group B, andmore preferably a C₁₋₆ alkyldisulfanyl group which may be substitutedwith one or more substituents selected from Substituent group B, a C₁₋₆alkoxycarbonyloxy group which may be substituted with one or moresubstituents selected from Substituent group B, a C₂₋₆ alkanoyloxy groupwhich may be substituted with one or more substituents selected fromSubstituent group B, or a C₂₋₆ alkanoylthio group which may besubstituted with one or more substituents selected from Substituentgroup B.

Here, the substituent of the C₁₋₆ alkyldisulfanyl group which may besubstituted with one or more substituents selected from Substituentgroup B is preferably a hydroxyl group, a C₁₋₆ alkoxy group, an ar-C₁₋₆alkoxy group, or an acyloxy group and more preferably a hydroxyl group,a C₁₋₆ alkoxy group, an ar-C₁₋₆ alkoxy group, or a C₂₋₆ alkanoyloxygroup.

The substituent of the aryloxy group which may be substituted with oneor more substituents selected from Substituent group A in the definitionof R¹ is preferably a halogen atom or a C₁₋₆ alkoxy group which may besubstituted with one or more substituents selected from Substituentgroup B.

The substituent of the amino group which may be substituted with one ormore substituents selected from Substituent group A in the definition ofR¹ is preferably a C₁₋₆ alkyl group which may be substituted with one ormore substituents selected from Substituent group B.

Here, the substituent of the C₁₋₆ alkyl group which may be substitutedwith one or more substituents selected from Substituent group B ispreferably a C₁₋₆ alkoxycarbonyl group, an aryl group, or an ar-C₁₋₆alkoxycarbonyl group.

R²

R² is a C₁₋₂₀ alkoxy group which may be substituted, a C₃₋₈ cycloalkoxygroup which may be substituted, an aryloxy group which may besubstituted, a heterocyclic oxy group which may be substituted, or anamino group which may be substituted.

R² is preferably a C₁₋₆ alkoxy group which may be substituted with oneor more substituents selected from Substituent group A, an aryloxy groupwhich may be substituted with one or more substituents selected fromSubstituent group A, or an amino group which may be substituted with oneor more substituents selected from Substituent group A and morepreferably a C₁₋₆ alkoxy group which may be substituted with one or moresubstituents selected from Substituent group A or an amino group whichmay be substituted with one or more substituents selected fromSubstituent group A.

The substituent of the C₁₋₆ alkoxy group which may be substituted withone or more substituents selected from Substituent group A in thedefinition of R² is preferably a C₁₋₆ alkyldisulfanyl group which may besubstituted with one or more substituents selected from Substituentgroup B, a C₁₋₆ alkoxycarbonyloxy group which may be substituted withone or more substituents selected from Substituent group B, aheterocyclic oxy group which may be substituted with one or moresubstituents selected from Substituent group B, an acyloxy group whichmay be substituted with one or more substituents selected fromSubstituent group B, an acylthio group which may be substituted with oneor more substituents selected from Substituent group B, anaminocarbonyloxy group which may be substituted with one or moresubstituents selected from Substituent group B, or an aminocarbonylthiogroup which may be substituted with one or more substituents selectedfrom Substituent group B, more preferably a C₁₋₆ alkyldisulfanyl groupwhich may be substituted with one or more substituents selected fromSubstituent group B, a C₁₋₆ alkoxycarbonyloxy group which may besubstituted with one or more substituents selected from Substituentgroup B, an acyloxy group which may be substituted with one or moresubstituents selected from Substituent group B, or an acylthio groupwhich may be substituted with one or more substituents selected fromSubstituent group B, and still more preferably a C₁₋₆ alkyldisulfanylgroup which may be substituted with one or more substituents selectedfrom Substituent group B, a C₁₋₆ alkoxycarbonyloxy group which may besubstituted with one or more substituents selected from Substituentgroup B, a C₂₋₆ alkanoyloxy group which may be substituted with one ormore substituents selected from Substituent group B, or a C₂₋₆alkanoylthio group which may be substituted with one or moresubstituents selected from Substituent group B.

Here, the substituent of the C₁₋₆ alkyldisulfanyl group which may besubstituted with one or more substituents selected from Substituentgroup B is preferably a hydroxyl group, an ar-C₁₋₆ alkoxy group, or anacyloxy group and more preferably a hydroxyl group, an ar-C₁₋₆ alkoxygroup, or a C₁₋₆ alkanoyloxy group.

The substituent of the heterocyclic oxy group which may be substitutedwith one or more substituents selected from Substituent group B ispreferably a hydroxyl group or a hydroxymethyl group.

The substituent of the amino group which may be substituted with one ormore substituents selected from Substituent group A in the definition ofR² is preferably a C₁₋₆ alkyl group which may be substituted with one ormore substituents selected from Substituent group B or a heterocyclicgroup which may be substituted with one or more substituents selectedfrom Substituent group B.

Here, the substituent of the C₁₋₆ alkyl group which may be substitutedwith one or more substituents selected from Substituent group B ispreferably a carboxyl group, a C₁₋₆ alkoxycarbonyl group, a C₃₋₈cycloalkoxycarbonyl group, an aryl group, or an ar-C₁₋₆ alkoxycarbonylgroup.

R¹ and R², together with the phosphorus atom to which they are bonded,may form a 5- to 10-membered nitrogen.phosphorus-containing heterocyclicring which may be substituted, a 5- to 10-memberedoxygen.phosphorus-containing heterocyclic ring which may be substituted,or a 5- to 10-membered nitrogen.oxygen.phosphorus-containingheterocyclic ring which may be substituted.

The ring formed by R¹ and R² together with the phosphorus atom to whichthey are bonded is preferably a 5- to 10-memberedoxygen.phosphorus-containing heterocyclic ring which may be substitutedand more preferably 1,3,2-dioxaphosphinane or4H-benzo[d][1,3,2]dioxaphosphinine.

The substituent of the 5- to 10-membered nitrogen.phosphorus-containingheterocyclic ring which may be substituted, the 5- to 10-memberedoxygen.phosphorus-containing heterocyclic ring which may be substituted,or the 5- to 10-membered nitrogen.oxygen.phosphorus-containingheterocyclic ring which may be substituted, each of which being formedby R¹ and R² together with the phosphorus atom to which they are bonded,is preferably a C₁₋₆ alkoxy group which may be substituted with one ormore substituents selected from Substituent group A or an aryl groupwhich may be substituted with one or more substituents selected fromSubstituent group A.

Here, the substituent of the aryl group which may be substituted withone or more substituents selected from Substituent group A is preferablya halogen atom.

R³

R³ is a hydrogen atom.

R² and R³, together with the phosphorus atom to which R² is bonded, anoxygen atom, methylene, two carbon atoms constituting thetetrahydrothiophene ring and the oxygen atom to which R³ is bonded, mayform a 6 to 10-membered oxygen.phosphorus-containing heterocyclic ringwhich may be substituted.

The ring formed by R² and R³ together with the phosphorus atom to whichR² is bonded, an oxygen atom, methylene, two carbon atoms constitutingthe tetrahydrothiophene ring and the oxygen atom to which R³ is bondedis preferably 1,3,2-dioxaphosphinane.

The compound represented by General Formula [1] is preferably a compoundin which R¹ is a hydroxyl group which may be protected, a C₁₋₂₀ alkoxygroup which may be substituted, a C₃₋₈ cycloalkoxy group which may besubstituted, an aryloxy group which may be substituted, a heterocyclicoxy group which may be substituted, or an amino group which may besubstituted; R² is a C₁₋₂₀ alkoxy group which may be substituted, a C₃₋₈cycloalkoxy group which may be substituted, an aryloxy group which maybe substituted, a heterocyclic oxy group which may be substituted, or anamino group which may be substituted; and R³ is a hydrogen atom, andmore preferably a compound in which R¹ is a hydroxyl group which may beprotected, a C₁₋₆ alkoxy group which may be substituted with one or moresubstituents selected from Substituent group A, an aryloxy group whichmay be substituted with one or more substituents selected fromSubstituent group A, a heterocyclic oxy group which may be substitutedwith one or more substituents selected from Substituent group A, or anamino group which may be substituted with one or more substituentsselected from Substituent group A; R² is a C₁₋₆ alkoxy group which maybe substituted with one or more substituents selected from Substituentgroup A, an aryloxy group which may be substituted with one or moresubstituents selected from Substituent group A, or an amino group whichmay be substituted with one or more substituents selected fromSubstituent group A; and R³ is a hydrogen atom.

In the case where isomers (for example, a tautomer, an optical isomer,and a geometric isomer) are present for the thionucleoside derivativerepresented by General Formula [1] or the salt thereof, the presentinvention also encompasses those isomers and further encompassessolvates, hydrates, and various forms of crystals.

Next, the production method of the compound of the present inventionwill be described.

The compound of the present invention is produced by combining per seknown methods, and for example, can be produced according to thefollowing production methods.

[Production Method A]

(in the formulae, R^(a) represents a silyl group which may besubstituted; R^(b) represents a C₁₋₂₀ alkoxycarbonyl group which may besubstituted or a C_(m) cycloalkoxycarbonyl group which may besubstituted; and X¹ represents a leaving group).

First Step

As the compound of General Formula [S1], for example,tert-butyldiphenylchlorosilane is known.

The compound of General Formula [A2] can be produced by reacting thecompound of Formula [A1] with the compound of General Formula [S1] inthe presence of a base.

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction, and examples thereof include aliphatichydrocarbons, halogenated hydrocarbons, ethers, ketones, esters, amides,nitriles, sulfoxides, and aromatic hydrocarbons. These solvents may beused as a mixture thereof.

Examples of the preferred solvent include amides. More preferred isN,N-dimethylformamide.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of Formula[A1].

The amount of the compound of General Formula [S1] to be used may be 1to 5-fold molar excess and preferably 1 to 2-fold molar excess withrespect to the compound of Formula [A1].

The base used in this reaction may be, for example, an inorganic base oran organic base and is preferably an organic base and more preferablyimidazole.

The amount of the base to be used may be 1 to 10-fold molar excess andpreferably 1 to 5-fold molar excess with respect to the compound ofFormula [A1].

This reaction may be carried out at 0° C. to 100° C., preferably 10° C.to 50° C. for 30 minutes to 48 hours.

Second Step

As the compound of General Formula [S2], for example,di-tert-butyldicarbonate is known.

The compound of General Formula [A3] can be produced by reacting thecompound of General Formula [A2] with the compound of General Formula[S2] in the presence of a base.

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction, and examples thereof include aliphatichydrocarbons, halogenated hydrocarbons, ethers, ketones, esters, amides,nitriles, sulfoxides, and aromatic hydrocarbons. These solvents may beused as a mixture thereof.

Examples of the preferred solvent include halogenated hydrocarbons. Morepreferred is methylene chloride.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of GeneralFormula [A2].

The amount of the compound of General Formula [S2] to be used may be 3to 10-fold molar excess and preferably 3 to 6-fold molar excess withrespect to the compound of General Formula [A2].

The base used in this reaction may be, for example, an inorganic base oran organic base and is preferably an organic base and more preferablypyridine, triethylamine, or diisopropylethylamine. These bases may beused as a mixture thereof.

The amount of the base to be used may be 3 to 20-fold molar excess andpreferably 3 to 10-fold molar excess with respect to the compound ofGeneral Formula [A2]. In addition, the base may be used as a solvent.

It is preferred to add a reaction accelerator to this reaction.

The reaction accelerator may be, for example, 4-dimethylaminopyridine.

The amount of the reaction accelerator to be used may be 0.01 to 1-foldmolar excess with respect to the compound of General Formula [A2].

This reaction may be carried out at 0° C. to 100° C., preferably 10° C.to 50° C. for 30 minutes to 48 hours.

Third Step

The compound of General Formula [A4] can be produced by deprotecting thecompound of General Formula [A3].

This reaction may be carried out in accordance with the method describedin, for example, T. W. Greene et al., Protective Groups in OrganicSynthesis, 4th edition, pp. 16 to 366, 2007, John Wiley & Sons, Inc.

[Production Method B]

(in the formulae, R^(c) represents an acyl group which may besubstituted, a C₁₋₂₀ alkoxycarbonyl group which may be substituted, or aC₃₋₈ cycloalkoxycarbonyl group which may be substituted; X² represents aleaving group; and R^(a) has the same meaning as above).

First Step

As the compound of General Formula [S3], for example, benzoyl chlorideis known.

The compound of General Formula [A5] can be produced by reacting thecompound of General Formula [A2] with the compound of General Formula[S3] in the presence of a base.

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction and examples thereof include aliphatichydrocarbons, halogenated hydrocarbons, ethers, ketones, esters, amides,nitriles, sulfoxides, and aromatic hydrocarbons. These solvents may beused as a mixture thereof.

Examples of the preferred solvent include halogenated hydrocarbons,ethers, and amides. More preferred are methylene chloride,tetrahydrofuran, and N,N-dimethylformamide.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of GeneralFormula [A2].

The amount of the compound of General Formula [S3] to be used may be 2to 20-fold molar excess and preferably 2 to 5-fold molar excess withrespect to the compound of General Formula [A2].

The base used in this reaction may be, for example, an inorganic base oran organic base and is preferably an organic base and more preferablypyridine, triethylamine, or diisopropylethylamine. These bases may beused as a mixture thereof.

The amount of the base to be used may be 2 to 20-fold molar excess andpreferably 2 to 10-fold molar excess with respect to the compound ofGeneral Formula [A2]. In addition, the base may be used as a solvent.

If necessary, a reaction accelerator may be added to this reaction.

The reaction accelerator may be, for example, 4-dimethylaminopyridine.

The amount of the reaction accelerator to be used may be 0.01 to 1-foldmolar excess with respect to the compound of General Formula [A2].

This reaction may be carried out at 0° C. to 100° C., preferably 0° C.to 40° C. for 30 minutes to 48 hours.

Second Step

The compound of General Formula [A6] can be produced by deprotecting thecompound of General Formula [A5].

This reaction may be carried out in accordance with the third step ofproduction method A.

[Production Method C]

(in the formulae, R^(b), R^(c), and X² have the same meanings as above).

First Step

As the compound of General Formula [S2], for example,di-tert-butyldicarbonate is known.

The compound of General Formula [A7] can be produced by reacting thecompound of Formula [A1] with the compound of General Formula [S2] inthe presence of a base.

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction and examples thereof include ethers andwater. These solvents may be used as a mixture thereof.

Examples of the preferred solvent include tetrahydrofuran, 1,4-dioxane,and water. More preferred are a mixed solvent of tetrahydrofuran andwater and a mixed solvent of 1,4-dioxane and water.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of GeneralFormula [A1].

The amount of the compound of General Formula [S2] to be used may be 2to 20-fold molar excess and preferably 2 to 10-fold molar excess withrespect to the compound of General Formula [A1].

The base used in this reaction may be, for example, an inorganic base oran organic base and is preferably an inorganic base and more preferablysodium hydroxide or potassium hydroxide. These bases may be used as amixture thereof.

The amount of the base to be used may be 2 to 30-fold molar excess andpreferably 2 to 15-fold molar excess with respect to the compound ofGeneral Formula [A1]. In addition, the base may be used as a solvent.

If necessary, a reaction accelerator may be added to this reaction.

The reaction accelerator may be, for example, 4-dimethylaminopyridine.

The amount of the reaction accelerator to be used may be 0.01 to 1-foldmolar excess with respect to the compound of General Formula [A1].

This reaction may be carried out at 0° C. to 100° C., preferably 0° C.to 40° C. for 30 minutes to 48 hours.

Second Step

The compound of General Formula [A8] can be produced by reacting thecompound of General Formula [A7] with the compound of General Formula[S3] in the presence of a base.

This reaction may be carried out in accordance with the first step ofproduction method B.

Third Step

The compound of General Formula [A9] can be produced by deprotecting thecompound of General Formula [A8].

This reaction may be carried out in accordance with the third step ofproduction method A.

[Production Method 1]

(in the formulae, R^(1a) and R^(2a) are the same or different andrepresent a C₁₋₂₀ alkoxy group which may be substituted, a C₃₋₈cycloalkoxy group which may be substituted, an aryloxy group which maybe substituted, a heterocyclic oxy group which may be substituted, or anamino group which may be substituted; or R^(1a) and R^(2a), togetherwith the phosphorus atom to which they are bonded, may form a 5- to10-membered nitrogen.phosphorus-containing heterocyclic ring which maybe substituted, a 5- to 10-membered oxygen.phosphorus-containingheterocyclic ring which may be substituted, or a 5- to 10-memberednitrogen.oxygen.phosphorus-containing heterocyclic ring which may besubstituted; X³ represents a leaving group: and R^(b) has the samemeaning as above).

First Step

As the compound of General Formula [S4], for example, (2S)-benzyl2-(((RS)-chloro(phenoxy)phosphoryl)amino)propanoate, (2S)-benzyl2-(((RS)-chloro(4-chlorophenoxy)phosphoryl)amino)propanoate,S-(2-(((RS)-chloro(phenoxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate, and(2RS,4R)-2-(4-nitrophenoxy)-4-phenyl-1,3,2-dioxaphosphinane 2-oxide areknown.

The compound of General Formula [A10] can be produced by reacting thecompound of General Formula [A4] with the compound of General Formula[S4] in the presence of a base.

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction and examples thereof include ethers andaromatic hydrocarbons. These solvents may be used as a mixture thereof.

Examples of the preferred solvent include ethers. More preferred istetrahydrofuran.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of GeneralFormula [A4].

The amount of the compound of General Formula [S4] to be used may be 1to 20-fold molar excess and preferably 1 to 10-fold molar excess withrespect to the compound of General Formula [A4].

The base used in this reaction may be, for example, tert-butyl magnesiumchloride.

The amount of the base to be used may be 1 to 5-fold molar excess andpreferably 1 to 2-fold molar excess with respect to the compound ofGeneral Formula [A4].

This reaction may be carried out at −78° C. to 100° C., preferably −78°C. to 40° C. for 30 minutes to 48 hours.

Second Step

The compound of General Formula [1a] can be produced by deprotecting thecompound of General Formula [A10].

This reaction may be carried out in accordance with the third step ofproduction method A.

[Production Method 2]

(in the formulae, R^(1b) and R^(2b) are the same or different andrepresent a C₁₋₂₀ alkoxy group which may be substituted or a C₃₋₈cycloalkoxy group which may be substituted; R^(d) and R^(e) are the sameor different and represent a C₁₋₂₀ alkyl group which may be substituted;and R^(b) has the same meaning as above).

First Step

As the compound of General Formula [S5], for example,S,S′-((((diisopropylamino)phosphinediyl)bis(oxy))bis(ethane-2,1-diyl))bis(2,2-dimethylpropanethioate) andS-(2-(((2-cyanoethoxy)(diisopropylamino)phosphino)oxy)ethyl)2,2-dimethylpropanethioate are known.

The compound of General Formula [A11] can be produced by reacting thecompound of General Formula [A4] with the compound of General Formula[S5], followed by reaction with an oxidizing agent.

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction and examples thereof include halogenatedhydrocarbons, ethers, amides, and nitriles. These solvents may be usedas a mixture thereof.

Examples of the preferred solvent include methylene chloride,tetrahydrofuran, N,N-dimethylformamide, and acetonitrile. More preferredis methylene chloride.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of GeneralFormula [A4].

The amount of the compound of General Formula [S5] to be used may be 1to 10-fold molar excess and preferably 1 to 5-fold molar excess withrespect to the compound of General Formula [A4].

It is preferred to add a reaction accelerator to this reaction.

The reaction accelerator may be, for example, 1H-tetrazole.

The amount of the reaction accelerator to be used may be 1 to 10-foldmolar excess and preferably 1 to 5-fold molar excess with respect to thecompound of General Formula [A4].

The reaction with the compound of General Formula [S5] may be carriedout at −78° C. to 40° C. for 30 minutes to 24 hours.

The oxidizing agent to be used in this reaction may be, for example,meta-chloroperbenzoic acid.

The amount of the oxidizing agent to be used may be 1 to 5-fold molarexcess and preferably 1 to 2-fold molar excess with respect to thecompound of General Formula [A4].

The reaction with the oxidizing agent may be carried out at −78° C. to40° C. for 30 minutes to 24 hours.

Second Step

The compound of General Formula [1b] can be produced by deprotecting thecompound of General Formula [A11].

This reaction may be carried out in accordance with the third step ofproduction method A.

[Production Method 3]

(in the formulae, R^(1c) represents a C₁₋₂₀ alkoxy group which may besubstituted, a C₃₋₈ cycloalkoxy group which may be substituted, or anamino group which may be substituted; X⁴ represents a leaving group: andR^(b) has the same meaning as above).

First Step

As the compound of General Formula [S6], for example, phosphorusoxychloride is known.

As the compound of General Formula [S7], for example, L-alanine benzylester and 2,2′-disulfanediyldiethanol are known.

The compounds of General Formula [A12] and General Formula [A13] can beproduced by reacting the compound of General Formula [A4] with thecompound of General Formula [S6] in the presence of a base, followed byreaction with the compound of General Formula [S7].

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction and examples thereof include halogenatedhydrocarbons, ethers, and aromatic hydrocarbons. These solvents may beused as a mixture thereof.

Examples of the preferred solvent include halogenated hydrocarbons. Morepreferred is methylene chloride.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of GeneralFormula [A4].

The amount of the compound of General Formula [S6] to be used may be 1to 3-fold molar excess and preferably 1 to 2-fold molar excess withrespect to the compound of General Formula [A4].

The base used in this reaction is preferably an organic base and morepreferably triethylamine or diisopropylethylamine. These bases may beused as a mixture thereof.

The amount of the base to be used may be 3 to 15-fold molar excess andpreferably 3 to 6-fold molar excess with respect to the compound ofGeneral Formula [A4].

The reaction with the compound of General Formula [S6] may be carriedout at −78° C. to 0° C. for 30 minutes to 24 hours.

The amount of the compound of General Formula [S7] to be used may be 1to 5-fold molar excess and preferably 2 to 3-fold molar excess withrespect to the compound of General Formula [A4].

The reaction with the compound of General Formula [S7] may be carriedout at −78° C. to 0° C. for 30 minutes to 24 hours.

The reaction with the compound of General Formula [S7] may be carriedout at 0° C. to 100° C., preferably 0° C. to 40° C. for 30 minutes to 24hours.

Second Step

The compounds of General Formula [1c] and General Formula [1d] can beproduced by deprotecting the compounds of General Formula [A12] andGeneral Formula [A13].

This reaction may be carried out in accordance with the third step ofproduction method A.

[Production Method 4]

(in the formulae, R^(4a) represents a C₁₋₂₀ alkyl group which may besubstituted; X⁵ represents a leaving group: and R^(b) and R^(1c) havethe same meanings as above).

First Step

As the compound of General Formula [S8], for example, chloromethylisopropyl carbonate and chloromethyl pivalate are known.

The compound of General Formula [A14] can be produced by reacting thecompound of General Formula [A12] with the compound of General Formula[S8] in the presence of a base.

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction and examples thereof include amides,nitriles, and sulfoxides. These solvents may be used as a mixturethereof.

Examples of the preferred solvent include amides. More preferred isN,N-dimethylformamide.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of GeneralFormula [A12].

The amount of the compound of General Formula [S8] to be used may be 1to 10-fold molar excess and preferably 1 to 5-fold molar excess withrespect to the compound of General Formula [A12].

The base used in this reaction may be, for example, an inorganic base oran organic base and is preferably an organic base and more preferablytriethylamine or N,N-diisopropylethylamine. These bases may be used as amixture thereof.

The amount of the base to be used may be 1 to 20-fold molar excess andpreferably 1 to 10-fold molar excess with respect to the compound ofGeneral Formula [A12]. In addition, the base may be used as a solvent.

This reaction may be carried out at 0° C. to 100° C., preferably 50° C.to 80° C. for 30 minutes to 48 hours.

Second Step

The compound of General Formula [1e] can be produced by deprotecting thecompound of General Formula [A14].

This reaction may be carried out in accordance with the third step ofproduction method A.

[Production Method 5]

(in the formulae, R^(4a), R^(b), X⁴, and X⁵ have the same meanings asabove).

First Step

As the compound of General Formula [S6], for example, phosphorusoxychloride is known.

The compound of General Formula [A15] can be produced by reacting thecompound of Formula [A4] with the compound of General Formula [S6] inthe presence of a base.

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction and examples thereof include halogenatedhydrocarbons, ethers, and aromatic hydrocarbons. These solvents may beused as a mixture thereof.

Examples of the preferred solvent include halogenated hydrocarbons. Morepreferred is methylene chloride.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of GeneralFormula [A4].

The amount of the compound of General Formula [S6] to be used may be 1to 3-fold molar excess and preferably 1 to 2-fold molar excess withrespect to the compound of General Formula [A4].

The base used in this reaction is preferably an organic base and morepreferably triethylamine or diisopropylethylamine. These bases may beused as a mixture thereof.

The amount of the base to be used may be 1 to 5-fold molar excess andpreferably 1 to 2-fold molar excess with respect to the compound ofGeneral Formula [A4].

The reaction with the compound of General Formula [S6] may be carriedout at −78° C. to 0° C. for 30 minutes to 24 hours.

The compound of General Formula [A15] is preferably used in the nextstep without isolation thereof.

Second Step

The compound of General Formula [A16] can be produced by reacting thecompound of General Formula [A15] with water in the presence of a base.

The base used in this reaction is preferably an organic base and morepreferably triethylamine or diisopropylethylamine. These bases may beused as a mixture thereof.

The amount of the base to be used may be 2 to 10-fold molar excess andpreferably 2 to 4-fold molar excess with respect to the compound ofGeneral Formula [A15].

This reaction may be carried out at 0° C. to 50° C. for 30 minutes to 24hours.

Third Step

As the compound of General Formula [S8], for example, chloromethylisopropylcarbonate and chloromethyl pivalate are known.

The compounds of General Formula [A17] and General Formula [A18] can beproduced by reacting the compound of General Formula [A16] with thecompound of General Formula [S8] in the presence of a base.

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction and examples thereof include amides,nitriles, and sulfoxides. These solvents may be used as a mixturethereof

Examples of the preferred solvent include amides. More preferred isN,N-dimethylformamide.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of GeneralFormula [A16].

The amount of the compound of General Formula [S8] to be used may be 2to 20-fold molar excess and preferably 2 to 10-fold molar excess withrespect to the compound of General Formula [A16].

The base used in this reaction may be, for example, an inorganic base oran organic base and is preferably an organic base and more preferablytriethylamine or N,N-diisopropylethylamine. These bases may be used as amixture thereof

The amount of the base to be used may be 2 to 20-fold molar excess andpreferably 2 to 10-fold molar excess with respect to the compound ofGeneral Formula [A16]. In addition, the base may be used as a solvent.

This reaction may be carried out at 0° C. to 100° C., preferably 50° C.to 80° C. for 30 minutes to 48 hours.

Fourth Step

The compounds of General Formulae [1f] and [1g] can be produced bydeprotecting the compounds of General Formula [A17] and General Formula[A18].

This reaction may be carried out in accordance with the third step ofproduction method A.

[Production method 6]

(in the formulae, R^(f) represents a C₁₋₂₀ alkoxy group which may besubstituted; and R^(e), R^(e), and R^(1c) have the same meanings asabove).

First Step

As the compound of General Formula [S9], for example, 2-cyanoethylN,N,N′,N′-tetraisopropyl phosphorodiamidite is known.

The compound of General Formula [A19] can be produced by reacting thecompound of General Formula [A9] with the compound of General Formula[S9], followed by reaction with an oxidizing agent.

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction and examples thereof include halogenatedhydrocarbons, ethers, amides, and nitriles. These solvents may be usedas a mixture thereof.

Examples of the preferred solvent include methylene chloride,tetrahydrofuran, N,N-dimethylformamide, and acetonitrile. More preferredis methylene chloride.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of GeneralFormula [A9].

The amount of the compound of General Formula [S9] to be used may be 1to 10-fold molar excess and preferably 1 to 5-fold molar excess withrespect to the compound of General Formula [A9].

It is preferred to add a reaction accelerator to this reaction.

The reaction accelerator may be, for example, 1H-tetrazole.

The amount of the reaction accelerator to be used may be 2 to 10-foldmolar excess and preferably 2 to 5-fold molar excess with respect to thecompound of General Formula [A9].

The reaction with the compound of General Formula [S9] may be carriedout at −78° C. to 40° C. for 30 minutes to 24 hours.

The oxidizing agent to be used in this reaction may be, for example,meta-chloroperbenzoic acid.

The amount of the oxidizing agent to be used may be 1 to 5-fold molarexcess and preferably 1 to 2-fold molar excess with respect to thecompound of General Formula [A9].

The reaction with the oxidizing agent may be carried out at −78° C. to40° C. for 30 minutes to 24 hours.

Second Step

The compound of Formula [1h] can be produced by deprotecting thecompound of General Formula [A19].

This reaction may be carried out in accordance with the third step ofproduction method A.

Third Step

As the compound of General Formula [S7], for example, L-alanine benzylester and isopropyl alcohol are known.

The compound of General Formula [1i] can be produced by reacting thecompound of Formula [1h] with an activating agent, followed by reactionwith the compound of General Formula [S7].

The solvent used in this reaction is not particularly limited as long asit does not affect the reaction and examples thereof include halogenatedhydrocarbons, ethers, and aromatic hydrocarbons. These solvents may beused as a mixture thereof.

Examples of the preferred solvent include halogenated hydrocarbons. Morepreferred is methylene chloride.

The amount of the solvent to be used is not particularly limited, butmay be 1 to 50-fold amount (v/w) with respect to the compound of Formula[1h].

The activating agent may be, for example, oxalyl chloride.

The amount of the activating agent to be used may be 1 to 5-fold molarexcess and preferably 1 to 2-fold molar excess with respect to thecompound of Formula [1h].

The reaction with the activating agent may be carried out at −78° C. to40° C., preferably −78° C. to 0° C. for 30 minutes to 24 hours.

The amount of the compound of General Formula [S7] to be used may be 1to 5-fold molar excess and preferably 2 to 3-fold molar excess withrespect to the compound of Formula [1h].

It is preferred to add a reaction accelerator to this reaction.

The reaction accelerator may be, for example, N,N-dimethylformamide.

The amount of the reaction accelerator to be used may be 0.01 to 1-foldmolar excess with respect to the compound of Formula [1h].

The reaction with the compound of General Formula [S7] may be carriedout at 0° C. to 100° C., preferably 0° C. to 40° C. for 30 minutes to 24hours.

The compounds obtained by the above-mentioned production methods can bederived into other compounds, for example, by a per se known reactionsuch as condensation, addition, oxidation, reduction, rearrangement,substitution, halogenation, dehydration, or hydrolysis, or by suitablycombining these reactions.

In the case where an amino group, a hydroxyl group, or a carboxyl groupis present in the compounds obtained by the above-mentioned productionmethods and the intermediates thereof, the reaction can be carried outby suitably rearranging those protective groups. Further, in the casewhere two or more protecting groups are present, a per se known reactioncan be carried out to make selective deprotection.

With respect to the compounds used in the above-mentioned productionmethods, the compound capable of taking the form of a salt may be usedas a salt. Examples of such a salt include the same salts as the saltsof the thionucleoside derivative represented by General Formula [1]which is the thionucleoside derivative of the present inventiondescribed above.

In the case where isomers (for example, a tautomer, an optical isomer,and a geometric isomer) are present for the compounds used in theabove-mentioned production methods, these isomers may also be used. Inaddition, in the case where solvates, hydrates and various forms ofcrystals are present, these solvates, hydrates and various forms ofcrystals may also be used.

In a pharmaceutical composition containing the thionucleoside derivativerepresented by General Formula [1] or the salt thereof according to thepresent invention, an additive commonly used in formulation may beappropriately mixed.

Examples of the additive include an excipient, a disintegrating agent, abinding agent, a lubricant, a flavoring agent, a colorant, anaromatizer, a surfactant, a coating agent, and a plasticizer.

Examples of the excipient include sugar alcohols such as erythritol,mannitol, xylitol, and sorbitol; sugars such as white sugar, powderedsugar, lactose, and glucose; cyclodextrins such as α-cyclodextrin,β-cyclodextrin, γ-cyclodextrin, hydroxypropyl β-cyclodextrin, and sodiumsulfobutylether β-cyclodextrin; celluloses such as crystalline celluloseand microcrystalline cellulose; and starches such as a corn starch, apotato starch, and a pregelatinized starch.

Examples of the disintegrating agent include carmellose, carmellosecalcium, croscarmellose sodium, sodium carboxymethyl starch,crospovidone, low-substituted hydroxypropyl cellulose, and a partiallypregelatinized starch.

Examples of the binding agent include hydroxypropyl cellulose,carmellose sodium, and methylcellulose.

Examples of the lubricant include stearic acid, magnesium stearate,calcium stearate, talc, hydrated silicon dioxide, light anhydroussilicic acid, and sucrose fatty acid ester.

Examples of the flavoring agent include aspartame, saccharin, stevia,thaumatin, and acesulfame potassium.

Examples of the colorant include titanium dioxide, iron sesquioxide,yellow ferric oxide, black iron oxide, Food Red No. 102, Food Yellow No.4, and Food Yellow No. 5.

Examples of the aromatizer include an essential oil such as an orangeoil, a lemon oil, a peppermint oil, or a pine oil; an essence such as anorange essence or a peppermint essence; a flavor such as a cherryflavor, a vanilla flavor, or a fruit flavor; a powder fragrance such asan apple micron, a banana micron, a peach micron, a strawberry micron,or an orange micron; vanillin; and ethyl vanillin.

Examples of the surfactant include sodium lauryl sulfate, dioctyl sodiumsulfosuccinate, polysorbate, and polyoxyethylene hydrogenated castoroil.

Examples of the coating agent include hydroxypropyl methyl cellulose, anaminoalkyl methacrylate copolymer E, an aminoalkyl methacrylatecopolymer RS, ethyl cellulose, cellulose acetate phthalate,hydroxypropyl methyl cellulose phthalate, a methacrylic acid copolymerL, a methacrylic acid copolymer LD, and a methacrylic acid copolymer S.

Examples of the plasticizer include triethyl citrate, macrogol,triacetin, and propylene glycol.

These additives may be used alone or in combination of two or morethereof.

Although the blending amount of the additives is not particularlylimited, the additives may be suitably blended such that the effectsthereof are sufficiently exhibited depending on the respective purposes.

The pharmaceutical composition to which a mixture has been suitablyadded can be orally or parenterally administered according to aconventional method in the form of a tablet, a capsule, a powder, asyrup, a granule, a pill, a suspension, an emulsion, a solution, apowdered formulation, a suppository, an eye drop, a nasal drop, an eardrop, a patch, an ointment, an injection, or the like. It is preferredthat the pharmaceutical composition is orally administered in the formof a tablet, a capsule, a powder, a syrup, a granule, a pill, asuspension, an emulsion, a solution, a powdered formulation, or thelike.

The administration method, dosage, and administration frequency of thethionucleoside derivative represented by General Formula [1] or the saltthereof according to the present invention can be appropriately selecteddepending on a patient's age, body weight, and symptoms. Typically, foran adult, 0.01 to 1000 mg/kg/day may be administered orally orparenterally once or in several divided portions. It is preferred that0.01 to 1000 mg/kg/day is administered orally once or in several dividedportions.

EXAMPLES

Hereinafter, the present invention will be described with reference toReference Examples and Examples, but the present invention is notlimited thereto.

Unless otherwise specified, purification by column chromatography wascarried out using an automated purification apparatus ISOLERA(manufactured by Biotage AB) or a medium-pressure liquid chromatographYFLC-Wprep2XY.N (manufactured by Yamazen Corporation).

Unless otherwise specified, a SNAPKP-Sil Cartridge (manufactured byBiotage AB), or a HI-FLASH COLUMN W001, W002, W003, W004, or W005(manufactured by Yamazen Corporation) was used as a carrier in silicagel column chromatography, and a SNAP KP-NH Cartridge (manufactured byBiotage AB) was used as a carrier in basic silica gel columnchromatography.

In preparative thin layer chromatography, PLC glass plate silica gel F₆₀(Merck Ltd.) was used.

In preparative reversed phase HPLC, a Waters 2998 Photodiode Array (PDA)Detector (manufactured by Waters Corporation), a Waters 600 Controller(manufactured by Waters Corporation), a Waters 2767 Sample Manager(manufactured by Waters Corporation), and a YMC-Actus ProC18, 30×50 mmcolumn (manufactured by YMC Co., Ltd.) were used.

The mixing ratio in the eluent was a volume ratio. For example,“hexane:ethyl acetate gradient elution=100:0 to 50:50” means that aneluent of 100% hexane/0% ethyl acetate was finally changed to an eluentof 50% hexane/50% ethyl acetate.

MS spectra were measured using an ACQUITY SQD LC/MS System (manufacturedby Waters Corporation, ionization method: Electro Spray Ionization (ESI)method), an M-8000 type (manufactured by Hitachi, Ltd., ionizationmethod: ESI method), or an LCMS-2010EV (manufactured by ShimadzuCorporation, ionization method: method of carrying out ESI andAtmospheric Pressure Chemical Ionization (APCI) at the same time).

NMR spectra were measured using a Bruker AV300 (manufactured by BrukerCorporation, 300 MHz) and using tetramethylsilane as an internalstandard, and all 6 values were shown in ppm.

The retention time (RT) was measured using a SQD (manufactured by WatersCorporation), and was shown in minutes (min).

Column: BEHC 18 1.7 μm, 2.1×30 mm (manufactured by Waters Corporation)

Solvent: liquid A: 0.1% formic acid-water

liquid B: 0.1% formic acid-acetonitrile

Gradient cycle: 0.00 min (liquid A/liquid B=95/5), 2.00 min (liquidA/liquid B=5/95), 3.00 min (liquid A/liquid B=5/95), 3.01 min (liquidA/liquid B=100/0), 3.80 min (liquid A/liquid B=100/0)

Flow rate: 0.5 mL/min

Column temperature: room temperature

Detection wavelength: 254 nm

Abbreviations in individual Examples have the following meanings.

Ac: acetyl

Boc: tert-butoxycarbonyl

TBDPS: tert-butyldiphenylsilyl

Ts: tosyl (para-toluenesulfonyl)

RT (min): retention time (min)

DMSO-d₆: deuterated dimethyl sulfoxide

*: bonding position

Reference Example 1

First Step

Imidazole (5.70 g) and tert-butyldiphenylchlorosilane (11.5 g) wereadded to a mixture of methanesulfonate (10.0 g) of4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-oneand N,N-dimethylformamide (100 mL) which was then stirred at roomtemperature for 1.5 hours. Water was added to the reaction liquid whichwas then extracted with ethyl acetate, and the organic layer was driedover anhydrous sodium sulfate. The solvent was distilled off underreduced pressure to give4-amino-1-((2R,3S,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-fluoro-4-hydroxytetrahydrothiophen-2-yl)pyrimidin-2(1H)-one(13.8 g) as a colorless oil.

MS(ESI m/z): 500(M+H)

RT(min): 1.50

Second Step

N,N-dimethyl-4-aminopyridine (100 mg) and triethylamine (12.5 mL) wereadded to a mixture of4-amino-1-((2R,3S,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-fluoro-4-hydroxytetrahydrothiophen-2-yl)pyrimidin-2(1H)-one(13.8 g) obtained in the first step and methylene chloride (100 mL), anda mixture of di-tert-butyldicarbonate (20 mL) and methylene chloride (20mL) was slowly added dropwise thereto at room temperature. Afterstirring at room temperature for 6 hours, triethylamine (5.0 mL) anddi-tert-butyldicarbonate (5.0 mL) were added thereto, followed bystirring for 20 minutes. Triethylamine (3.0 mL) anddi-tert-butyldicarbonate (3.0 mL) were added to the reaction liquidwhich was then stirred for 30 minutes, and the solvent was distilled offunder reduced pressure. The resulting residue was purified by silica gelcolumn chromatography (hexane:ethyl acetate=100:0 to 70:30) to givetert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-fluorotetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(21.8 g) as a white solid.

MS(ESI m/z): 800 (M+H)

RT(min): 2.52

Third Step

A mixture of acetic acid (3.0 mL) and a 1 mol/L tetrabutylammoniumfluoride/tetrahydrofuran solution (30 mL) was added to a mixture oftert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-fluorotetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(14.8 g) and tetrahydrofuran (30 mL) which was then stirred at roomtemperature for 45 minutes. The solvent was distilled off under reducedpressure and the resulting residue was purified by silica gel columnchromatography (hexane:ethyl acetate=100:0 to 50:50) to give tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(7.50 g) as a white solid.

MS(ESI m/z): 562(M+H)

RT(min): 1.71

Reference Example 2

First Step

Benzoyl chloride (7.94 mL) was added under ice-cooling to a mixture of4-amino-1-((2R,3S,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-fluoro-4-hydroxytetrahydrothiophen-2-yl)pyrimidin-2(1H)-one(11.5 g) and pyridine (115 mL) which was then stirred at roomtemperature for 1 hour. The solvent was distilled off under reducedpressure, and water was added to the resulting residue which was thenextracted with ethyl acetate. The organic layer was washed with waterand an aqueous saturated sodium chloride solution and dried overanhydrous sodium sulfate. The solvent was distilled off under reducedpressure and the resulting residue was purified by silica gel columnchromatography (hexane:ethyl acetate=90:10 to 0:100) to give(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-4-fluorotetrahydrothiophen-3-ylbenzoate (8.48 g) as a white solid.

MS(ESI m/z): 708(M+H)

RT(min): 2.28

Second Step

A 1 mol/L tetrabutylammonium fluoride/tetrahydrofuran solution (24 mL)was added to a mixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-4-fluorotetrahydrothiophen-3-ylbenzoate (8.48 g) and tetrahydrofuran (48 mL) which was then stirred atroom temperature for 30 minutes. Methylene chloride was added to thereaction liquid, and the organic layer was washed with water and driedover anhydrous sodium sulfate. The solvent was distilled off underreduced pressure and the resulting residue was purified by silica gelcolumn chromatography (hexane:ethyl acetate=90:10 to 0:100) to give(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrothiophen-3-ylbenzoate (5.56 g) as a white solid.

¹H-NMR (DMSO-d₆) δ: 11.36 (s, 1H), 8.71 (d, 1H, J=7.6 Hz), 8.05-7.99 (m,4H), 7.76-7.45 (m, 7H), 6.60 (dd, 1H, J=12.4, 5.4 Hz), 5.86-5.79 (m,1H), 5.71-5.48 (m, 2H), 3.82-3.68 (m, 3H).

MS(ESI m/z): 470(M+H)

RT(min): 1.24

Reference Example 3

First Step

Di-tert-butyl N,N-diisopropyl phosphoramidite (12.8 mL) was added to amixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrothiophen-3-ylbenzoate (9.50 g), 1H-tetrazole (4.30 g) and methylene chloride (190 mL)which was then stirred at room temperature for 30 minutes.meta-Chloroperbenzoic acid (7.00 g) was added thereto at −40° C.,followed by stirring for 30 minutes under ice-cooling. Underice-cooling, a mixture of sodium sulfite (7.70 g) and water (100 mL) wasadded thereto, followed by stirring at room temperature for 30 minutes.The water layer was removed, and the organic layer was dried overanhydrous sodium sulfate. The solvent was distilled off under reducedpressure and the resulting residue was purified by silica gel columnchromatography (hexane:ethyl acetate=50:50 to 20:80) to give(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-(((di-tert-butoxyphosphoryl)oxy)methyl)-4-fluorotetrahydrothiophen-3-yl benzoate (4.93 g) as a whitesolid.

¹H-NMR (DMSO-d₆) δ: 11.38 (s, 1H), 8.56 (d, 1H, J=7.9 Hz), 8.05-8.00 (m,4H), 7.76-7.71 (m, 1H), 7.67-7.45 (m, 6H), 6.62 (dd, 1H, J=14.4, 5.1Hz), 5.92-5.83 (m, 1H), 5.76-5.53 (m, 1H), 4.37-4.17 (m, 2H), 3.97-3.89(m, 1H), 1.42 (s, 9H), 1.41 (s, 9H).

MS(ESI m/z): 662(M+H)

RT(min): 1.71

Second Step

A mixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-(((di-tert-butoxyphosphoryl)oxy)methyl)-4-fluorotetrahydrothiophen-3-yl benzoate (3.50 g) and a 4.0mol/L hydrogen chloride/1,4-dioxane solution (27 mL) was stirred at roomtemperature for 30 minutes. The solvent was distilled off under reducedpressure and the resulting residue was washed with ethyl acetate to give(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-fluoro-2-((phosphonooxy)methyl)tetrahydrothiophen-3-yl benzoate (2.63 g) as a white solid.

¹H-NMR (DMSO-d₆) δ: 8.61 (d, 1H, J=7.6 Hz), 8.05-8.00 (m, 4H), 7.77-7.70(m, 1H), 7.68-7.49 (m, 5H), 7.45 (d, 1H, J=7.6 Hz), 6.62 (dd, 1H,J=13.5, 5.3 Hz), 5.87-5.80 (m, 1H), 5.74-5.54 (m, 1H), 4.31-4.12 (m,2H), 3.91 (dd, 1H, J=11.1, 6.1 Hz).

MS(ESI m/z): 550(M+H)

RT(min): 0.92

Reference Example 4

A mixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-fluoro-2-((phosphonooxy)methyl)tetrahydrothiophen-3-yl benzoate (1.70 g) and a 7.0 mol/Lammonia/methanol solution (100 mL) was stirred at room temperature for17 hours. The insoluble matter was separated by filtration and thesolvent was distilled off under reduced pressure. The resulting residuewas washed with acetone to give((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyldihydrogen phosphate (733 mg) as a white solid.

¹H-NMR (DMSO-d₆) δ: 8.00 (d, 1H, J=7.6 Hz), 7.31 (s, 1H), 7.17 (s, 1H),6.42 (dd, 1H, J=11.2, 5.3 Hz), 5.80 (d, 1H, J=7.6 Hz), 5.04-4.80 (m,1H), 4.34-4.22 (m, 1H), 3.97-3.79 (m, 2H), 3.34-3.26 (m, 1H).

MS(ESI m/z): 342(M+H)

RT(min): 0.19

Reference Example 5

First Step

To a mixture of methanesulfonate (2.40 g) of4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-oneand a 1.0 mol/L aqueous potassium hydroxide solution (160 mL), a mixtureof di-tert-butyldicarbonate (17.4 g) and 1,4-dioxane (160 mL) was slowlyadded over 20 minutes. After stirring at room temperature for 3.5 hoursfollowing the completion of the dropwise addition, a 1.0 mol/L aqueouspotassium hydroxide solution (80 mL) and di-tert-butyldicarbonate (8.72g) were added to the reaction liquid which was then stirred at roomtemperature for 30 minutes. After standing at room temperature for 15hours, the reaction liquid was extracted with ethyl acetate. The organiclayer was washed with water and an aqueous saturated sodium chloridesolution and dried over anhydrous sodium sulfate. The solvent wasdistilled off under reduced pressure and the resulting residue waspurified by silica gel column chromatography (ethylacetate:methanol=100:0 to 90:10) to give tert-butyl((2R,3S,4S,5R)-3-((tert-butoxycarbonyl)oxy)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluorotetrahydrothiophen-2-yl)methylcarbonate (1.35 g) as a colorless oil.

MS(ESI m/z): 462(M+H)

RT(min): 1.29

Second Step

Benzoyl chloride (18.8 μL) was added to a mixture of tert-butyl((2R,3S,4S,5R)-3-((tert-butoxycarbonyl)oxy)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluorotetrahydrothiophen-2-yl)methylcarbonate (50.0 mg), N,N-diisopropylethylamine (36.7 μL) and methylenechloride (1.0 mL) which was then stirred at room temperature for 18hours. An aqueous saturated sodium hydrogen carbonate solution was addedto the reaction liquid which was then extracted with ethyl acetate anddried over anhydrous sodium sulfate. The solvent was distilled off underreduced pressure. Ethyl acetate was added to the resulting residue, andthe precipitated solid was collected by filtration to give tert-butyl(((2R,3S,4S,5R)-3-((tert-butoxycarbonyl)oxy)-4-fluoro-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)tetrahydrothiophen-2-yl)methyl)carbonate (38.0 mg) as a white solid.

MS(ESI m/z): 566(M+H)

RT(min): 1.78

Third Step

Trifluoroacetic acid (1.0 mL) was added to tert-butyl(((2R,3S,4S,5R)-3-((tert-butoxycarbonyl)oxy)-4-fluoro-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)tetrahydrothiophen-2-yl)methyl)carbonate (31.0 mg) which was then stirred at room temperature for 3hours. The solvent was distilled off under reduced pressure. Ethylacetate (1.0 mL) and an aqueous saturated sodium hydrogen carbonatesolution (1.0 mL) were added to the resulting residue which was thenstirred. The water layer was removed, the organic layer was dried overanhydrous sodium sulfate, and the solvent was distilled off underreduced pressure. The resulting residue was purified by silica gelcolumn chromatography (chloroform:methanol=95:5 to 88:12) to giveN-(1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide(9.2 mg) as a white solid.

¹H-NMR (DMSO-d₆) δ: 11.31 (s, 1H), 8.63 (d, 1H, J=7.6 Hz), 8.01 (d, 2H,J=7.6 Hz), 7.67-7.59 (m, 1H), 7.56-7.47 (m, 2H), 7.40 (d, 1H, J=7.3 Hz),6.47 (dd, 1H, J=10.9, 5.6 Hz), 5.96 (d, 1H, J=5.3 Hz), 5.38-5.30 (m,1H), 5.20-4.95 (m, 1H), 4.34-4.21 (m, 1H), 3.83-3.62 (m, 2H), 3.30-3.21(m, 1H).

MS(ESI m/z): 366(M+H)

RT(min): 0.88

Reference Example 6

A mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(400 mg) and pyridine (1.8 mL) was added to a mixture of diphenylphosphite (272 μL) and pyridine (1.8 mL) which was then stirred at roomtemperature for 10 minutes. A mixture of water (712 μL) andtriethylamine (712 μL) was added thereto, followed by stirring at roomtemperature for 5 minutes. The solvent was distilled off under reducedpressure and the resulting residue was purified by silica gel columnchromatography (chloroform:methanol=100:0 to 60:40) to give((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylhydrogen phosphonate (283 mg) as a colorless oil.

MS(ESI m/z): 626(M+H)

RT(min): 1.26

Reference Example 7

1H-tetrazole (870 mg) was added to a mixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrothiophen-3-ylbenzoate (3.90 g), 2-cyanoethylN,N,N′,N′-tetraisopropylphosphorodiamidite (5.00 g),N,N-diisopropylethylamine (2.2 mL), acetonitrile (28 mL) andtetrahydrofuran (28 mL) which was then stirred at room temperature for20 minutes. Water was added to the reaction liquid which was thenextracted with ethyl acetate, and the organic layer was dried overanhydrous magnesium sulfate. Then, the solvent was distilled off underreduced pressure. The resulting residue was purified by silica gelcolumn chromatography (hexane:ethyl acetate=50:50 to 0:100) to give awhite solid. The resulting white solid was dissolved in methanol andethyl acetate, and hexane was added to result in precipitation, therebyaffording(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((((2-cyanoethoxy)(diisopropylamino)phosphoryl)oxy)methyl)-4-fluorotetrahydrothiophen-3-ylbenzoate (1.50 g) as a white solid.

¹H-NMR (DMSO-d₆) δ: 11.37 (s, 1H), 8.70-8.54 (m, 1H), 8.07-7.39 (m,10H), 6.66-6.55 (m, 1H), 5.93-5.80 (m, 1H), 5.76-5.66 (m, 1H), 5.60-5.48(m, 1H), 4.12-3.70 (m, 5H), 3.65-3.48 (m, 2H), 2.85-2.74 (m, 2H),1.18-1.09 (m, 12H).

Reference Example 8-1

First Step

To a mixture of 2-mercaptoethanol (1.5 mL), triethylamine (4.0 mL) andmethylene chloride (55 mL), pivaloyl chloride (2.64 mL) was slowly addeddropwise at −78° C. over 1 hour, followed by stirring at roomtemperature for 1 hour. Water (30 mL) was added to the reaction liquidwhich was then stirred for 30 minutes and extracted with ethyl acetate,and the organic layer was dried over anhydrous sodium sulfate. Thesolvent was distilled off under reduced pressure to giveS-(2-hydroxyethyl) 2,2-dimethylpropanethioate (3.69 g) as a colorlessoil.

¹H-NMR (CDCl₃) δ: 3.76 (t, 2H, J=6.1 Hz), 3.06 (t, 2H, J=6.1 Hz), 1.25(s, 9H).

Second Step

A mixture of 1,1-dichloro-N,N-diisopropylphosphineamine (1.01 g) andtetrahydrofuran (35 mL) was added dropwise at −78° C. to a mixture ofS-(2-hydroxyethyl) 2,2-dimethylpropanethioate (1.62 g), triethylamine(3.0 mL) and tetrahydrofuran (25 mL) which was then stirred at roomtemperature for 2 hours. The insoluble matter was separated byfiltration, and the solvent was distilled off under reduced pressure.The resulting residue was purified by silica gel column chromatography(hexane:ethyl acetate=96:4 to 75:25) to giveS,S′-((((diisopropylamino)phosphinediyl)bis(oxy))bis(ethane-2,1-diyl))bis(2,2-dimethylpropanethioate) (751 mg) as a colorless oil.

¹H-NMR (CDCl₃) δ: 4.24 (t, 4H, J=7.3 Hz), 3.79-3.59 (m, 2H), 2.89-2.76(m, 4H), 1.27-1.15 (m, 30H).

Reference Example 8-2

The following compound was obtained in the same manner as in ReferenceExample 8-1.

S,S′-((((diisopropylamino)phosphinediyl)bis(oxy))bis(ethane-2,1-diyl))bis(2-methylpropanethioate)

¹H-NMR (CDCl₃) δ: 4.25 (t, 4H, J=6.9 Hz), 2.89-2.77 (m, 4H), 2.63-2.47(m, 4H), 1.24-1.14 (m, 24H).

Reference Example 8-3

The following compound was obtained in the same manner as in ReferenceExample 8-1.

S,S′-((((diisopropylamino)phosphinediyl)bis(oxy))bis(ethane-2,1-diyl))dipropanethioate

¹H-NMR (CDCl₃) δ: 4.26 (t, 4H, J=6.9 Hz), 3.79-3.60 (m, 2H), 2.90-2.73(m, 4H), 1.19 (d, 12H, J=6.6 Hz), 1.14 (t, 6H, J=7.6 Hz).

Reference Example 9-1

Para-toluenesulfonyl chloride (881 mg) was added to a mixture ofS-(2-hydroxyethyl) 2,2-dimethylpropanethioate (500 mg), pyridine (0.5mL) and methylene chloride (5.0 mL) which was then stirred at roomtemperature for 19 hours. An aqueous saturated sodium hydrogen carbonatesolution (5.0 mL) was added to the reaction liquid which was thenstirred for 1.5 hours and extracted with ethyl acetate. The organiclayer was washed with 1.0 mol/L hydrochloric acid, water and an aqueoussaturated sodium chloride solution, and dried over anhydrous sodiumsulfate. The solvent was distilled off under reduced pressure to giveS-(2-(tosyloxy)ethyl) 2,2-dimethylpropanethioate (762 mg) as a colorlessoil.

¹H-NMR (CDCl₃) δ: 7.80 (d, 2H, J=8.3 Hz), 7.35 (d, 2H, J=8.3 Hz), 4.08(t, 2H, J=6.6 Hz), 3.08 (t, 2H, J=6.6 Hz), 2.45 (s, 3H), 1.18 (s, 9H).

Reference Example 9-2

The following compound was obtained in the same manner as in ReferenceExample 9-1.

S-(4-(tosyloxy)butyl) 2,2-dimethylpropanethioate

MS(ESI m/z): 345(M+H)

RT(min): 1.90

Reference Example 10-1

Under a nitrogen atmosphere, 60% sodium hydride (130 mg) was added to amixture of 2,2′-disulfanediyldiethanol (500 mg) and tetrahydrofuran (5.0mL) which was then stirred at room temperature for 10 minutes. Methyliodide (202 μL) was added to the reaction liquid which was then stirredfor 3 hours, and water was added thereto, followed by extraction withethyl acetate. The organic layer was washed with an aqueous saturatedsodium chloride solution and dried over anhydrous sodium sulfate, andthe solvent was distilled off under reduced pressure. The resultingresidue was purified by silica gel column chromatography (hexane:ethylacetate=72:28 to 51:49) to give 2-((2-methoxyethyl)disulfanyl)ethanol(187 mg) as a colorless oil.

¹H-NMR (CDCl₃) δ: 3.95-3.85 (m, 2H), 3.67 (t, 2H, J=6.3 Hz), 3.39 (s,3H), 2.91 (t, 2H, J=6.3 Hz), 2.88 (t, 2H, J=5.6 Hz), 2.23-2.15 (m, 1H).

Reference Example 10-2

The following compound was obtained in the same manner as in ReferenceExample 10-1.

2-((2-(benzyloxy)ethyl)disulfanyl)ethanol

¹H-NMR (CDCl₃) δ: 7.39-7.27 (m, 5H), 4.56 (s, 2H), 3.92-3.81 (m, 2H),3.75 (t, 2H, J=6.3 Hz), 2.94 (t, 2H, J=6.3 Hz), 2.83 (t, 2H, J=5.9 Hz),2.12-1.95 (m, 1H).

Reference Example 11-1

First Step

Ethyl isocyanate (1.1 mL) was added at −78° C. to a mixture of2-mercaptoethanol (980 μL), triethylamine (3.9 mL) and toluene (14 mL)which was then stirred at room temperature for 1 hour. The solvent wasdistilled off under reduced pressure to give S-(2-hydroxyethyl)ethylcarbamothioate (2.10 g).

Second Step

Under ice-cooling, para-toluenesulfonyl chloride (2.00 g) was added to amixture of S-(2-hydroxyethyl) ethylcarbamothioate (1.05 g), pyridine(1.1 mL) and methylene chloride (14 mL) which was then stirred at roomtemperature for 18 hours. An aqueous saturated sodium hydrogen carbonatesolution was added to the reaction liquid which was then stirred for 30minutes and extracted with ethyl acetate. The organic layer was washedwith water and an aqueous saturated sodium chloride solution and driedover anhydrous sodium sulfate. The solvent was distilled off underreduced pressure to give 2-((ethylcarbamoyl)thio)ethyl 4-methylbenzenesulfonate (470 mg).

MS(ESI m/z): 304(M+H)

RT(min): 1.35

Reference Example 11-2

The following compound was obtained in the same manner as in ReferenceExample 11-1.

2-((isopropylcarbamoyl)thio)ethyl 4-methylbenzene sulfonate

MS(ESI m/z): 318(M+H)

RT(min): 1.46

Reference Example 11-3

The following compound was obtained in the same manner as in ReferenceExample 11-1.

2-((cyclohexylcarbamoyl)thio)ethyl 4-methylbenzene sulfonate

MS(ESI m/z): 358(M+H)

RT(min): 1.60

Reference Example 12-1

Under a nitrogen atmosphere, a mixture of N,N-diisopropylethylamine (172μL), 1-dodecanol (224 μL) and diethyl ether (6.0 mL) was added dropwiseunder ice-cooling to a mixture of 2-cyanoethylN,N-diisopropylchlorophosphoramidite (223 μL) and diethyl ether (4.0mL). After stirring at room temperature for 2.5 hours, the insolublematter was separated by filtration and the solvent was distilled offunder reduced pressure to give 2-cyanoethyl dodecylN,N-diisopropylphosphoramidite (298 mg) as a colorless oil.

Reference Example 12-2

The following compound was obtained in the same manner as in ReferenceExample 12-1.

2-cyanoethyl 2-ethylhexyl diisopropyl phosphoramidite

Reference Example 12-3

The following compound was obtained in the same manner as in ReferenceExample 12-1.

2-cyanoethyl octadecyl diisopropylphosphoramidite

Reference Example 13-1

Pyridine (4.8 mL) was added under ice-cooling to a mixture of4-nitrophenyl phosphorodichloridate (5.12 g) and tetrahydrofuran (51mL). After stirring for 30 minutes under ice-cooling, 1,3-propanediol(1.52 g) was added under ice-cooling, followed by stirring at roomtemperature for 1 hour. An aqueous saturated ammonium chloride solutionwas added thereto, followed by extraction with ethyl acetate. Theorganic layer was washed with an aqueous saturated sodium chloridesolution and dried over anhydrous sodium sulfate, and then the solventwas distilled off under reduced pressure. The resulting residue waspurified by silica gel column chromatography (hexane:ethyl acetate=80:20to 20:80) to give 2-(4-nitrophenoxy)-1,3,2-dioxaphosphinane 2-oxide(2.74 g) as a white solid.

MS(ESI m/z): 260(M+H)

RT(min): 0.98

Reference Example 13-2

The following compound was obtained in the same manner as in ReferenceExample 13-1.

(2RS,4R)-2-(4-nitrophenoxy)-4-phenyl-1,3,2-dioxaphosphinane 2-oxide

MS(ESI m/z): 336(M+H)

RT(min): 1.39

Reference Example 13-3

The following compound was obtained in the same manner as in ReferenceExample 13-1.

(2RS,4RS)-4-(3-chlorophenyl)-2-(4-nitrophenoxy)-1,3,2-dioxaphosphinane2-oxide

MS(ESI m/z): 370(M+H)

RT(min): 1.51

Reference Example 13-4

The following compound was obtained in the same manner as in ReferenceExample 13-1.

(RS)-2-(4-nitrophenoxy)-4H-benzo[d][1,3,2]dioxaphosphinine 2-oxide

MS(ESI m/z): 308(M+H)

RT(min): 1.36

Reference Example 13-5

The following compound was obtained in the same manner as in ReferenceExample 13-1.

(RS)-8-methoxy-2-(4-nitrophenoxy)-4H-benzo[d][1,3,2]dioxaphosphinine2-oxide

MS(ESI m/z): 338(M+H)

RT(min): 1.34

Reference Example 14-1

Imidazole (8.30 g) was added to a mixture of ethylene glycol (11.4 mL),tert-butyldiphenylchlorosilane (10.6 mL) and methylene chloride (80 mL)which was then stirred at room temperature for 25 minutes. Water wasadded to the reaction liquid which was then extracted with methylenechloride, the organic layer was dried over anhydrous magnesium sulfate,and then the solvent was distilled off under reduced pressure. Theresulting residue was purified by silica gel column chromatography(hexane:ethyl acetate=95:5 to 60:40) to give2-((tert-butyldiphenylsilyl)oxy)ethanol (3.87 g) as a colorless oil.

¹H-NMR (CDCl₃) δ: 7.74-7.33 (m, 10H), 3.80-3.73 (m, 2H), 3.72-3.64 (m,2H), 1.07 (s, 9H).

Reference Example 14-2

The following compound was obtained in the same manner as in ReferenceExample 14-1.

2((2-((tert-butyldiphenylsilyl)oxy)ethyl)disulfanyl)ethanol

¹H-NMR (CDCl₃) δ: 7.70-7.36 (m, 10H), 3.90 (t, 2H, J=6.6 Hz), 3.87-3.79(m, 2H), 2.85 (t, 2H, J=6.6 Hz), 2.75 (t, 2H, J=5.9 Hz), 1.90 (t, 1H,J=5.9 Hz), 1.06 (s, 9H).

Reference Example 15

Trichloroacetonitrile (115 μL) was added under ice-cooling to a mixtureof 2,3,4,6-tetra-O-acetyl-β-D-glucopyranose (100 mg) and methylenechloride (1.5 mL) which was then stirred for 5 minutes.Diazabicycloundecene (10 μL) was added to the reaction liquid which wasthen stirred at room temperature for 40 minutes, and the solvent wasdistilled off under reduced pressure. The resulting residue was purifiedby silica gel column chromatography (hexane:ethyl acetate=80:20 to65:35) to give(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (95.0 mg) as a colorless oil.

¹H-NMR (CDCl₃) δ: 8.70 (s, 1H), 6.56 (d, 1H, J=4.0 Hz), 5.62-5.51 (m,1H), 5.22-5.07 (m, 2H), 4.33-4.06 (m, 3H), 2.12-1.96 (m, 12H).

Reference Example 16-1

First Step

A boron trifluoride diethyl ether complex (54 μL) was added underice-cooling to a mixture of(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (525 mg), 2-((tert-butyldiphenylsilyl)oxy)ethanol (318 mg), amolecular sieve 4A and methylene chloride (5.3 mL) which was thenstirred at room temperature for 10 minutes. Water was added to thereaction liquid which was then extracted with methylene chloride. Theorganic layer was dried over anhydrous magnesium sulfate and the solventwas distilled off under reduced pressure. The resulting residue waspurified by silica gel column chromatography (hexane:ethyl acetate=80:20to 50:50) to give(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-((tert-butyldiphenylsilyl)oxy)ethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (170 mg) as a white solid.

¹H-NMR (CDCl₃) δ: 7.71-7.33 (m, 10H), 5.26-4.96 (m, 3H), 4.63 (d, 1H,J=7.9 Hz), 4.30-4.21 (m, 1H), 4.14-4.07 (m, 1H), 3.94-3.61 (m, 5H),2.13-1.93 (m, 12H), 1.03 (s, 9H).

Second Step

A 1 mol/L tetrabutylammonium fluoride/tetrahydrofuran solution (540 μL)was added to a mixture of(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-((tert-butyldiphenylsilyl)oxy)ethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (170 mg), acetic acid (31 μL) and tetrahydrofuran (2.7 mL)which was then stirred at room temperature for 30 minutes. The solventwas distilled off under reduced pressure and the resulting residue waspurified by silica gel column chromatography (hexane:ethyl acetate=50:50to 0:100) to give(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-hydroxyethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (79.0 mg) as a colorless oil.

¹H-NMR (CDCl₃) δ: 5.30-5.16 (m, 1H), 5.11-4.97 (m, 2H), 4.56 (d, 1H,J=7.9 Hz), 4.20 (d, 2H, J=4.0 Hz), 3.88-3.66 (m, 5H), 2.13-1.97 (m,12H).

Reference Example 16-2

First Step

A boron trifluoride diethyl ether complex (54 μL) was added underice-cooling to a mixture of(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (525 mg),2-((2-((tert-butyldiphenylsilyl)oxy)ethyl)disulfanyl)ethanol (417 mg), amolecular sieve 4A and methylene chloride (5.3 mL) which was thenstirred at room temperature for 10 minutes. Water was added to thereaction liquid which was then extracted with methylene chloride, theorganic layer was dried over anhydrous magnesium sulfate, and then thesolvent was distilled off under reduced pressure. The resulting residuewas purified by silica gel column chromatography (hexane:ethylacetate=80:20 to 50:50) to give(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-((2-((tert-butyldiphenylsilyl)oxy)ethyl)disulfanyl)ethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (75.0 mg) as a colorless oil.

¹H-NMR (CDCl₃) δ: 7.70-7.34 (m, 10H), 5.24-4.94 (m, 3H), 4.51 (d, 1H,J=8.9 Hz), 4.31-3.99 (m, 3H), 3.92-3.64 (m, 4H), 2.86-2.71 (m, 4H),2.15-1.98 (m, 12H), 1.06 (s, 9H).

Second Step

A 1 mol/L tetrabutylammonium fluoride/tetrahydrofuran solution (540 μL)was added to a mixture of(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-((2-((tert-butyldiphenylsilyl)oxy)ethyl)disulfanyl)ethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (75.0 mg), acetic acid (12 μL) and tetrahydrofuran (1.0 mL)which was then stirred at room temperature for 30 minutes. The solventwas distilled off under reduced pressure and the resulting residue waspurified by silica gel column chromatography (hexane:ethyl acetate=50:50to 0:100) to give(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-((2-hydroxyethyl)disulfanyl)ethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (33.0 mg) as a colorless oil.

¹H-NMR (CDCl₃) δ: 5.26-5.17 (m, 1H), 5.14-5.05 (m, 1H), 5.04-4.96 (m,1H), 4.57-4.54 (m, 1H), 4.32-2.82 (m, 11H), 2.06-2.02 (m, 12H).

Example 1-1

First Step

(1) Triethylamine (1.1 mL) was added at −78° C. to a mixture of phenyldichlorophosphate (600 μL), L-alanine benzyl ester hydrochloride (864mg) and methylene chloride (20 mL) which was then stirred at roomtemperature for 2 hours and 11 minutes. The solvent was distilled offunder reduced pressure. Diethyl ether was added to the resultingresidue, and the insoluble matter was separated by filtration. Thesolvent was distilled off under reduced pressure to give (2S)-benzyl2-(((RS)-chloro(phenoxy)phosphoryl)amino)propanoate as a crude product.

(2) Under a nitrogen atmosphere, a 1.0 mol/L tert-butyl magnesiumchloride/tetrahydrofuran solution (710 μL) was added dropwise at −78° C.to a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(80.0 mg) and tetrahydrofuran (2.0 mL) which was then stirred at roomtemperature for 10 minutes. A mixture of (2S)-benzyl2-(((RS)-chloro(phenoxy)phosphoryl)amino)propanoate (150 mg) obtained in(1) and tetrahydrofuran (900 μL) was added to the reaction liquid whichwas then stirred at room temperature for 40 minutes. An aqueoussaturated ammonium chloride solution was added to the reaction liquidwhich was then extracted with ethyl acetate and dried over anhydrousmagnesium sulfate. The solvent was distilled off under reduced pressureto give (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate.

MS(ESI m/z): 879(M+H)

RT(min): 2.06

Second Step

Trifluoroacetic acid (1.4 mL) was added under ice-cooling to a mixtureof (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoateand methylene chloride (1.4 mL) which was then stirred at roomtemperature for 30 minutes. The solvent was distilled off under reducedpressure and the resulting residue was purified by silica gel columnchromatography (ethyl acetate:methanol=100:0 to 85:15) to give acolorless oil. The resulting colorless oil was purified by reverse phasepreparative HPLC (0.1% aqueous formic acid solution-0.1% formic acidacetonitrile solution) to give a formate (3.6 mg) of (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoateas a colorless oil.

¹H-NMR (CD₃OD) δ: 8.14 (s, 1H), 8.16-7.99 (m, 1H), 7.42-7.13 (m, 10H),6.69-6.58 (m, 1H), 5.92-5.85 (m, 1H), 5.15 (s, 2H), 5.09-4.86 (m, 1H),4.45-4.17 (m, 3H), 4.09-3.94 (m, 1H), 3.61-3.48 (m, 1H), 1.41-1.30 (m,3H).

MS(ESI m/z): 579(M+H)

RT(min): 1.13

Example 1-2

Compounds of Table 1 and Table 2 were obtained in the same manner as inExample 1-1.

TABLE 1

MS (ESI m/z) RT R Compound name (M + H) (min)

Methyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(phenoxy)phosphoryl) amino)-2-methylpropanoate 8171.96

(2S)-isopropyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(phenoxy)phosphoryl) amino)propanoate 831 2.03

(2S)-ethyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(phenoxy)phosphoryl) amino)-3-methylbutanoate 8452.07

(2S)-ethyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(phenoxy)phosphoryl) amino)propanoate 817 1.96

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)- 4-fluorotetrahydrothiophen-2-yl)methoxy)(4-chlorophenoxy) phosphoryl)amino)propanoate 837 1.99

(2S)-ethyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)- 4-fluorotetrahydrothiophen-2-yl)methoxy)(naphthalen-1-yloxy) phosphoryl)amino)propanoate 867 2.06

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)- 4-fluorotetrahydrothiophen-2-yl)methoxy)(naphthalen-1-yloxy) phosphoryl)amino)propanoate 929 2.14

TABLE 2

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 1-2-1

Methyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2- yl)methoxy)(phenoxy)phosphoryl)amino)-2- methylpropanoate ¹H-NMR (CD₃OD) δ: 8.20 (s, 1H),8.13-8.03 (m, 1H), 7.42-7.13 (m, 6H), 6.72-6.59 (m, 1H), 5.93-5.85 (m,1H), 5.10-4.88 (m, 1H), 4.49-4.26 (m, 3H), 3.70 (s, 3H), 3.66-3.56 (m,1H), 1.54-1.43 (m, 6H). 517 0.89 1-2-2

(2S)-isopropyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2- yl)methoxy)(phenoxy)phosphoryl)amino)propanoate ¹H-NMR (CD₃OD) δ: 8.14-8.01 (m, 1H),7.43-7.30 (m, 2H), 7.30-7.13 (m, 3H), 6.74-6.57 (m, 1H), 5.92-5.84 (m,1H), 5.11-4.88 (m, 2H), 4.49-3.51 (m, 5H), 1.38-1.29 (m, 3H), 1.27-1.19(m, 6H). 531 1.02 1-2-3

(2S)-ethyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2- yl)methoxy)(phenoxy)phosphoryl)amino)-3- methylbutanoate ¹H-NMR (CD₃OD) δ: 8.13-8.02 (m,1H), 7.41-7.14 (m, 5H), 6.73-6.61 (m, 1H), 5.92-5.87 (m, 1H), 5.09-4.88(m, 1H), 4.47-3.52 (m, 7H), 2.13-1.96 (m, 1H), 1.34-1.19 (m, 3H),1.02-0.83 (m, 6H). 545 1.07 1-2-4

(2S)-ethyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2- yl)methoxy)(phenoxy)phosphoryl)amino)propanoate ¹H-NMR (CD₃OD) δ: 8.25-8.20 (m, 1H),8.14-8.03 (m, 1H), 7.42-7.31 (m, 2H), 7.29-7.16 (m, 3H), 6.73-6.58 (m,1H), 5.94-5.86 (m, 1H), 5.11-4.88 (m, 1H), 4.52-3.52 (m, 7H), 1.40-1.29(m, 3H), 1.28-1.20 (m, 3H). 517 0.92 1-2-5

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2- yl)methoxy)(4-chlorophenoxy)phosphoryl) amino)propanoate ¹H-NMR (CD₃OD) δ: 8.16-8.04(m, 2H), 7.42-7.33 (m, 2H), 7.29-7.17 (m, 2H), 6.75-6.57 (m, 1H),5.94-5.88 (m, 1H), 5.12-4.89 (m, 1H), 4.49-4.24 (m, 3H), 4.04-3.90 (m,1H), 3.69 (s, 3H), 3.56-3.55 (m, 1H), 1.41-1.30 (m, 3H). 537 0.96 1-2-6

(2S)-ethyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2-yl)methoxy)(naphthalen- 1-yloxy)phosphoryl)amino) propanoate ¹H-NMR(CD₃OD) δ: 8.27-7.30 (m, 9H), 6.71-6.67 (m, 1H), 5.89-5.81 (m, 1H),5.11-4.86 (m, 1H), 4.50-4.27 (m, 3H), 4.16-3.93 (m, 3H), 3.67-3.54 (m,1H), 1.32 (t, 3H, J = 6.3 Hz), 1.24-1.11 (m, 3H). 567 1.09 1-2-7

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2-yl)methoxy)(naphthalen- 1-yloxy)phosphoryl)amino) propanoate ¹H-NMR(CD₃OD) δ: 8.18-7.38 (m, 9H), 7.35-7.19 (m, 5H), 6.72-6.59 (m, 1H),5.91-5.75 (m, 1H), 5.16-4.84 (m, 3H), 4.47-4.25 (m, 3H), 4.11-4.06 (m,1H), 3.63-3.50 (m, 1H), 1.39-1.27 (m, 3H) 629 1.25

Example 2-1

First Step

(1) Triethylamine (553 μL) was added at −78° C. to a mixture of phenyldichlorophosphate (300 μL), L-phenylalanine benzyl ester hydrochloride(460 mg) and methylene chloride (10 mL) which was then stirred for 15minutes, followed by stirring at room temperature for 1 hour. Thesolvent was distilled off under reduced pressure. Diethyl ether wasadded to the resulting residue, and the insoluble matter was separatedby filtration. The solvent was distilled off under reduced pressure togive (2S)-ethyl2-(((RS)-chloro(phenoxy)phosphoryl)amino)-3-phenylpropanoate.

(2) Under a nitrogen atmosphere, a 1.0 mol/L tert-butyl magnesiumchloride/tetrahydrofuran (710 μL) solution was added dropwise at −78° C.to a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(80.0 mg) and tetrahydrofuran (2.0 mL) which was then stirred at roomtemperature for 10 minutes. A mixture of (2S)-ethyl2-(((RS)-chloro(phenoxy)phosphoryl)amino)-3-phenylpropanoate (150 mg)obtained in (1) and tetrahydrofuran (900 μL) was added to the reactionliquid which was then stirred at room temperature for 4 hours and 45minutes. An aqueous saturated ammonium chloride solution was added tothe reaction liquid which was then extracted with ethyl acetate anddried over anhydrous magnesium sulfate. The solvent was distilled offunder reduced pressure to give (2S)-ethyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)-3-phenylpropanoate.

MS(ESI m/z): 893(M+H)

RT(min): 2.09

Second Step

Trifluoroacetic acid (1.4 mL) was added under ice-cooling to a mixtureof (2S)-ethyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)-3-phenylpropanoateand methylene chloride (1.4 mL) which was then stirred at roomtemperature for 30 minutes. The solvent was distilled off under reducedpressure and the resulting residue was purified by reverse phasepreparative HPLC (0.1% aqueous formic acid solution-0.1% formic acidacetonitrile solution) to give a colorless oil. The resulting colorlessoil was purified by silica gel column chromatography (ethylacetate:methanol=100:0 to 85:15) to give (2S)-ethyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)-3-phenylpropanoate(2.3 mg) as a colorless oil.

¹H-NMR (CD₃OD) δ: 8.05-7.97 (m, 1H), 7.36-7.05 (m, 10H), 6.70-6.58 (m,1H), 5.91-5.83 (m, 1H), 5.07-4.86 (m, 1H), 4.39-3.40 (m, 7H), 3.15-3.01(m, 1H), 2.93-2.80 (m, 1H), 1.22-1.13 (m, 3H).

MS(ESI m/z): 593(M+H)

RT(min): 1.14

Example 2-2

First Step

The following compound was obtained in the same manner as in the firststep of Example 2-1.

(2S)-ethyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)-4-methylpentanoate

MS(ESI m/z): 859(M+H)

RT(min): 2.12

Second Step

The following compound was obtained in the same manner as in the secondstep of Example 2-1.

(2S)-ethyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)-4-methylpentanoate

¹H-NMR (CD₃OD) δ: 8.18-8.01 (m, 1H), 7.41-7.14 (m, 5H), 6.74-6.59 (m,1H), 5.93-5.86 (m, 1H), 5.10-4.88 (m, 1H), 4.50-3.52 (m, 7H), 1.81-1.68(m, 1H), 1.59-1.45 (m, 2H), 1.27-1.19 (m, 3H), 0.96-0.77 (m, 6H).

MS(ESI m/z): 559(M+H)

RT(min): 1.15

Example 3-1

First Step

(1) Triethylamine (827 μL) was added at −78° C. to a mixture ofL-alanine benzyl ester hydrochloride (646 mg),(4-chlorophenyl)phosphoryl dichloride (500 μL) and methylene chloride(1.5 mL) which was then stirred for 5 minutes, followed by stirring atroom temperature for 70 minutes. Hexane was added to the reactionliquid, and the insoluble matter was separated by filtration. Thesolvent was distilled off under reduced pressure to give (2S)-benzyl2-(((RS)-chloro(4-chlorophenoxy)phosphoryl)amino)propanoate.

(2) Under a nitrogen atmosphere, a 1.0 mol/L tert-butyl magnesiumchloride/tetrahydrofuran solution (2.0 mL) was added dropwise at −78° C.to a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(448 mg) and tetrahydrofuran (10.6 mL) which was then stirred for 5minutes. A mixture of (2S)-benzyl2-(((RS)-chloro(4-chlorophenoxy)phosphoryl)amino)propanoate obtained in(1) and tetrahydrofuran (5.3 mL) was added at −78° C. to the reactionliquid which was then stirred at room temperature for 30 minutes. Anaqueous saturated ammonium chloride solution was added to the reactionliquid which was then extracted with ethyl acetate and dried overanhydrous magnesium sulfate. The solvent was distilled off under reducedpressure and the resulting residue was purified by silica gel columnchromatography (hexane:ethyl acetate=80:20 to 0:100) to give (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(4-chlorophenoxy)phosphoryl)amino)propanoate(539 mg) as a yellow solid.

MS(ESI m/z): 913(M+H)

RT(min): 2.13

Second Step

Trifluoroacetic acid (1.5 mL) was added to a mixture of (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(4-chlorophenoxy)phosphoryl)amino)propanoate(514 mg) and methylene chloride (1.5 mL) which was then stirred at roomtemperature for 40 minutes. The solvent was distilled off under reducedpressure and the resulting residue was purified by basic silica gelcolumn chromatography (ethyl acetate:methanol=100:0 to 50:50) to give(2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(4-chlorophenoxy)phosphoryl)amino)propanoate(135 mg) as a white solid.

¹H-NMR (CD₃OD) δ: 8.08-8.00 (m, 1H), 7.38-7.13 (m, 9H), 6.71-6.59 (m,1H), 5.91-5.83 (m, 1H), 5.16-4.84 (m, 3H), 4.45-4.16 (m, 3H), 4.09-3.93(m, 1H), 3.62-3.47 (m, 1H), 1.40-1.34 (m, 3H).

MS(ESI m/z): 613(M+H)

RT(min): 1.23

Example 3-2

First Step

The following compound was obtained in the same manner as in the firststep of Example 3-1.

(2S)-methyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate

MS(ESI m/z): 803(M+H)

RT(min): 1.89

Second Step

The following compound was obtained in the same manner as in the secondstep of Example 3-1.

(2S)-methyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate

¹H-NMR (CD₃OD) δ: 8.15-8.05 (m, 1H), 7.42-7.16 (m, 5H), 6.73-6.61 (m,1H), 5.95-5.87 (m, 1H), 5.12-4.83 (m, 1H), 4.50-4.23 (m, 3H), 4.05-3.91(m, 1H), 3.72-3.53 (m, 4H), 1.40-1.29 (m, 3H).

MS(ESI m/z): 503(M+H)

RT(min): 0.87

Example 4-1

First Step

(1) Phenyl dichlorophosphate (153 μL) and triethylamine (143 μL) wereadded at −78° C. to a mixture of L-alanine cyclobutyl ester (148 mg) andmethylene chloride (1.5 mL) which was then stirred at room temperaturefor 1 hour. The solvent was distilled off under reduced pressure.Diethyl ether was added to the resulting residue and the insolublematter was separated by filtration. The solvent was distilled off underreduced pressure to give (2S)-cyclobutyl2-(((RS)-chloro(phenoxy)phosphoryl)amino)propanoate.

(2) Under a nitrogen atmosphere, a 1.0 mol/L tert-butyl magnesiumchloride/tetrahydrofuran solution (500 μL) was added dropwise at −78° C.to a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(100 mg) and tetrahydrofuran (2.0 mL) which was then stirred for 30minutes. A mixture of (2S)-cyclobutyl2-(((RS)-chloro(phenoxy)phosphoryl)amino)propanoate obtained in (1) andtetrahydrofuran (2.0 mL) was added at −78° C. to the reaction liquidwhich was then stirred at room temperature for 16 hours. Water was addedto the reaction liquid which was then extracted with ethyl acetate anddried over anhydrous sodium sulfate. The solvent was distilled off underreduced pressure and the resulting residue was purified by silica gelcolumn chromatography (hexane:ethyl acetate=100:0 to 70:30) to give(2S)-cyclobutyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate(33.7 mg) as a colorless oil.

MS(ESI m/z): 843(M+H)

RT(min): 1.76

Second Step

Trifluoroacetic acid (1.0 mL) was added to a mixture of (2S)-cyclobutyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate(33.7 mg) and methylene chloride (1.0 mL) which was then stirred at roomtemperature for 2.5 hours. The solvent was distilled off under reducedpressure. Methylene chloride (2.0 mL) and triethylamine (1.0 mL) wereadded to the resulting residue, and the solvent was distilled off underreduced pressure. The resulting residue was purified by basic silica gelcolumn chromatography (ethyl acetate:methanol=100:0 to 80:20) to give(2S)-cyclobutyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate(11.3 mg) as a white solid.

¹H-NMR(CD₃OD) δ: 8.13-8.00 (m, 1H), 7.42-7.32 (m, 2H), 7.29-7.15 (m,3H), 6.72-6.60 (m, 1H), 5.93-5.84 (m, 1H), 5.11-4.89 (m, 2H), 4.49-4.21(m, 3H), 3.99-3.86 (m, 1H), 3.66-3.51 (m, 1H), 2.39-2.24 (m, 2H),2.15-1.97 (m, 2H), 1.86-1.71 (m, 1H), 1.70-1.58 (m, 1H), 1.39-1.27 (m,3H).

MS(ESI m/z): 543(M+H)

RT(min): 1.09

Example 4-2

First Step

The following compound was obtained in the same manner as in the firststep of Example 4-1.

(2S)-cyclohexyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate

MS(ESI m/z): 871(M+H)

RT(min): 1.72

Second Step

The following compound was obtained in the same manner as in the secondstep of Example 4-1.

(2S)-cyclohexyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate

¹H-NMR (CD₃OD) δ: 8.12-8.02 (m, 1H), 7.41-7.32 (m, 2H), 7.28-7.15 (m,3H), 6.72-6.60 (m, 1H), 5.92-5.85 (m, 1H), 5.10-4.90 (m, 1H), 4.81-4.66(m, 1H), 4.49-4.23 (m, 3H), 3.99-3.86 (m, 1H), 3.65-3.50 (m, 1H),1.88-1.66 (m, 4H), 1.58-1.23 (m, 9H).

MS(ESI m/z): 571(M+H)

RT(min): 1.27

Example 5-1

First Step

(1) 4-iodophenol (330 mg) and triethylamine (207 μL) were added at −78°C. to a mixture of phosphorus oxychloride (139 μL) and methylenechloride (15 mL) which was then stirred for 5 minutes. The reactionliquid was stirred at room temperature for 10 minutes, and L-alaninebenzyl ester hydrochloride (324 mg) and triethylamine (415 μL) wereadded thereto at −78° C., followed by stirring for 5 minutes. Afterstirring at room temperature for 30 minutes, hexane was added to thereaction liquid and the insoluble matter was separated by filtration.The solvent was distilled off under reduced pressure to give (2S)-benzyl2-(((RS)-chloro(4-iodophenoxy)phosphoryl)amino)propanoate

(2) Under a nitrogen atmosphere, a 1.0 mol/L tert-butyl magnesiumchloride/tetrahydrofuran solution (833 μL) was added dropwise at −78° C.to a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(185 mg) and tetrahydrofuran (4.5 mL) which was then stirred for 5minutes. A mixture of (2S)-benzyl2-(((RS)-chloro(4-iodophenoxy)phosphoryl)amino)propanoate obtained in(1) and tetrahydrofuran (2.2 mL) was added at −78° C. to the reactionliquid which was then stirred at room temperature for 30 minutes. Anaqueous saturated ammonium chloride solution was added to the reactionliquid which was then extracted with ethyl acetate and dried overanhydrous magnesium sulfate. The solvent was distilled off under reducedpressure and the resulting residue was purified by silica gel columnchromatography (hexane:ethyl acetate=80:20 to 0:100) to give (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(4-iodophenoxy)phosphoryl)amino)propanoate(123 mg) as a colorless oil.

MS(ESI m/z): 1005(M+H)

RT(min): 2.14

Second Step

Trifluoroacetic acid (1.0 mL) was added to a mixture of (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(4-iodophenoxy)phosphoryl)amino)propanoate(123 mg) and methylene chloride (1.0 mL) which was then stirred at roomtemperature for 30 minutes. The solvent was distilled off under reducedpressure and the resulting residue was purified by basic silica gelcolumn chromatography (ethyl acetate:methanol=100:0 to 50:50) to give(2S)-benzyl2-(((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(4-iodophenoxy)phosphoryl)amino)propanoate(68.0 mg) as a white solid.

¹H-NMR (CD₃OD) δ: 8.11-7.99 (m, 1H), 7.89-7.79 (m, 1H), 7.50-7.24 (m,7H), 6.99-6.88 (m, 1H), 6.73-6.58 (m, 1H), 5.94-5.83 (m, 1H), 5.21-4.83(m, 3H), 4.50-4.02 (m, 4H), 3.70-3.48 (m, 1H), 1.46-1.31 (m, 3H).

MS(ESI m/z): 705(M+H)

RT(min): 1.26

Example 5-2

Compounds of Table 3, Table 4-1 and Table 4-2 were obtained in the samemanner as in Example 5-1.

TABLE 3

MS (ESI m/z) RT R Compound name (M + H) (min)

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(4-fluorophenoxy)phosphoryl)amino) propanoate 897 2.06

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(4-fluorophenoxy)phosphoryl)amino) propanoate 821 1.91

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy) (4-bromophenoxy)phosphoryl)amino)propanoate 959 2.27

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetra-hydrothiophen-2-yl)methoxy)(4-methoxy-phenoxy)phosphoryl)amino)propanoate 909 2.04

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetra-hydrothiophen-2-yl)methoxy)(4-methoxy-phenoxy)phosphoryl)amino)propanoate 833 1.88

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetra-hydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)-4-methylpentanoate 921 2.19

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(4-bromo- phenoxy)phosphoryl)amino)propanoate 8832.00

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(4-iodo- phenoxy)phosphoryl)amino)propanoate 9291.99

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(p-tolyloxy) phosphoryl)amino)propanoate 893 2.11

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(p-tolyloxy) phosphoryl)amino)propanoate 817 1.95

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(phenoxy)phosphoryl) amino)-4-methylpentanoate 8452.06

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(phenoxy)phosphoryl) amino)-3-methylbutanoate 9072.15

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(phenoxy)phosphoryl) amino)-3-methylbutanoate 8312.00

TABLE 4-1

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 5-2-1

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2-yl)methoxy)(4-fluorophenoxy) phosphoryl)amino)propanoate ¹H-NMR (CD₃OD)δ: 8.09-8.00 (m, 1H), 7.37-7.01 (m, 9H), 6.71-6.58 (m, 1H), 5.92-5.84(m, 1H), 5.18-4.88 (m, 3H), 4.45-4.17 (m, 3H), 4.07-3.92 (m, 1H),3.60-3.50 (m, 1H), 1.41-1.30 (m, 3H). 597 1.16 5-2-2

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2-yl)methoxy)(4-fluorophenoxy) phosphoryl)amino)propanoate ¹H-NMR (CD₃OD)δ: 8.14-8.02 (m, 1H), 7.30-7.03 (m, 4H), 6.72-6.58 (m, 1H), 5.94-5.85(m, 1H), 5.12-4.89 (m, 1H), 4.50-4.20 (m, 3H), 4.04-3.91 (m, 1H),3.73-3.53 (m, 4H), 1.40-1.29 (m, 3H). 521 0.88 5-2-3

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2-yl)methoxy)(4-bromophenoxy) phosphoryl)amino)propanoate ¹H-NMR (CD₃OD)δ: 8.09-7.98 (m, 1H), 7.62-7.07 (m, 9H), 6.72-6.59 (m, 1H), 5.94-5.84(m, 1H), 5.18-4.84 (m, 3H), 4.48-4.18 (m, 3H), 4.09-3.95 (m, 1H),3.63-3.51 (m, 1H), 1.41-1.31 (m, 3H). 659 1.23 5-2-4

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2-yl)methoxy)(4-bromophenoxy) phosphoryl)amino)propanoate ¹H-NMR (CD₃OD)δ: 8.12-8.04 (m, 1H), 7.56-7.49 (m, 2H), 7.22-7.14 (m, 2H), 6.73-6.61(m, 1H), 5.94-5.87 (m, 1H), 6.11-4.89 (m, 1H), 4.50-4.22 (m, 3H),4.14-3.90 (m, 1H), 3.71-3.52 (m, 4H), 1.39-1.31 (m, 3H). 583 0.99 5-2-5

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2-yl)methoxy)(4-iodophenoxy) phosphoryl)amino)propanoate ¹H-NMR (CD₃OD) δ:8.16-8.04 (m, 1H), 7.91-7.81 (m, 1H), 7.68-7.11 (m, 2H), 7.00-6.91 (m,1H), 6.72-6.59 (m, 1H), 6.10-5.90 (m, 1H), 5.12-4.89 (m, 1H), 4.64-4.29(m, 3H), 4.18-3.98 (m, 1H), 3.73-3.56 (m, 4H), 1.44-1.31 (m, 3H). 6290.98 5-2-6

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydrothiophen-2-yl)methoxy)(p-tolyloxy) phosphoryl)amino)propanoate ¹H-NMR (CD₃OD)) δ:8.31-8.19 (m, 1H), 7.42-7.03 (m, 9H), 6.63-6.51 (m, 1H), 6.04-5.96 (m,1H), 5.17-4.89 (m, 3H), 4.45-3.93 (m, 4H), 3.61-3.50 (m, 1H), 2.30 (s,3H), 1.55-1.29 (m, 3H). 593 1.23

TABLE 4-2

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 5-2-7

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(p-tolyloxy)phosphoryl)amino) propanoate ¹H-NMR (CD₃OD) δ: 8.14-8.04 (m,1H), 7.21-7.06 (m, 4H), 6.72-6.60 (m, 1H), 5.92-5.86 (m, 1H), 5.11-4.89(m, 1H), 4.49-4.22 (m, 3H), 4.02-3.90 (m, 1H), 3.69 (s, 3H), 3.66-3.51(m, 1H), 2.31 (s, 3H), 1.39-1.28 (m, 3H). 517 0.97 5-2-8

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(4-methoxy-phenoxy)phosphoryl)amino) propanoate ¹H-NMR (CD₃OD) δ: 8.10-7.99 (m,1H), 7.39-7.26 (m, 5H), 7.16-7.07 (m, 2H), 6.90-6.83 (m, 2H), 6.70-6.58(m, 1H), 5.91-5.82 (m, 1H), 5.17-4.87 (m, 3H), 4.45-4.15 (m, 3H),4.07-3.92 (m, 1H), 3.75 (s, 3H), 3.60-3.47 (m, 1H), 1.40-1.29 (m, 3H).609 1.18 5-2-9

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(4-methoxy-phenoxy)phosphoryl)amino) propanoate ¹H-NMR (CD₃OD) δ: 8.16-8.04 (m,1H), 7.21-7.08 (m, 2H), 6.94-6.84 (m, 2H), 6.72-6.59 (m, 1H), 5.93-5.86(m, 1H), 5.11-4.89 (m, 1H), 4.50-4.19 (m, 3H), 4.03-3.87 (m, 1H), 3.77(s, 3H), 3.71-3.67 (m, 3H), 3.65-3.52 (m, 1H), 1.39-1.29 (m, 3H). 5330.89 5-2-10

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)-4- methylpentanoate ¹H-NMR (CD₃OD) δ: 8.10-7.99 (m,1H), 7.39-7.13 (m, 10H), 6.71-6.59 (m, 1H), 5.92-5.82 (m, 1H), 5.15-4.83(m, 3H), 4.44-4.15 (m, 3H), 3.99-3.84 (m, 1H), 3.61-3.47 (m, 1H),1.79-1.62 (m, 1H), 1.58-1.44 (m, 2H), 0.95-0.72 (m, 6H). 621 1.33 5-2-11

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)-4- methylpentanoate ¹H-NMR (CD₃OD) δ: 8.15-8.02 (m,1H), 7.42-7.14 (m, 6H), 6.73-6.59 (m, 1H), 5.94-5.85 (m, 1H), 5.08-4.86(m, 1H), 4.49-4.21 (m, 3H), 3.95-3.83 (m, 1H), 3.70-3.51 (m, 4H),1.80-1.44 (m, 3H), 1.02-0.75 (m, 6H). 545 1.10 5-2-12

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)-3- methylbutanoate ¹H-NMR (CD₃OD) δ: 8.07-8.02 (m,1H), 7.40-7.12 (m, 10H), 6.71-6.58 (m, 1H), 5.90-5.83 (m, 1H), 5.16-4.82(m, 3H), 4.44-4.16 (m, 3H), 3.78-3.64 (m, 1H), 3.60-3.48 (m, 1H),2.12-1.95 (m, 1H), 0.96-0.78 (m, 6H). 607 1.28 5-2-13

(2S)-methyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)-3- methylbutanoate ¹H-NMR (CD₃OD) δ: 8.11-8.03 (m,1H), 7.41-7.15 (m, 5H), 6.73-6.60 (m, 1H), 5.93-5.83 (m, 1H), 5.09-4.82(m, 1H), 4.48-4.21 (m, 2H), 4.37-4.01 (m, 3H), 3.75-3.51 (m, 3H),2.11-1.94 (m, 1H), 1.00-0.82 (m, 6H). 531 1.02

Example 6-1

First Step

(1) Under a nitrogen atmosphere, 4-chloro-3-fluorophenol (146 mg) andtriethylamine (150 μL) were added at −78° C. to a mixture of phosphorusoxychloride (96 μL) and methylene chloride (2.0 mL) which was thenstirred for 1 hour. L-alanine benzyl ester hydrochloride (226 mg) andtriethylamine (300 μL) were added at −78° C. to the reaction liquidwhich was then stirred at room temperature for 1.5 hours. The solventwas distilled off under reduced pressure. Diethyl ether was added to theresulting residue and the insoluble matter was separated by filtration.The solvent was distilled off under reduced pressure to give (2S)-benzyl2-(((RS)-chloro(4-chloro-3-fluorophenoxy)phosphoryl)amino)propanoate.

(2) Under a nitrogen atmosphere, a 1.0 mol/L tert-butyl magnesiumchloride/tetrahydrofuran solution (500 μL) was added dropwise at −78° C.to a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(100 mg) and tetrahydrofuran (2.0 mL) which was then stirred for 30minutes. A mixture of (2S)-benzyl2-(((RS)-chloro(4-chloro-3-fluorophenoxy)phosphoryl)amino)propanoateobtained in (1) and tetrahydrofuran (2.0 mL) was added at −78° C. to thereaction liquid which was then stirred at room temperature for 12 hours.Water was added to the reaction liquid which was then extracted withethyl acetate, washed with an aqueous saturated sodium chloride solutionand then dried over anhydrous sodium sulfate. The solvent was distilledoff under reduced pressure and the resulting residue was purified bysilica gel column chromatography (hexane:ethyl acetate=100:0 to 70:30)to give (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(4-chloro-3-fluorophenoxy)phosphoryl)amino)propanoate(79.7 mg) as a colorless oil.

MS(ESI m/z): 931(M+H)

RT(min): 2.14

Second Step

Trifluoroacetic acid (1.0 mL) was added to a mixture of (25)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(4-chloro-3-fluorophenoxy)phosphoryl)amino)propanoate(79.7 mg) and methylene chloride (1.0 mL) which was then stirred at roomtemperature for 2.5 hours. The solvent was distilled off under reducedpressure. Methylene chloride (2.0 mL) and triethylamine (1.0 mL) wereadded to the resulting residue, and the solvent was distilled off underreduced pressure. The resulting residue was purified by basic silica gelcolumn chromatography (ethyl acetate:methanol=100:0 to 80:20) to give(2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(4-chloro-3-fluorophenoxy)phosphoryl)amino)propanoate(23.2 mg) as a white solid.

¹H-NMR(CD₃OD) δ: 8.09-7.99 (m, 1H), 7.48-7.40 (m, 114), 7.39-7.29 (m,5H), 7.23-7.12 (m, 1H), 7.10-7.01 (m, 1H), 6.71-6.61 (m, 1H), 5.92-5.86(m, 1H), 5.19-5.04 (m, 3H), 4.45-4.19 (m, 3H), 4.14-3.97 (m, 1H),3.63-3.51 (m, 1H), 1.43-1.34 (m, 3H).

MS(ESI m/z): 631(M+H)

RT(min): 1.32, 1.33

Example 6-2

Compounds of Table 5 and Table 6 were obtained in the same manner as inExample 6-1.

TABLE 5

MS (ESI m/z) RT R Compound name (M + H) (min)

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(3,4-dichlorophenoxy) phosphoryl)amino)propanoate947 2.20

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(2,4-difluorophenoxy) phosphoryl)amino)propanoate915 2.07

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(2-chloro-4-fluorophenoxy)phosphoryl)amino)propanoate 931 2.12

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxy-carbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydro-thiophen-2-yl)methoxy)(2,4-dichloro- phenoxy)phosphoryl)amino)propanoate947 2.20

TABLE 6

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 6-2-1

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(3,4-dichlorophenoxy)phosphoryl) amino)propanoate ¹H-NMR (CD₃OD) δ: 8.09-7.99(m, 1H), 7.52-7.41 (m, 2H), 7.39-7.29 (m, 5H), 7.21-7.12 (m, 1H),6.72-6.61 (m, 1H), 5.92-5.86 (m, 1H), 5.20-5.02 (m, 3H), 4.45-4.19 (m,3H), 4.10-3.96 (m, 1H), 3.62-3.53 (m, 1H), 1.43-1.34 (m, 3H). 647 1.381.39 6-2-2

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(2,4-difluorophenoxy)phosphoryl) amino)propanoate ¹H-NMR (CD₃OD) δ: 8.09-8.00(m, 1H), 7.46-7.27 (m, 6H), 7.14-7.04 (m, 1H), 6.97-6.85 (m, 1H),6.71-6.60 (m, 1H), 5.93-5.85 (m, 1H), 5.19-5.01 (m, 3H), 4.45-4.19 (m,3H), 4.10-3.97 (m, 1H), 3.73-3.51 (m, 1H), 1.44-1.35 (m, 3H). 615 1.231.25 6-2-3

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(2-chloro-4-fluorophenoxy)phosphoryl) amino)propanoate ¹H-NMR (CD₃OD) δ: 8.12-7.99(m, 1H), 7.51-7.42 (m, 1H), 7.40-7.23 (m, 6H), 7.12-6.97 (m, 1H),6.72-6.59 (m, 1H), 5.94-5.85 (m, 1H), 5.20-5.00 (m, 3H), 4.49-4.19 (m,3H), 4.15-4.01 (m, 1H), 3.74-3.51 (m, 1H), 1.43-1.36 (m, 3H). 631 1.281.31 6-2-4

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(2,4-dichlorophenoxy)phosphoryl) amino)propanoate ¹H-NMR (CD₃OD) δ: 8.06-7.98(m, 1H), 7.55-7.42 (m, 2H), 7.39-7.24 (m, 6H), 6.72-6.50 (m, 1H),5.91-5.85 (m, 1H), 5.19-5.00 (m, 3H), 4.46-4.18 (m, 3H), 4.14-4.03 (m,1H), 3.73-3.53 (m, 1H), 1.43-1.37 (m, 9H). 647 1.37 1.40

Example 6-3

First Step

The following compound was obtained in the same manner as in the firststep of Example 6-1.

(2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(tert-butoxycarbonylamino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(pyridin-3-yloxy)phosphoryl)amino)propanoate

MS(ESI m/z): 780(M+H)

RT(min): 1.59

Second Step

The following compound was obtained in the same manner as in the secondstep of Example 6-1.

(2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(pyridin-3-yloxy)phosphoryl)amino)propanoate

MS(ESI m/z): 580(M+H)

RT(min): 0.93

Example 7-1

First Step

Under a nitrogen atmosphere, triethylamine (620 μL) was added at −78° C.to a mixture of phosphorus oxychloride (84 μL) and methylene chloride(2.2 mL), and then a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(500 mg) and methylene chloride (2.2 mL) was added thereto, followed bystirring for 1 hour. A mixture of L-alanine benzyl ester hydrochloride(192 mg) and methylene chloride (0.9 mL) was added to the reactionliquid which was then stirred at room temperature for 30 minutes. Water(0.5 mL) was added thereto, followed by stirring for 1.5 hours andextraction with ethyl acetate. The organic layer was washed with anaqueous saturated sodium chloride solution and dried over anhydroussodium sulfate, and then the solvent was distilled off under reducedpressure. The resulting residue was purified by silica gel columnchromatography (chloroform:methanol=95:5 to 70:30) to give (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoate(308 mg) as a yellow solid.

MS(ESI m/z): 803(M+H)

RT(min): 1.70

Second Step

Chloromethyl isopropyl carbonate (10 μL) was added to a mixture of(2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoate(20.0 mg), N,N-diisopropylethylamine (17 μL) and N,N-dimethylformamide(1.0 mL) which was then stirred at 80° C. for 5 hours. Water was addedat room temperature to the reaction liquid which was then extracted withisopropyl acetate. The organic layer was washed with water and anaqueous saturated sodium chloride solution and dried over anhydroussodium sulfate, and then the solvent was distilled off under reducedpressure. Methylene chloride (0.5 mL) and trifluoroacetic acid (0.5 mL)were added to the resulting residue which was then stirred at roomtemperature for 1.5 hours. The solvent was distilled off under reducedpressure. Triethylamine (2.0 mL) was added to the resulting residue, andthe solvent was distilled off under reduced pressure. The resultingresidue was purified by silica gel column chromatography(chloroform:methanol=95:5 to 88:12) to give (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(((isopropoxycarbonyl)oxy)methoxy)phosphoryl)amino)propanoate(6.0 mg) as a white solid.

¹H-NMR(CD₃OD) δ: 8.11-8.02 (m, 1H), 7.41-7.27 (m, 5H), 6.72-6.58 (m,1H), 5.92 (d, 1H, J=7.9 Hz), 5.64-5.51 (m, 2H), 5.18 (s, 2H), 5.10-4.88(m, 1H), 4.47-4.36 (m, 1H), 4.34-4.11 (m, 2H), 4.05-3.89 (m, 1H),3.70-3.42 (m, 2H), 1.41 (d, 3H, J=7.3 Hz), 1.28 (d, 6H, J=6.6 Hz).

MS(ESI m/z): 619(M+H)

RT(min): 1.17

Example 7-2

First Step

The following compound was obtained in the same manner as in the firststep of Example 7-1.

(2S)-isopropyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoate

MS(ESI m/z): 755(M+H)

RT(min): 1.61

Second Step

The following compound was obtained in the same manner as in the secondstep of Example 7-1.

(2S)-isopropyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(((isopropoxycarbonyl)oxy)methoxy)phosphoryl)amino)propanoate

¹H-NMR(CD₃OD) δ: 8.14-8.01 (m, 1H), 6.74-6.58 (m, 1H), 5.97-5.88 (m,1H), 5.69-5.54 (m, 2H), 5.11-4.78 (m, 3H), 4.50-4.40 (m, 1H), 4.38-4.15(m, 2H), 3.94-3.77 (m, 1H), 3.65-3.50 (m, 1H), 1.44-1.34 (m, 3H),1.33-1.16 (m, 12H).

MS(ESI m/z): 571(M+H)

RT(min): 1.05

Example 7-3

Compounds of Table 7 were obtained in the same manner as in the secondstep of Example 7-1.

TABLE 7

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 7-3-1

(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(((S)-1-isopropoxy-1-oxopropan-2- yl)amino)phosphoryl)oxy) methyl pivalate¹H-NMR (CD₃OD) δ: 8.12-8.03 (m, 1H), 6.74-6.60 (m, 1H), 5.97-5.88 (m,1H), 5.70-5.55 (m, 2H), 5.10-4.85 (m, 2H), 4.50-4.39 (m, 1H), 4.38-4.13(m, 2H), 3.93-3.78 (m, 1H), 3.66-3.49 (m, 1H), 1.39 (d, 3H, J = 7.3 Hz),1.34-1.14 (m, 15H). 569 1.10 7-3-2

(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(((S)-1-(benzyloxy)-1-oxopropan-2- yl)amino)phosphoryl)oxy) methyl pivalate¹H-NMR (CD₃OD) δ: 8.10-7.99 (m, 1H), 7.42-7.22 (m, 5H), 6.66 (dd, 1H, J= 18.8, 3.6 Hz), 5.92 (dd, 1H, J = 7.3, 2.0 Hz), 5.65-5.52 (m, 2H), 6.19(s, 2H), 5.00-4.87 (m, 1H), 4.46-4.38 (m, 1H), 4.34-4.09 (m, 2H),4.04-3.89 (m, 1H), 3.61-3.49 (m, 1H), 1.42 (d, 3H, J = 7.3 Hz), 1.22 (s,3H). 617 1.24 7-3-3

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(2-(pivaloylthio)ethoxy)phosphoryl) amino)propanoate ¹H-NMR (CD₃OD) δ:8.11-8.02 (m, 1H), 7.41-7.27 (m, 5H), 6.71-6.08 (m, 1H), 5.92 (d, 1H, J= 7.3 Hz), 5.21-5.11 (m, 2H), 5.09-4.89 (m, 1H), 4.49-4.36 (m, 1H),4.31-3.87 (m, 5H), 3.61-3.48 (m, 1H), 3.17-3.05 (m, 2H), 1.41 (d, 3H, J= 7.9 Hz), 1.25-1.19 (m, 9H). 647 1.34 7-3-4

(2S)-benzyl 2-(((RS)-(((2R,3S,4S,5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methoxy)(4-(pivaloylthio)butoxy)phosphoryl) amino)propanoate ¹H-NMR (CD₃OD) δ:8.11-8.02 (m, 1H), 7.41-7.27 (m, 5H), 6.65 (dd, 1H, J = 18.5, 4.6 Hz),5.91 (d, 1H, J = 7.3 Hz), 5.18 (s, 2H), 5.10-4.94 (m, 1H), 4.45-4.35 (m,1H), 4.30-3.88 (m, 5H), 3.60-3.49 (m, 1H), 2.91-2.79 (m, 2H), 1.79-1.53(m, 4H), 1.41 (d, 3H, J = 6.6 Hz), 1.20 (s, 9H). 675 1.45

Example 8

First Step

A mixture ofS,S′-((((diisopropylamino)phosphinediyl)bis(oxy))bis(ethane-2,1-diyl))bis(2,2-dimethylpropanethioate) (161 mg) and acetonitrile (0.5 mL) wasadded to a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(100 mg), 1H-tetrazole (49.9 mg) and acetonitrile (0.5 mL) which wasthen stirred at room temperature for 21.5 hours. meta-Chloroperbenzoicacid (88.0 mg) was added to the reaction liquid which was then stirredat room temperature for 30 minutes. An aqueous saturated sodium hydrogencarbonate solution (1.0 mL) and sodium sulfite (10.0 mg) were added tothe reaction liquid which was then stirred at room temperature for 0.5hours and extracted with ethyl acetate. The organic layer was washedwith an aqueous saturated sodium chloride solution and dried overanhydrous sodium sulfate. The solvent was distilled off under reducedpressure and the resulting residue was purified by silica gel columnchromatography (hexane:ethyl acetate=71:29 to 50:50) to give((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(S-pivaloyl-2-mercaptoethan-1-yl) phosphate (54.0 mg) as a colorlessoil.

MS(ESI m/z): 930(M+H)

RT(min): 2.26

Second Step

Trifluoroacetic acid (0.5 mL) was added to a mixture of((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(S-pivaloyl-2-mercaptoethan-1-yl) phosphate (25.0 mg) and methylenechloride (0.5 mL) which was then allowed to stand at room temperaturefor 1 hour. The solvent was distilled off under reduced pressure. Ethylacetate (1.0 mL) was added to the resulting residue which was thenstirred, and a 4.0 mol/L hydrogen chloride/1,4-dioxane solution (10 μL)was added thereto. Hexane (0.5 mL) was added to the reaction liquidwhich was then stirred for 1 hour. Thereafter, the precipitated solidwas collected by filtration to give a hydrochloride (12.0 mg) of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(S-pivaloyl-2-mercaptoethan-1-yl) phosphate as a white solid.

¹H-NMR (DMSO-d₆) δ: 9.36-9.15 (m, 1H), 8.39-8.25 (m, 1H), 8.19 (d, 1H,J=7.6 Hz), 6.42 (dd, 1H, J=16.2, 5.0 Hz), 6.32-6.17 (m, 1H), 6.09 (d,1H, J=7.6 Hz), 5.20-4.96 (m, 1H), 4.55-4.42 (m, 1H), 4.39-4.21 (m, 6H),3.68-2.96 (m, 5H), 1.16 (s, 18H).

MS(ESI m/z): 630(M+H)

RT(min): 1.32

Example 9-1

First Step

A mixture ofS,S′-((((diisopropylamino)phosphinediyl)bis(oxy))bis(ethane-2,1-diyl))bis(2-methylpropanethioate) (75.8 mg) and acetonitrile (0.4 mL) wasadded to a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(50.0 mg), 1H-tetrazole (24.9 mg) and acetonitrile (0.5 mL) which wasthen stirred at room temperature for 18 hours. A mixture of iodine (57.4mg), water (90 μL) and pyridine (0.9 mL) was added to the reactionliquid which was then stirred at room temperature for 1 hour. Sodiumsulfite (10.0 mg) was added to the reaction liquid which was thenstirred at room temperature for 0.5 hours and extracted with ethylacetate. The organic layer was washed with an aqueous saturated sodiumchloride solution and dried over anhydrous sodium sulfate. The solventwas distilled off under reduced pressure and the resulting residue waspurified by silica gel column chromatography (hexane:ethyl acetate=70:30to 50:50) to give((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(S-isobutyryl-2-mercaptoethan-1-yl) phosphate (63.3 mg) as acolorless oil.

MS(ESI m/z): 902(M+H)

RT(min): 2.14

Second Step

Trifluoroacetic acid (0.5 mL) was added to a mixture of((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(S-isobutyryl-2-mercaptoethan-1-yl) phosphate (61.3 mg) and methylenechloride (0.5 mL) which was then stirred at room temperature for 1 hour.The solvent was distilled off under reduced pressure. A 4.0 mol/Lhydrogen chloride/1,4-dioxane solution (26 μL) was added to a mixture ofthe resulting residue and ethyl acetate (1.0 mL) which was then stirredat room temperature for 30 minutes. Hexane (1.5 mL) was added to thereaction liquid which was then stirred for 1 hour, and the solvent wasdistilled off under reduced pressure. Ethyl acetate (1.0 mL) was addedto the resulting residue which was then stirred for 30 minutes.Thereafter, the precipitated solid was collected by filtration to give ahydrochloride (13.7 mg) of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(S-isobutyryl-2-mercaptoethan-1-yl) phosphate as a white solid.

MS(ESI m/z): 602(M+H)

RT(min): 1.21

Example 9-2

Compounds of Table 8 and Table 9 were obtained in the same manner as inExample 9-1.

TABLE 8

MS (ESI m/z) RT R Compound name (M + H) (min)

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl) methylbis(S-propionyl-2-mercaptoethan-1-yl) phosphate 874 2.01

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen- 2-yl)methylbis(isobutyryloxyethyl) phosphate 870 1.99

TABLE 9

MS Example (ESI m/z) RT No. Compound name ¹H-NMR (M + H) (min) 9-2-1

((2R,3S,4S,5R)-5-(4-amino-2- oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetra- hydrothiophen-2-yl)methylbis(S-propionyl-2-mercaptoethan- 1-yl) phosphate — 574 1.03 9-2-2

((2R,3S,4S,5R)-5-(4-amino-2- oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetra- hydrothiophen-2-yl)methylbis(isobutyryloxyethyl) phosphate ¹H-NMR (CD₃OD) δ: 8.30 (dd, 1H, J =7.6, 1.7 Hz), 6.61 (dd, 1H, J = 18.5, 4.6 Hz), 6.10 (d, 1H, J = 7.9 Hz),5.17-4.94 (m, 1H), 4.51-4.01 (m, 11H), 3.69-3.61 (m, 1H), 2.69-2.54 (m,2H), 1.17 (d, 12H, J = 7.3 Hz). 570 1.04

Example 10-1

First Step

(1) Under a nitrogen atmosphere, a mixture of S-(2-hydroxyethyl)2,2-dimethylpropanethioate (137 mg) and tetrahydrofuran (0.5 mL) wasadded under ice-cooling to a mixture of 2-cyanoethylN,N-diisopropylchlorophosphoramidite (200 mg), triethylamine (1.5 mL)and tetrahydrofuran (2.0 mL) which was then stirred at room temperaturefor 1.5 hours. The insoluble matter was separated by filtration, and thesolvent was distilled off under reduced pressure to giveS-(2-(((2-cyanoethoxy)(diisopropylamino)phosphino)oxy)ethyl)2,2-dimethylpropanethioate.

(2) 1H-tetrazole (118 mg) was added to a mixture ofS-(2-(((2-cyanoethoxy)(diisopropylamino)phosphino)oxy)ethyl)2,2-dimethylpropanethioate obtained in (1), tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(316 mg) and tetrahydrofuran (3.0 mL) which was then stirred at roomtemperature for 2 hours. A mixture of iodine (214 mg), water (0.1 mL)and pyridine (1.0 mL) was added to the reaction liquid which was thenstirred for 30 minutes. Sodium sulfite (213 mg) was added to thereaction liquid which was then extracted with ethyl acetate. The organiclayer was washed with an aqueous saturated sodium chloride solution anddried over anhydrous sodium sulfate. The solvent was distilled off underreduced pressure to giveS-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(2-cyanoethoxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate (593 mg).

MS(ESI m/z): 839(M+H)

RT(min): 2.05

Second Step

A mixture ofS-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(2-cyanoethoxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate (593 mg) and a 7.0 mol/L ammonia/methanolsolution (3.0 mL) was stirred at room temperature for 1 hour. Thesolvent was distilled off under reduced pressure to give an ammoniumsalt (459 mg) ofS-(2-(((((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate.

MS(ESI m/z): 786(M+H)

RT(min): 1.59

Third Step

A mixture of the ammonium salt (50.0 mg) ofS-(2-(((((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate, chloromethyl isopropyl carbonate (27 μL),N,N-diisopropylethylamine (43 μL) and N,N-dimethylformamide (0.5 mL) wasstirred at 80° C. for 2 hours. Water was added at room temperature tothe reaction liquid which was then extracted with ethyl acetate. Theorganic layer was washed with water and an aqueous saturated sodiumchloride solution and dried over anhydrous sodium sulfate. The solventwas distilled off under reduced pressure to give(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(2-(pivaloylthio)ethoxy)phosphoryl)oxy)methylpivalate.

MS(ESI m/z): 900(M+H)

RT(min): 2.21

Fourth Step

Trifluoroacetic acid (0.5 mL) was added to a mixture of(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(2-(pivaloylthio)ethoxy)phosphoryl)oxy)methylpivalate and methylene chloride (0.5 mL) which was then stirred at roomtemperature for 30 minutes. The solvent was distilled off under reducedpressure. Triethylamine (2.0 mL) was added to the resulting residue, andthe solvent was distilled off under reduced pressure. The resultingresidue was purified by silica gel column chromatography(chloroform:methanol=95:5 to 88:12) to give(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(2-(pivaloylthio)ethoxy)phosphoryl)oxy)methylpivalate (12.8 mg) as a colorless oil.

¹H-NMR (CDCl₃) δ: 8.06-7.95 (m, 1H), 6.76-6.60 (m, 1H), 6.10-5.98 (m,1H), 5.73-5.58 (m, 2H), 5.27-5.01 (m, 1H), 4.63-4.51 (m, 1H), 4.42-4.05(m, 4H), 3.75-3.64 (m, 1H), 3.21-3.03 (m, 3H), 1.23 (s, 18H).

MS(ESI m/z): 600(M+H)

RT(min): 1.35

Example 10-2

First Step

The following compound was obtained in the same manner as in the thirdstep of Example 10-1.

S-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(((isopropoxycarbonyl)oxy)methoxy)phosphoryl)oxy)ethyl) 2,2-dimethylpropanethioate

MS(ESI m/z): 902(M+H)

RT(min): 2.14

Second Step

The following compound was obtained in the same manner as in the fourthstep of Example 10-1.

S-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(((isopropoxycarbonyl)oxy)methoxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate

¹H-NMR (CDCl₃) δ: 8.03-7.92 (m, 1H), 6.85-6.72 (m, 1H), 5.99-5.89 (m,1H), 5.72-5.60 (m, 2H), 5.27-5.03 (m, 1H), 5.01-4.86 (m, 1H), 4.66-4.52(m, 1H), 4.42-4.07 (m, 4H), 3.75-3.64 (m, 1H), 3.21-3.08 (m, 2H), 1.32(d, 6H, J=6.6 Hz), 1.24 (s, 9H).

MS(ESI m/z): 602(M+H)

RT(min): 1.22

Example 11-1

First Step

Under a nitrogen atmosphere, triethylamine (620 μL) was added at −78° C.to a mixture of phosphorus oxychloride (84 μL) and methylene chloride(2.2 mL), and then a mixture of tert-butyl tert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(500 mg) and methylene chloride (2.2 mL) was added thereto, followed bystirring for 1 hour. Water (0.5 mL) was added to the reaction liquidwhich was then stirred at room temperature for 1 hour and extracted withethyl acetate. The organic layer was dried over anhydrous sodium sulfateand then the solvent was distilled off under reduced pressure. Theresulting residue was purified by silica gel column chromatography(chloroform:methanol=95:5 to 70:30) to give((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methyldihydrogen phosphate (306 mg).

MS(ESI m/z): 642(M+H)

RT(min): 1.33

Second Step

A mixture of((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methyldihydrogen phosphate (100 mg), chloromethyl isopropyl carbonate (124μL), N,N-diisopropylethylamine (221 μL) and N,N-dimethylformamide (1.0mL) was stirred at 60° C. for 4.5 hours, followed by stirring at 80° C.for 3 hours. Water was added at room temperature to the reaction liquidwhich was then extracted with ethyl acetate. The organic layer waswashed with water and an aqueous saturated sodium chloride solution anddried over anhydrous sodium sulfate. The solvent was distilled off underreduced pressure. Trifluoroacetic acid (0.5 mL) was added to a mixtureof the resulting residue and methylene chloride (0.5 mL) which was thenstirred at room temperature for 1 hour. The solvent was distilled offunder reduced pressure. Triethylamine (2.0 mL) was added to theresulting residue, and the solvent was distilled off under reducedpressure. The resulting residue was purified by silica gel columnchromatography (chloroform:methanol=100:0 to 70:30) to give(((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)oxy)methylisopropyl carbonate (2.8 mg) and((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(isopropyloxycarbonyloxymethyl) phosphate (1.8 mg) as a colorlessoil.

Example 11-1-1(((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)oxy)methylisopropyl carbonate

¹H-NMR (CD₃OD) δ: 8.31-8.23 (m, 1H), 6.62-6.52 (m, 1H), 5.99-5.92 (m,1H), 5.57-5.47 (m, 2H), 5.09-4.89 (m, 1H), 4.51-4.38 (m, 1H), 4.15-4.05(m, 2H), 3.55-3.26 (m, 2H), 1.27 (d, 6H, J=5.9 Hz).

MS(ESI m/z): 458(M+H)

RT(min): 0.63

Example 11-1-2((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(isopropyloxycarbonyloxymethyl) phosphate

¹H-NMR (CDCl₃) δ: 8.00 (dd, 1H, J=7.6, 1.7 Hz), 6.84 (dd, 1H, J=21.8,4.0 Hz), 5.78 (d, 1H, J=7.6 Hz), 5.74-5.61 (m, 5H), 5.24-5.02 (m, 1H),5.01-4.87 (m, 2H), 4.66-4.58 (m, 1H), 4.39-4.28 (m, 2H), 3.72-3.59 (m,1H), 1.33 (d, 12H).

MS(ESI m/z): 574(M+H)

RT(min): 1.08

Example 11-2

Compounds of Table 10 were obtained in the same manner as in the secondstep of Example 11-1.

TABLE 10

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 11-2-1

(((((2R,3S,4S,5R)-5-(4-amino-2- oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2- yl)methoxy)(hydroxy)phosphoryl)oxy)methyl pivalate ¹H-NMR (CD₃OD) δ: 8.25 (dd, 1H, J = 7.3,1.3 Hz), 6.59 (dd, 1H, J = 14.5, 5.3 Hz), 5.97 (d, 1H, J = 7.3 Hz),5.61-5.48 (m, 2H), 5.10-4.88 (m, 1H), 4.50-4.38 (m, 1H), 4.18-4.07 (m,2H), 3.56-3.44 (m, 1H), 1.22 (s, 9H). 456 0.71 11-2-2

((2R,3S,4S,5R)-5-(4-amino-2- oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2- yl)methyl bis(pivaloyloxymethyl)phosphate ¹H-NMR (CDCl₂) δ: 8.00 (dd, 1H, J = 7.3, 2.0 Hz), 6.85 (dd,1H, J = 21.8, 4.0 Hz), 5.75-6.48 (m, 1H), 5.77 (d, 1H), J = 7.3 Hz),5.74-5.59 (m, 4H), 5.25-5.02 (m, 1H), 4.75 (d, 2H, J = 5.9 Hz), 4.65-4.56 (m, 1H), 4.35-4.25 (m, 2H), 3.69- 3.60 (m, 1H), 1.24 (s, 18H). 5701.17 11-2-3

((2R,3S,4S,5R)-5-(4-amino-2- oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2- yl)methyl bis(1-isopropyloxy-carbonyloxyethan-1-yl) phosphate ¹H-NMR (CD₃OD) δ: 8.15-8.08 (m, 1H),6.75-6.62 (m, 1H), 6.50-6.37 (m, 2H), 5.99 (d, 1H, J = 7.9 Hz),5.13-5.00 (m, 1H), 4.53-4.26 (m, 3H), 3.76-3.56 (m, 3H), 1.62-1.55 (m,6H), 1.41-1.27 (m, 12H). 602 1.20

Example 12-1

First Step

Under a nitrogen atmosphere, triethylamine (620 μL) was added at −78° C.to a mixture of phosphorus oxychloride (84 μL) and methylene chloride(2.2 mL), and then a mixture of tert-butyl tert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)-tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(500 mg) and methylene chloride (2.2 mL) was added thereto, followed bystirring for 1 hour. A mixture of 2,2′-disulfanediyldiethanol (685 mg)and methylene chloride (2.2 mL) was added at −78° C. to the reactionliquid which was then stirred for 1.5 hours, followed by stirring atroom temperature for 3 hours. Water was added to the reaction liquidwhich was then stirred for 2 hours and extracted with ethyl acetate. Theorganic layer was washed with an aqueous saturated sodium chloridesolution and dried over anhydrous sodium sulfate, and then the solventwas distilled off under reduced pressure. The resulting residue waspurified by silica gel column chromatography (chloroform:methanol=100:0to 70:30) to give((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(2-((2-hydroxyethyl)disulfanyl)ethyl) phosphate (218 mg) as a yellowsolid.

MS(ESI m/z): 914(M+H)

RT(min): 1.71

Second Step

Trifluoroacetic acid (0.5 mL) was added to a mixture of((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(2-((2-hydroxyethyl)disulfanyl)ethyl) phosphate (50.0 mg) andmethylene chloride (0.5 mL) which was then stirred at room temperaturefor 1 hour. The solvent was distilled off under reduced pressure.Triethylamine (2.0 mL) was added to the resulting residue, and thesolvent was distilled off under reduced pressure. The resulting residuewas purified by silica gel column chromatography(chloroform:methanol=90:10 to 70:30) to give((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(2-((2-hydroxyethyl)disulfanyl)ethyl) phosphate (2.6 mg) as acolorless oil.

¹H-NMR (CD₃OD) δ: 8.08 (dd, 1H, J=7.3, 2.0 Hz), 6.69 (dd, 1H, J=19.5,4.3 Hz), 5.94 (d, 1H, J=7.3 Hz), 5.12-4.89 (m, 1H), 4.51-4.26 (m, 7H),3.79 (t, 4H, J=6.3 Hz), 3.68-3.59 (m, 1H), 3.04 (t, 4H, J=6.3 Hz), 2.87(t, 4H, J=6.3 Hz).

MS(ESI m/z): 614(M+H)

RT(min): 0.80

Example 12-2

Compounds of Table 11 and Table 12 were obtained in the same manner asin Example 12-1.

TABLE 11

MS (ESI m/z) RT R Compound name (M + H) (min)

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methyl(2-((2-hydroxyethyl)disulfanyl)ethyl) hydrogen phosphate 778 1.33

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(S-pivaloyl-4-mercaptobutan-1-yl) phosphate 986 2.37

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(2-((2-methoxyethyl)disulfanyl)ethyl) phosphate 942 2.03

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(2-((2-(benzyloxy)ethyl)disulfanyl)ethyl) phosphate 1094  2.29

TABLE 12

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 12-2-1

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothio- phen-2-yl)methyl (2-((2-hydroxyethyl)disuIfanyl)ethyl) hydrogen phosphate ¹H-NMR (MeOD) δ: 8.33-8.26 (m, 1H),6.57 (dd, 1H, J = 13.2, 5.3 Hz), 5.99 (d, 1H, J = 7.3 Hz), 5.12-4.90 (m,1H), 4.49-4.38 (m, 1H), 4.21-4.04 (m, 4H), 3.79 (t, 2H, J = 6.6 Hz),3.52-3.44 (m, 1H), 2.98 (t, 2H), J = 6.6 Hz), 2.85 (t, 2H), J = 6.3 Hz).478 0.55 12-2-2

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methyl bis (S-pivaloyl-4-mercapto-butan-1-yl) phosphate ¹H-NMR (MeOD) δ: 9.08 (dd, 1H, J = 7.6, 2.0 Hz),5.68 (dd, 1H, J = 19.2, 4.6 Hz), 5.93 (d, 1H, J = 7.6 Hz), 5.11-4.89 (m,1H), 4.40-4.41 (m, 1H), 4.41- 4.21 (m, 2H), 4.19-4.08 (m, 4H), 3.68-3.56(m, 1H), 2.89 (t, 4H, J = 7.3 Hz), 1.85-1.62 (m, 8H), 1.21 (m, 18H). 6861.58 12-2-3

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methyl bis(2-((2-methoxyethyl)disulfanyl)ethyl) phosphate ¹H-NMR (MeOD) δ: 8.08 (dd, 1H, J = 7.9, 2.0Hz), 6.59 (dd, 1H, J = 19.8, 4.6 Hz), 5.93 (d, 1H, J = 7.9 Hz),5.12-4.90 (m, 1H), 4.51-4.25 (m, 1H), 3.78 (t, 4H, J = 6.6 Hz),3.17-3.60 (m, 1H), 3.35 (s, 6H), 3.03 (t, 4H, J = 6.3 Hz), 2.93 (t, 1H),J = 6.3 Hz). 642 1.10 12-2-4

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methyl bis(2-((2-benzyloxy)ethyl)disulfanyl)ethyl) phosphate ¹H-NMR (MeOD) δ: 8.05 (dd, 1H, J =7.0, 1.3 Hz), 7.38-7.21 (m, 10H), 5.08 (dd, 1H, J = 18.2, 4.6 Hz), 6.91(d, 1H, J = 7.9 Hz), 5.09-4.69 (m, 1H), 4.53 (m, 1H), 4.48-4.23 (m, 7H),3.73 (t, 4H, J = 5.9 Hz), 3.70-3.50 (m, 1H), 3.01-2.92 (m, 8H). 794 1.60

Example 13-1

First Step

Pivaloyl chloride (36 μL) was added under ice-cooling to a mixture of((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(2-((2-hydroxyethyl)disulfanyl)ethyl) phosphate (100 mg),triethylamine (68.7 μL) and tetrahydrofuran (1.0 mL) which was thenstirred at room temperature for 2.5 hours. Triethylamine (137 μL) andpivaloyl chloride (73 μL) were added under ice-cooling to the reactionliquid which was then stirred at room temperature for 5 hours, and anaqueous saturated sodium hydrogen carbonate solution was added thereto,followed by stirring for 30 minutes and extraction with ethyl acetate.The organic layer was washed with an aqueous saturated sodium chloridesolution and dried over anhydrous sodium sulfate, and then the solventwas distilled off under reduced pressure to give((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(2-((2-pivaloyloxyethyl)disulfanyl)ethyl) phosphate.

MS(ESI m/z): 1082(M+H)

RT(min): 2.33

Second Step

Trifluoroacetic acid (1.0 mL) was added to a mixture of((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(2-((2-pivaloyloxyethyl)disulfanyl)ethyl) phosphate obtained in thefirst step and methylene chloride (1.0 mL) which was then stirred atroom temperature for 1 hour. The solvent was distilled off under reducedpressure. Triethylamine (2.0 mL) was added to the resulting residue, andthe solvent was distilled off under reduced pressure. The resultingresidue was purified by silica gel column chromatography(chloroform:methanol=94:6 to 70:30) to give((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(2-((2-pivaloyloxyethyl)disulfanyl)ethyl) phosphate (1.7 mg) as acolorless oil.

¹H-NMR (CD₃OD) δ: 8.07 (dd, 1H, J=7.3, 2.0 Hz), 6.69 (dd, 1H, J=19.5,4.3 Hz), 5.93 (d, 1H, J=7.3 Hz), 5.11-4.90 (m, 1H), 4.51-4.26 (m, 11H),3.70-3.59 (m, 1H), 3.05 (t, 4H, J=5.9 Hz), 2.99 (t, 4H, J=6.3 Hz), 1.20(s, 18H).

MS(ESI m/z): 782(M+H)

RT(min): 1.67

Example 13-2

Compounds of Table 13 and Table 14 were obtained in the same manner asin Example 13-1.

TABLE 13

MS (ESI m/z) RT R Compound name (M + H) (min)

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(2-((2-isobutyroyloxyethyl)disulfanyl)ethyl) phosphate 1054 2.22

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylbis(2-((2-acetoxyethyl)disulfanyl)ethyl) phosphate  998 1.99

TABLE 14

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 13-2-1

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothio- phen-2-yl)methyl bis(2-((2-isobutyroyloxy-ethyl)disulfanyl)ethyl) phosphate ¹H-NMR (MeOD) δ: 8.07 (dd, 1H, J =7.9, 2.0 Hz), 6.59 (dd, 1H, J = 19.5, 4.3 Hz), 5.93 (d, 1H, J = 7.9 Hz),5.11-4.88 (m, 1H), 4.51-4.28 (m, 11H), 3.68- 3.60 (m, 1H), 3.06 (t, 4H,J = 6.3 Hz), 2.99 (t, 4H, J = 6.6 Hz), 2.56-2.49 (m, 2H), 1.16 (d, 12H,J = 7.3 Hz). 754 1.50 13-2-2

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methyl bis (2-((2-acetoxyethyl)disulfanyl)ethyl) phosphate ¹H-NMR (MeOD) δ: 8.09 (dd, 1H, J = 7.9, 2.0Hz), 6.69 (dd, 1H, J = 19.2, 4.6 Hz), 5.93 (d, 1H, J = 7.3 Hz),5.13-4.87 (m, 1H), 4.53-4.25 (m, 11H), 3.69- 3.59 (m, 1H), 3.05 (t, 4H,J = 6.3 Hz), 2.98 (t, 1H, J = 6.6 Hz), 2.05 (s, 6H). 698 1.15

Example 14-1

First Step

(1) Under a nitrogen atmosphere, a mixture of S-(2-hydroxyethyl)2,2-dimethylpropanethioate (57.8 mg) and methylene chloride (1.0 mL) wasadded under ice-cooling to a mixture of phenyl dichlorophosphate (58μL), triethylamine (99 μL) and methylene chloride (1.0 mL) which wasthen stirred for 2 hours under ice-cooling. The solvent was distilledoff under reduced pressure, methyl tert-butyl ether (5.0 mL) was added,and the insoluble matter was separated by filtration. The solvent wasdistilled off under reduced pressure to giveS-(2-(((RS)-chloro(phenoxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate.

(2) Under a nitrogen atmosphere, a 1.0 mol/L tert-butyl magnesiumchloride/tetrahydrofuran solution (214 μL) was added at −78° C. to amixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)-tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(100 mg) and tetrahydrofuran (1.0 mL) which was then stirred for 30minutes. A mixture ofS-(2-((chloro(phenoxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioateobtained in (1) and tetrahydrofuran (1.0 mL) was added to the reactionliquid which was then stirred at room temperature for 42 hours. Waterwas added to the reaction liquid which was then extracted with ethylacetate, and the organic layer was washed with an aqueous saturatedsodium chloride solution and dried over anhydrous sodium sulfate. Thesolvent was distilled off under reduced pressure to giveS-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)oxy)ethyl) 2,2-dimethylpropanethioate as a crude product.

MS(ESI m/z): 862(M+H)

RT(min): 2.18

Second Step

Trifluoroacetic acid (0.5 mL) was added to a mixture ofS-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)oxy)ethyl) 2,2-dimethylpropanethioate obtained in the first step andmethylene chloride (0.5 mL) which was then stirred at room temperaturefor 1 hour. The solvent was distilled off under reduced pressure. Anaqueous saturated sodium hydrogen carbonate solution was added to theresulting residue which was then extracted with ethyl acetate. Theorganic layer was washed with an aqueous saturated sodium chloridesolution and dried over anhydrous sodium sulfate, and the solvent wasdistilled off under reduced pressure. The resulting residue was purifiedby silica gel column chromatography (chloroform:methanol=100:0 to 70:30)to giveS-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate (1.7 mg) as a colorless oil.

¹H-NMR (CD₃OD) δ: 8.08-7.99 (m, 1H), 7.46-7.21 (m, 5H), 6.73-6.62 (m,1H), 5.89 (d, 1H, J=7.3 Hz), 5.37-5.04 (m, 1H), 4.55-4.32 (m, 3H),4.31-4.20 (m, 2H), 3.68-3.58 (m, 1H), 3.19 (t, 2H, J=6.3 Hz), 1.24-1.15(m, 9H).

MS(ESI m/z): 562(M+H)

RT(min): 1.28

Example 14-2

First Step

The following compound was obtained in the same manner as in the firststep of Example 14-1.

S-(4-(((RS)-(((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)oxy)butyl)2,2-dimethylpropanethioate

MS(ESI m/z): 890(M+H)

RT(min): 2.24

Second Step

The following compound was obtained in the same manner as in the secondstep of Example 14-1.

S-(4-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)oxy)butyl)2,2-dimethylpropanethioate

¹H-NMR(CD₃OD) δ: 8.08-7.99 (m, 1H), 7.46-7.19 (m, 5H), 6.73-6.61 (m,1H), 5.89 (d, 1H, J=7.9 Hz), 5.10-4.96 (m, 1H), 4.53-4.31 (m, 3H),4.29-4.19 (m, 2H), 3.68-3.58 (m, 1H), 2.86 (t, 2H, J=6.9 Hz), 1.84-1.55(m, 4H), 1.21 (s, 9H).

MS(ESI m/z): 590(M+H)

RT(min): 1.38

Example 15-1

Triethylamine (775 μL) was added at −78° C. to a mixture ofL-phenylalanine ethyl ester hydrochloride (644 mg), phosphorusoxychloride (130 μL) and methylene chloride (5.6 mL) which was thenstirred at room temperature for 25 minutes. Methanesulfonate (100 mg) of4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-oneand triethylamine (775 μL) were added to the reaction liquid which wasthen stirred at room temperature for 3 hours, and an aqueous saturatedammonium chloride solution was added thereto, followed by extractionwith chloroform and drying over magnesium sulfate. The solvent wasdistilled off under reduced pressure and the resulting residue waspurified by silica gel column chromatography (ethylacetate:methanol=100:0 to 85:15) to give a colorless oil. The resultingcolorless oil was purified by reverse phase preparative HPLC (0.1%aqueous formic acid solution-0.1% formic acid acetonitrile solution) togive a formate (3.2 mg) of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylN,N′-bis((1S)-1-ethoxycarbonyl-2-phenylethan-1-yl)phosphorodiamidate asa colorless oil.

¹H-NMR (CD₃OD) δ: 8.32 (d, 1H, J=7.6 Hz), 8.12 (s, 1H), 7.28-7.04 (m,10H), 6.62-6.49 (m, 1H), 5.92 (d, 1H, J=7.6 Hz), 5.19-4.93 (m, 1H),4.50-4.37 (m, 1H), 4.22-4.07 (m, 4H), 4.01-3.90 (m, 2H), 3.87-3.80 (m,2H), 3.44-3.33 (m, 1H), 3.27-3.13 (m, 4H), 1.39-1.18 (m, 3H), 1.14-1.02(m, 3H).

MS(ESI m/z): 692(M+H)

RT(min): 1.27

Example 15-2

The following compound was obtained in the same manner as in Example15-1.

A formate of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylN,N′-bis((1S)-1-ethoxycarbonyl-3-methylbutan-1-yl)phosphorodiamidate

¹H-NMR (CD₃OD) δ: 8.55-8.42 (m, 1H), 6.61-6.48 (m, 1H), 6.24-6.11 (m,1H), 5.13-4.90 (m, 1H), 4.45-4.31 (m, 1H), 4.17 (q, 2H, J=7.0 Hz), 4.02(q, 2H, J=7.3 Hz), 3.96-3.76 (m, 4H), 3.42-3.32 (m, 1H), 1.92-1.75 (m,1H), 1.75-1.60 (m, 1H), 1.60-1.45 (m, 4H), 1.35-1.09 (m, 6H), 1.01-0.91(m, 6H), 0.91-0.76 (m, 6H).

MS(ESI m/z): 624(M+H)

RT(min): 1.27

Example 16-1

First Step

Under a nitrogen atmosphere, triethylamine (248 μL) was added at −78° C.to a mixture of phosphorus oxychloride (17 μL) and methylene chloride(0.9 mL), and then a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(50.0 mg) and methylene chloride (0.9 mL) was added thereto, followed bystirring for 30 minutes. A mixture of L-alanine benzyl esterhydrochloride (76.8 mg) and methylene chloride (1.7 mL) was added at−78° C. to the reaction liquid which was then stirred for 20 minutes,followed by stirring at room temperature for 30 minutes. Water was addedto the reaction liquid which was then extracted with ethyl acetate, andthe organic layer was washed with an aqueous saturated sodium chloridesolution and dried over anhydrous sodium sulfate. The solvent wasdistilled off under reduced pressure to give((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylN,N′-bis((1S)-1-benzyloxycarbonylethan-1-yl)phosphorodiamidate.

MS(ESI m/z): 964(M+H)

RT(min): 2.05

Second Step

Trifluoroacetic acid (0.5 mL) was added to a mixture of((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylN,N′-bis((1S)-1-benzyloxycarbonylethan-1-yl)phosphorodiamidate andmethylene chloride (0.5 mL) which was then stirred at room temperaturefor 1.5 hours. The solvent was distilled off under reduced pressure. Anaqueous saturated sodium hydrogen carbonate solution was added to theresulting residue which was then extracted with ethyl acetate. Theorganic layer was washed with an aqueous saturated sodium chloridesolution and dried over anhydrous sodium sulfate. The solvent wasdistilled off under reduced pressure and the resulting residue waspurified by basic silica gel column chromatography(chloroform:methanol=94:6 to 86:14) to give((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylN,N′-bis((1S)-1-benzyloxycarbonylethan-1-yl)phosphorodiamidate (6.0 mg)as a white solid.

¹H-NMR (DMSO-d₆) δ: 7.88-7.82 (m, 1H), 7.39-7.18 (m, 12H), 6.53 (dd, 1H,J=17.8, 4.6 Hz), 6.01 (d, 1H, J=4.6 Hz), 5.79 (d, 1H, J=7.3 Hz),5.16-4.81 (m, 7H), 4.36-4.25 (m, 1H), 4.18-4.05 (m, 1H), 3.99-3.76 (m,3H), 3.52-3.24 (m, 1H), 1.33-1.21 (m, 6H).

MS(ESI m/z): 664(M+H)

RT(min): 1.21

Example 16-2

Compounds of Table 15 and Table 16 were obtained in the same manner asin Example 16-1.

TABLE 15

MS (ESI m/z) RT R Compound name (M + H) (min)

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl) methylN,N′-bis((1S)-1-methoxycarbonylethan-1-yl) phosphorodiamidate 812 1.72

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen- 2-yl)methylN,N′-bis((1S)-1-isopropoxycarbonylethan-1-yl) phosphorodiamidate 8681.97

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen- 2-yl)methylN,N′-bis((1S)-1-tert-butoxycarbonylethan-1- yl)phosphorodiamidate 8962.10

((2R,3S,4S,5R)-5-(4-bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen- 2-yl)methylN,N′-dibenzylphosphorodiamidate 820 1.95

TABLE 16

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 16-2-1

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothio- phen-2-yl)methyl N,N′-bis((1S)-1-methoxy-carbonylethan-1-yl) phosphorodiamidate ¹H-NMR (DMSO-d₆) δ: 7.88 (dd, 1H,J = 7.6, 1.7 Hz), 7.37-7.17 (m, 2H), 6.53 (dd, 1H, J = 17.8, 4.6 Hz),5.79 (d, 1H, J = 7.3 Hz), 5.06-4.83 (m, 3H), 4.36-4.25 (m, 1H),4.18-4.05 (m, 1H), 4.01- 3.89 (m, 1H), 3.87-3.70 (m, 2H), 3.65-3.58 (m,6H), 3.50-3.22 (m, 1H), 1.32-1.20 (m, 5H). 512 0.66 16-2-2

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methyl N,N′-bis((1S)-1-iso-propoxycarbonylethan- 1-yl)phosphorodiamidate ¹H-NMR (DMSO-d₆) δ: 7.87(dd, 1H, J = 7.6, 1.7 Hz), 7.37-7.21 (m, 2H), 6.54 (dd, 1H, J = 18.2,5.0 Hz), 6.00 (d, 1H, J = 4.6 Hz), 5.78 (d, 1H, J = 7.9 Hz), 5.06- 4.77(m, 5H), 4.37-4.26 (m, 1H), 4.19-4.04 (m, 1H), 4.02-3.89 (m, 1H),3.82-3.64 (m, 2H), 3.48- 3.35 (m, 1H), 1.26 (d, 6H, J = 7.3 Hz),1.23-1.14 (m, 12H). 568 1.00 16-2-3

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methyl N,N′-bis((1S)-1-tert-butoxycarbonylethan- 1-yl)phosphorodiamidate ¹H-NMR (CD₃OD) δ: 8.09 (dd,1H, J = 7.3, 2.0 Hz), 6.67 (dd, 1H, J = 19.2, 4.6 Hz), 5.93 (d, 1H, J =7.3 Hz), 5.10-4.84 (m, 1H), 4.49-4.39 (m, 1H), 4.28- 4.05 (m, 2H),3.88-3.70 (m, 2H), 3.60-3.49 (m, 1H), 1.48 (s, 18H), 1.40-1.32 (m, 6H).596 1.19 16-2-4

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methyl N,N′-dibenzyl-phosphorodiamidate ¹H-NMR (CD₃OD) δ: 8.01 (dd, 1H, J = 7.6, 1.7 Hz),7.39-7.17 (m, 10H), 6.62 (dd, 1H, J = 18.5, 4.6 Hz), 5.86 (d, 1H, J =7.6 Hz), 5.07-4.85 (m, 1H), 4.41-4.31 (m, 1H), 4.16-3.95 (m, 6H),3.49-3.39 (m, 1H). 520 1.02

Example 17

N,N-dimethylaminopyridine (1.7 mg) was added to a mixture ofmethanesulfonate (50.0 mg) of4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one,diphenyl chlorophosphate (35 μL) and pyridine (1.0 mL). After stirringat room temperature for 1 hour, diphenyl chlorophosphate (35 μL) wasadded to the reaction liquid which was then stirred at room temperaturefor 2 hours. Methanol (35 μL) was added to the reaction liquid which wasthen purified by silica gel column chromatography (ethylacetate:methanol=90:10 to 81:19) to give a white solid. The resultingwhite solid was purified by reverse phase preparative HPLC (0.1% aqueousformic acid solution-0.1% formic acid acetonitrile solution) to give aformate (2.0 mg) of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyldiphenyl phosphate as a white solid.

¹H-NMR (CDCl₃) δ: 8.12 (s, 1H), 7.89-7.71 (m, 1H), 7.39-7.10 (m, 12H),7.06-6.93 (m, 1H), 6.68-6.49 (m, 1H), 5.94-5.77 (m, 1H), 5.19-4.88 (m,1H), 4.50-4.22 (m, 3H), 3.72-3.59 (m, 1H).

MS(ESI m/z): 494(M+H)

RT(min): 1.08

Example 18

A 28% sodium methoxide/methanol solution (15.0 mL) was added to asuspension of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-(((di-tert-butoxyphosphoryl)oxy)methyl)-4-fluorotetrahydrothiophen-3-yl benzoate (50.0 mg) in methanol(1.0 mL) which was then stirred at room temperature for 1.5 hours.Acetic acid (30 μL) was added to the reaction liquid, and the solventwas distilled off under reduced pressure. The resulting residue waspurified by silica gel column chromatography (ethylacetate:methanol=100:0 to 70:30) to give((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyldi-tert-butyl phosphate (28.8 mg) as a white solid.

¹H-NMR (DMSO-d₆) δ: 7.92-7.87 (m, 1H), 7.33-7.21 (m, 2H), 6.53 (dd, 1H,J=17.1, 5.1 Hz), 6.06 (d, 1H, J=4.8 Hz), 5.78 (d, 1H, J=7.2 Hz),5.08-4.86 (m, 1H), 4.36-4.25 (m, 1H), 4.25-4.14 (m, 1H), 4.10-3.98 (m,1H), 3.48-3.38 (m, 1H), 1.43 (s, 18H).

MS(ESI m/z): 454(M+H)

RT(min): 0.93

Example 19-1

A mixture of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyldihydrogen phosphate (100 mg), 2-((ethylcarbamoyl)thio)ethyl4-methylbenzene sulfonate (445 mg), N,N-diisopropylethylamine (250 μL)and N,N-dimethylformamide (1.0 mL) was stirred at 80° C. for 6 hours.The solvent was distilled off under reduced pressure and the resultingresidue was purified by silica gel column chromatography(chloroform:methanol=86:14 to 39:61) to giveS-(2-(((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)oxy)ethyl)ethylcarbamothioate (2.9 mg) as a colorless oil.

¹H-NMR(CD₃OD) δ: 8.30 (d, 1H, J=7.3 Hz), 6.56 (dd, 1H, J=13.2, 5.3 Hz),5.98 (d, 1H, J=7.9 Hz), 5.11-4.87 (m, 1H), 4.49-4.38 (m, 1H), 4.19-4.07(m, 2H), 4.04-3.91 (m, 2H), 3.57-3.41 (m, 1H), 3.27-3.07 (m, 4H), 1.10(t, 3H, J=7.3 Hz).

MS(ESI m/z): 473(M+H)

RT(min): 0.56

Example 19-2

Compounds of Table 17 were obtained in the same manner as in Example19-1.

TABLE 17

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 19-2-1

S-(2-(((((2R,3S,4S,5R)- 5-(4-amino-2-oxo- pyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetra- hydrothiophen-2-yl) methoxy)(hydroxy)phosphoryl)oxy)ethyl) isopropylcarbamothioate ¹H-NMR (CD₃OD) δ: 8.31(dd, 1H, J = 7.9, 1.3 Hz), 6.55 (dd, 1H, J = 12.6, 5.3 Hz), 5.98 (d, 1H,J = 7.9 Hz), 5.10-4.88 (m, 1H), 4.48-4.33 (m, 1H), 4.18- 4.06 (m, 2H),4.03-3.88 (m, 3H), 3.51-3.41 (m, 1H), 3.11 (t, 2H, J = 6.9 Hz), 1.12 (d,6H, J = 6.0 Hz). 487 0.63 19-2-2

S-(2-(((((2R,3S,4S,5R)- 5-(4-amino-2-oxo- pyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetra- hydrothiophen-2-yl) methoxy)(hydroxy)phosphoryl)oxy)ethyl) cyclohexyl- carbamothioate ¹H-NMR (CD₃OD) δ: 8.31(dd, 1H, (J = 7.3, 1.3 Hz), 6.55 (dd, 1H, J = 13.2, 5.3 Hz), 5.98 (d,1H, J = 7.3 Hz), 5.11-4.90 (m, 1H), 4.49-4.37 (m, 1H), 4.17- 4.05 (m,2H), 4.03-3.91 (m, 2H), 3.78-3.51 (m, 1H), 3.50- 3.40 (m, 1H), 3.11 (t,2H, J = 6.9 Hz), 1.94-1.52 (m, 4H), 1.44-1.06 (m, 6H). 527 0.83

Example 20-1

First Step

A mixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrothiophen-3-ylbenzoate (100 mg), 2-cyanoethyl octadecyl diisopropylphosphoramidite(314 mg), 1H-tetrazole (100 mg) and methylene chloride (4.0 mL) wasstirred at room temperature for 5 hours. After standing for 14.5 hours,meta-chloroperbenzoic acid (60.0 mg) was added thereto at −78° C.,followed by elevation of the temperature to −10° C. over 1.5 hours andstirring for 1 hour. Water was added to the reaction liquid which wasthen extracted with methylene chloride, and the organic layer was washedwith an aqueous saturated sodium hydrogen carbonate solution, a 10%aqueous sodium bisulfite solution and water and then dried overanhydrous sodium sulfate. The solvent was distilled off under reducedpressure and the resulting residue was purified by silica gel columnchromatography (hexane:ethyl acetate=57:43 to 0:100) to give(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((((RS)-(2-cyanoethoxy)(octadecyloxy)phosphoryl)oxy)methyl)-4-fluorotetrahydrothiophen-3-ylbenzoate (41.0 mg) as a colorless oil.

MS(ESI m/z): 855(M+H)

RT(min): 2.64

Second Step

A mixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((((RS)-(2-cyanoethoxy)(octadecyloxy)phosphoryl)oxy)methyl)-4-fluorotetrahydrothiophen-3-yl benzoate(41.0 mg) and a 7.0 mol/L ammonia/methanol solution (4.0 mL) was stirredat room temperature for 10 hours. After standing for 12 hours, thesolvent was distilled off under reduced pressure. Acetone was added tothe resulting residue, and the precipitated solid was collected byfiltration to give an ammonium salt (13.8 mg) of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyloctadecyl hydrogen phosphate as a white solid.

¹H-NMR (DMSO-d₆) δ: 7.99 (d, 1H, J=7.3 Hz), 7.43-6.89 (m, 4H), 6.44 (dd,1H, J=12.9, 5.6 Hz), 5.79 (d, 1H, J=7.3 Hz), 5.06-4.78 (m, 1H),4.32-4.20 (m, 1H), 4.01-3.78 (m, 2H), 3.71-3.57 (m, 2H), 3.50-3.17 (m,1H), 1.56-1.37 (m, 2H), 1.37-1.12 (m, 30H), 0.92-0.78 (m, 3H).

MS(ESI m/z): 594(M+H)

RT(min): 2.12

Example 20-2

Compounds of Table 18 and Table 19 were obtained in the same manner asin Example 20-1.

TABLE 18

MS (ESI m/z) RT R Compound name (M + H) (min)

(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((((RS)-(2-cyanoethoxy)(((RS)-2-ethylhexyl)oxy)phosphoryl)oxy)methyl)-4- fluorotetrahydrothiophen-3-ylbenzoate 715 1.83

(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((((RS)-(2-cyanoethoxy)(((RS)-2-cyanoethoxy)(dodecyloxy)phosphoryl)oxy)methyl)-4-fluorotetrahydrothiophen-3-yl benzoate 771 2.20

TABLE 19

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 20-2-1

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methyl ((RS)-2-ethylhexyl) hydrogenphosphate ¹H-NMR (DMSO-d₆) δ: 7.98- 7.73 (m, 1H), 7.98 (d, 1H, J = 7.3Hz), 7.61-6.88 (m, 3H), 6.46 (dd, 1H, J = 13.9, 5.3 Hz), 5.79 (d, 1H, J= 7.3 Hz), 5.09-4.80 (m, 1H), 4.35-4.19 (m, 1H), 4.11- 3.82 (m, 2H),3.71-3.59 (m, 2H), 3.59-3.11 (m, 1H), 1.54-1.12 (m, 9H), 0.95-0.77 (m,6H). 454 0.98 20-2-2

((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin- (2H)-yl)-4-fluoro-3-hydroxytetrahydro- thiophen-2-yl)methyl dodecyl hydrogen phosphate¹H-NMR (DMSO-d₆) δ: 7.98 (d, 1H, J = 7.6 Hz), 7.52-6.90 (m, 4H), 6.48(dd, 1H, J = 14.5, 4.5 Hz), 5.80 (d, 1H, J = 7.6 Hz), 5.10-4.79 (m, 1H),4.36-4.22 (m, 1H), 4.13-3.89 (m, 2H), 3.62- 2.71 (m, 2H), 3.08-3.20 (m,1H), 1.60-1.47 (m, 2H), 1.35-1.17 (m, 18H), 0.90-0.81 (m, 3H). 510 1.42

Example 21-1

A mixture of N,N′-dicyclohexylcarbodiimide (90.0 mg) and tert-butylalcohol (1.0 mL) was added to a mixture of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyldihydrogen phosphate (100 mg), L-alanine benzyl ester hydrochloride (126mg), triethylamine (82 μL), tert-butyl alcohol (4.0 mL) and water (1.0mL) which was then stirred for 4 hours under heating to reflux. Thesolvent was distilled off under reduced pressure and the resultingresidue was purified by silica gel column chromatography (ethylacetate:methanol=50:50 to 25:75) to give (2S)-benzyl2-(((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoate(62.3 mg) as a white solid.

¹H-NMR (CD₃OD) δ: 8.30 (d, 1H, J=7.3 Hz), 7.46-7.22 (m, 5H), 6.60-6.43(m, 1H), 5.97 (d, 1H, J=7.3 Hz), 5.34-4.99 (m, 3H), 4.51-4.31 (m, 1H),4.18-3.87 (m, 3H), 3.66-3.50 (m, 1H), 1.46 (d, 3H, J=6.6 Hz).

MS(ESI m/z): 503(M+H)

RT(min): 0.79

Example 21-2

Compounds of Table 20 were obtained in the same manner as in Example21-1.

TABLE 20

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 21-2-1

(2S)-tert-butyl 2-(((((2R,3S,4S)5R)-5- (4-amino-2-oxopyrimidin-1(2H)-yl)- 4-fluoro-3-hydroxytetra- hydrothiophen-2-yl)methoxy)(hydroxy) phosphoryl)amino) propanoate ¹H-NMR (CD₃OD) δ: 8.29(dd, 1H, J = 7.3, 1.3 Hz), 6.55 (dd, 1H, J = 13.2, 5.3 Hz), 6.98 (d, 1H,J = 7.3 Hz), 5.08-4.83 (m, 1H), 4.47-4.38 (m, 1H), 4.07-3.97 (m, 2H),3.84-3.72 (m, 1H), 3.48-3.37 (m, 1H), 1.49-1.43 (m, 12H). 469 0.7421-2-2

(2S)-methyl 2- (((((2R,3S,4S,5R)-5-(4- amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3- hydroxytetrahydro- thiophen-2-yl)methoxy)(hydroxy) phosphoryl)amino) propanoate ¹H-NMR (CD₃OD) δ:8.34-8.29 (m, 1H), 6.59-6.53 (m, 1H), 6.03 (d, 1H, J = 7.3 Hz),5.11-4.82 (m, 1H), 4.56-4.46 (m, 1H), 4.05-3.98 (m, 2H), 3.94-3.86 (m,1H), 3.69 (s, 3H), 3.50-3.38 (m, 1H), 1.48 (d, 3H, J = 7.3 Hz). 427 0.51

Example 22

A mixture of (2S)-methyl2-(((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoate(10.0 mg), water (100 μL) and triethylamine (100 μL) was stirred at roomtemperature for 11.5 hours. The solvent was distilled off under reducedpressure. Acetone was added to the resulting residue, and theprecipitated solid was collected by filtration to give a triethylaminesalt (4.3 mg) of(2S)-2-(((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoic acid as awhite solid.

MS(ESI m/z): 413(M+H)

RT(min): 0.39

Example 23-1

First step Diphenyl chlorophosphate (142 μL) was added to a mixture of((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylhydrogen phosphonate (214 mg), 2-aminopyridine (64.0 mg), pyridine (340μL) and methylene chloride (3.4 mL) which was then stirred at roomtemperature for 10 minutes. A mixture of iodine (96.0 mg), pyridine (3.4mL) and water (308 μL) was added thereto, followed by stirring at roomtemperature for 30 minutes. An aqueous sodium bisulfite solution wasadded thereto, and then the solvent was distilled off under reducedpressure. The resulting residue was purified by silica gel columnchromatography (0.5% triethylaminechloroform solution:methanol=100:0 to50:50) to give a colorless oil. The resulting colorless oil was purifiedby silica gel column chromatography (0.5%triethylamine/chloroform:methanol=100:0 to 70:30) to give atriethylamine salt (213 mg) of((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylhydrogen (pyridin-2-yl)phosphoramidate as a colorless oil.

MS(ESI m/z): 718(M+H)

RT(min): 1.40

Second Step

Trifluoroacetic acid (2.0 mL) was added to a mixture of((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-2-yl)methylhydrogen (pyridin-2-yl)phosphoramidate (213 mg) and methylene chloride(2.0 mL) which was then stirred at room temperature for 30 minutes. Thesolvent was distilled off under reduced pressure and the resultingresidue was purified by silica gel column chromatography (0.5%triethylamine/chloroform:methanol=100:0 to 0:100) to give atriethylamine salt (29.5 mg) of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylhydrogen pyridin-2-ylphosphoramidate as a white solid.

¹H-NMR (DMSO-d₆) δ: 8.05-7.96 (m, 1H), 7.92-7.84 (m, 1H), 7.54-7.44 (m,1H), 7.39-7.14 (m, 3H), 6.96-6.79 (m, 1H), 6.72-6.61 (m, 1H), 6.49-6.36(m, 1H), 6.33-6.15 (m, 1H), 5.79-5.70 (m, 1H), 5.01-4.73 (m, 1H),4.31-4.16 (m, 1H), 4.04-3.75 (m, 2H), 3.38-3.25 (m, 1H), 3.07-2.93 (m,6H), 1.22-1.12 (m, 9H).

MS(ESI m/z): 418(M+H)

RT(min): 0.31

Example 23-2

First Step

The following compound was obtained in the same manner as in the firststep of Example 23-1.

((2R,3S,4S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4-fluorotetrahydrothiophen-3-yl)methylhydrogen (pyridin-2-yl)phosphoramidate

MS(ESI m/z): 718(M+H)

RT(min): 1.29

Second Step

The following compound was obtained in the same manner as in the secondstep of Example 23-1.

((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylhydrogen (pyridin-3-yl)phosphoramidate

¹H-NMR (DMSO-d₆) δ: 8.29-8.22 (m, 1H), 7.90-7.84 (m, 1H), 7.82-7.78 (m,1H), 7.47-7.40 (m, 1H), 7.34-7.14 (m, 2H), 7.05-6.99 (m, 1H), 6.79-6.71(m, 1H), 6.48-6.35 (m, 1H), 6.34-6.23 (m, 1H), 5.80-5.71 (m, 1H),5.05-4.75 (m, 1H), 4.29-4.15 (m, 1H), 3.96-3.73 (m, 2H), 3.31-3.24 (m,1H), 3.12-2.91 (m, 6H), 1.24-1.09 (m, 9H).

MS(ESI m/z): 418(M+H)

RT(min): 0.26

Example 24-1

First Step

1H-tetrazole (28.0 mg) was added to a mixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((((2-cyanoethoxy)(diisopropylamino)phosphino)oxy)methyl)-4-fluorotetrahydrothiophen-3-ylbenzoate (203 mg),(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-hydroxyethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (79.0 mg) and acetonitrile (4.0 mL) which was then stirred atroom temperature for 35 minutes. 1H-tetrazole (28.0 mg) was added to thereaction liquid which was then stirred at room temperature for 5minutes. A mixture of iodine (103 mg), pyridine (2.0 mL) and water (200μL) was added to the reaction liquid which was then stirred at roomtemperature for 10 minutes. An aqueous sodium bisulfite solution wasadded to the reaction liquid, and the solvent was distilled off underreduced pressure. The resulting residue was purified by silica gelcolumn chromatography (ethyl acetate:methanol=100:0 to 90:10) to give(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-(((((2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-3-(benzoyloxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(2-cyanoethoxy)phosphoryl)oxy)ethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (49.0 mg) as a colorless oil.

MS(ESI m/z): 977(M+H)

RT(min): 1.45

Second Step

A mixture of(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-(((((2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-3-(benzoyloxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(2-cyanoethoxy)phosphoryl)oxy)ethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (49.0 mg) and a 7.0 mol/L ammonia/methanol solution (3.0 mL)was stirred at room temperature for 8 hours and 40 minutes. The solventwas distilled off under reduced pressure. Water was added to theresulting residue, and the water layer was washed three times with ethylacetate. The solvent was distilled off under reduced pressure to give anammonium salt of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyl(2-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethylhydrogen phosphate as a white solid (27.3 mg).

¹H-NMR (D₂O) δ: 8.29 (d, 1H, J=7.9 Hz), 6.34-6.28 (m, 1H), 6.01 (d, 1H,J=7.9 Hz), 5.18-4.93 (m, 1H), 4.41-4.30 (m, 2H), 4.09-3.95 (m, 5H),3.81-3.76 (m, 2H), 3.62-3.54 (m, 1H), 3.44-3.16 (m, 5H).

MS(ESI m/z): 548(M+H)

RT(min): 0.26

Example 24-2

First Step

1H-tetrazole (9.5 mg) was added to a mixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((((2-cyanoethoxy)(diisopropylamino)phosphino)oxy)methyl)-4-fluorotetrahydrothiophen-3-ylbenzoate (68.0 mg),(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-((2-hydroxyethyl)disulfanyl)ethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (33.0 mg) and acetonitrile (1.4 mL) which was then stirred atroom temperature for 15 minutes. A mixture of iodine (35.0 mg), pyridine(680 μL) and water (68 μL) was added to the reaction liquid which wasthen stirred at room temperature for 10 minutes. The solvent wasdistilled off under reduced pressure and the resulting residue waspurified by silica gel column chromatography (ethylacetate:methanol=100:0 to 90:10) to give(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-((2-(((((2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-3-(benzoyloxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(2-cyanoethoxy)phosphoryl)oxy)ethyl)disulfanyl)ethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (36.0 mg) as a colorless oil.

MS(ESI m/z): 1069(M+H)

RT(min): 1.56

Second Step

A mixture of(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-((2-(((((2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-3-(benzoyloxy)-4-fluorotetrahydrothiophen-2-yl)methoxy)(2-cyanoethoxy)phosphoryl)oxy)ethyl)disulfanyl)ethoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (36.0 mg) and a 7.0 mol/L ammonia/methanol solution (3.0 mL)was stirred at room temperature for 8 hours and 40 minutes. The solventwas distilled off under reduced pressure. Water was added to theresulting residue, and the water layer was washed three times with ethylacetate. The solvent was distilled off under reduced pressure and theresulting residue was purified by reverse phase preparative HPLC (0.1%aqueous formic acid solution-0.1% formic acid acetonitrile solution) togive a formate (7.6 mg) of((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methyl(2-((2-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethyl)disulfanyl)ethyl) hydrogen phosphate as a white solid.

¹H-NMR (D₂O) δ: 8.52 (d, 1H, J=7.9 Hz), 6.31-6.25 (m, 1H), 6.16 (d, 1H,J=7.9 Hz), 5.23-4.99 (m, 1H), 4.41-4.29 (m, 2H), 4.13-4.00 (m, 5H),3.91-3.76 (m, 2H), 3.65-3.56 (m, 1H), 3.47-3.12 (m, 5H), 2.95-2.84 (m,4H).

MS(ESI m/z): 640(M+H)

RT(min): 0.51

Example 25

First Step

A mixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-fluoro-2-((phosphonooxy)methyl)tetrahydrothiophen-3-yl benzoate (43.3 mg), 1-chloroethyldiethylcarbamate (280 mg), N,N-diisopropylethylamine (0.60 mL) andN,N-dimethylformamide (0.9 mL) was stirred at 50° C. for 3 hours. Waterwas added at room temperature to the reaction liquid which was thenextracted with ethyl acetate. The organic layer was washed with waterand an aqueous saturated sodium chloride solution, and dried overanhydrous sodium sulfate. The solvent was distilled off under reducedpressure to give(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-(((1-((diethylcarbamoyl)oxy)ethoxy)(hydroxy)phosphoryl)oxy)methyl)-4-fluorotetrahydrothiophen-3-ylbenzoate.

MS(ESI m/z): 693(M+H)

RT(min): 1.24

Second Step

A mixture of(2R,3S,4S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((1-((diethylcarbamoyl)oxy)ethoxy)(hydroxy)phosphoryl)oxy)methyl)-4-fluorotetrahydrothiophen-3-ylbenzoate obtained in the first step and a 7.0 mol/L ammonia/methanolsolution (1.5 mL) was stirred at room temperature for 16.5 hours. Thesolvent was distilled off under reduced pressure and the resultingresidue was purified by silica gel column chromatography (ethylacetate:methanol=100:0 to 20:80) to give1-(((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(hydroxy)phosphoryl)oxy)ethyldiethylcarbamate (21.7 mg) as a yellow solid.

¹H-NMR (CD₃OD) δ: 8.40-8.19 (m, 1H), 6.63-6.46 (m, 1H), 6.46-6.32 (m,1H), 6.14-5.99 (m, 1H), 5.13-4.88 (m, 1H), 4.48-4.34 (m, 1H), 4.22-4.05(m, 2H), 3.56-3.43 (m, 1H), 3.43-3.23 (m, 4H), 1.53 (d, 3H, J=5.3 Hz),1.36-1.27 (m, 6H)

MS(ESI m/z): 485(M+H)

RT(min): 0.72

Example 26-1

First Step

Under a nitrogen atmosphere, a 2.0 mol/L tert-butyl magnesiumchloride/tetrahydrofuran solution (450 μL) was added dropwise at −78° C.to a mixture of tert-butyltert-butoxycarbonyl(1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate(168 mg) and tetrahydrofuran (17 mL) which was then stirred for 15minutes. A mixture of 2-(4-nitrophenoxy)-1,3,2-dioxaphosphinane 2-oxide(389 mg) and tetrahydrofuran (3.0 mL) was added at −78° C. to thereaction liquid which was then stirred at room temperature for 1.5hours. An aqueous saturated ammonium chloride solution was added to thereaction liquid which was then extracted with ethyl acetate, washed withan aqueous saturated sodium chloride solution and dried over anhydrousmagnesium sulfate. The solvent was distilled off under reduced pressureand the resulting residue was purified by silica gel columnchromatography (hexane:ethyl acetate=20:80 to 80:20) to give4-(bis(tert-butoxycarbonyl)amino)-1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(((2-oxido-1,3,2-dioxaphosphinan-2-yl)oxy)methyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one(204 mg) as a brown oil.

MS(ESI m/z): 682(M+H)

RT(min): 1.70

Second Step

A mixture of4-(bis(tert-butoxycarbonyl)amino)-1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-(((2-oxido-1,3,2-dioxaphosphinan-2-yl)oxy)methyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one(204 mg) and trifluoroacetic acid (1.0 mL) was stirred at roomtemperature for 1.5 hours. The solvent was distilled off under reducedpressure and the resulting residue was purified by silica gel columnchromatography (ethyl acetate:methanol=100:0 to 80:20) to give4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(((2-oxido-1,3,2-dioxaphosphinan-2-yl)oxy)methyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one (47.0 mg) as a whitesolid.

¹H-NMR (DMSO-d₆) δ: 7.90-7.88 (m, 1H), 7.34 (s, 1H), 7.28 (s, 1H),6.59-6.53 (m, 1H), 6.12 (d, 1H, J=4.6 Hz), 5.81-5.78 (m, 1H), 5.10-4.85(m, 1H), 4.45-4.31 (m, 6H), 4.22-4.11 (m, 1H), 3.56-3.47 (m, 1H),2.14-1.79 (m, 2H).

MS(ESI m/z): 382(M+H)

RT(min): 0.49

Example 26-2

Compounds of Table 21 and Table 22 were obtained in the same manner asin Example 26-1.

TABLE 21

MS (ESI m/z) RT R Compound name (M + H) (min)

4-(bis(tert-butoxycarbony])amino)-1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-((((1RS,4R)-2-oxido-4-phenyl-1,3,2-dioxaphosphinan-2-yl)oxy)methyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one 758 1.83

4-(bis(tert-butoxycarbonyl)amino)-1-((2R,3S,4S,5R)-5-((((1RS,4RS)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphinan-2-yl)oxy)methyl)-4-((tert-butoxy-carbonyl)oxy)-3-fluorotetrahydrothiophen-2-yl) pyrimidin-2(1H)-one 7921.92

4-(bis(tert-butoxycarbonyl)amino)-1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-((((RS)-2-oxido-4H-benzo[d][1,3,2]dioxaphosphinin-2-yl)oxy)methyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one 730 1.87

4-(bis(tert-butoxycarbonyl)amino)-1-((2R,3S,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3-fluoro-5-((((RS)-8-methoxy-2-oxido-4H-benzo[d][1,3,2]dioxaphosphinin-2-yl)oxy)methyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one 760 1.85

TABLE 22

MS Example (ESI m/z) RT No. R Compound name ¹H-NMR (M + H) (min) 26-2-1

4-amino-1-((2R,3S,4S,5R)- 3-fluoro-4-hydroxy-5-((((2RS,4R)-2-oxido-4-phenyl-1,3,2- dioxaphosphinan-2-yl)oxy)methyl)tetrahydrothiophen- 2-yl)pyrimidin-2(1H)-one ¹H-NMR (DMSO-d₆) δ:8.11 (d, 1H, J = 8.1 Hz), 7.45-7.38 (m, 6H), 7.33- 7.23 (m, 2H),6.47-6.33 (m, 1H), 6.06- 6.01 (m, 1H), 5.91 (d, 1H, J = 8.1 Hz),5.11-4.91 (m, 1H), 4.31-4.26 (m, 1H), 4.18-4.16 (m, 1H), 4.05-3.85 (m,3H), 3.17-3.09 (m, 1H), 2.42-2.36 (m, 1H), 2.28-2.15 (m, 1H), 1.91-1.85(m, 1H). 458 0.99 26-2-2

4-amino-1-((2R,3S,4S,5R)-5- ((((2RS,4RS)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphinan-2- yl)oxy)methyl)-3-fluoro-4-hydroxy-tetrahydrothiophen-2-yl)pyrimidin- 2(1H)-one ¹H-NMR (DMSO-d₆) δ:7.92-7.84 (m, 1H), 7.53-7.38 (m, 4H), 7.31 (m, 1H), 7.25 (s, 1H), 6.56(dd, 1H, J = 18.0, 4.8 Hz), 6.12 (d, 1H, J = 4.6 Hz), 5.76- 5.73 (m,2H), 5.07-4.87 (m, 1H), 4.63- 4.17 (m, 6H), 3.51-3.48 (m, 1H), 2.31-2.12 (m, 2H). 492 0.93 26-2-3

4-amino-1-((2R,3S,4S,5R)-3- fluoro-4-hydroxy-5-((((RS)-2-oxido-4H-benzo[d][1,3,2]dioxaphosphinin-2-yl)oxy)methyl)tetrahydrothiophen-2-yl) pyrimidin-2(1H)-one ¹H-NMR(DMSO-d₆) δ: 7.83-7.70 (m, 1H), 7.43-7.13 (m, 6H), 6.54-6.51 (m, 1H),6.11 (d, 1H, J = 4.0 Hz), 5.73 (t, 1H, J = 7.9 Hz), 5.57-5.50 (m, 2H),5.00-4.90 (m, 1H), 4.50-4.28 (m, 3H), 3.52-3.48 (m, 1H). 430 0.78 26-2-4

4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-((((RS)-8-methoxy-2-oxido-4H-benzo[d][1,3,2]dioxaphosphinin-2-yl)oxy)methyl)tetrahydrothiophen-2-yl) pyrimidin-2(1H)-one ¹H-NMR(DMSO-d₆) δ: 7.96-7.91 (m, 2H), 7.66 (s, 1H), 7.19-7.07 (m, 2H), 6.83(d, 1H, J = 5.6 Hz), 6.51-6.45 (m, 1H), 6.14-6.13 (m, 1H), 5.93 (t, 1H,J = 6.8 Hz), 6.53-6.46 (m, 2H), 5.12- 4.88 (m, 1H), 4.54-4.41 (m, 1H),4.34- 4.19 (m, 2H), 3.84 (s, 3H), 3.64-3.46 (m, 1H). 460 0.78

Example 27

First Step

A mixture ofN-(1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide(920 mg), 2-cyanoethyl N,N,N′,N′-tetraisopropylphosphorodiamidite (800mg), 1H-tetrazole (530 mg) and methylene chloride (10.0 mL) was stirredat room temperature for 1 hour and 20 minutes. A mixture ofmeta-chloroperbenzoic acid (618 mg) and methylene chloride (10.0 mL) wasadded at −40° C. to the reaction liquid which was then stirred for 2hours. An aqueous saturated sodium hydrogen carbonate solution and a 10%aqueous sodium bisulfite solution were added to the reaction liquidwhich was then extracted with methylene chloride. The organic layer waswashed with water and an aqueous saturated sodium chloride solution, andthen dried over anhydrous sodium sulfate. The solvent was distilled offunder reduced pressure. A mixture of hexane and ethyl acetate (=1/1) wasadded to the resulting residue, and the precipitated solid was collectedby filtration to giveN-(1-((2RS,4aR,6R,7S,7aS)-2-(2-cyanoethoxy)-7-fluoro-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-6-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide(580 mg) as a white solid.

MS(ESI m/z): 481(M+H)

RT(min): 1.02, 1.05

Second Step

A mixture ofN-(1-((2RS,4aR,6R,7S,7aS)-2-(2-cyanoethoxy)-7-fluoro-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-6-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide(580 mg) and a 7.0 mol/L ammonia/methanol solution (10.0 mL) was stirredat room temperature for 1 hour. The solvent was distilled off underreduced pressure. Ethyl acetate was added to the resulting residue, andthe precipitated solid was collected by filtration to giveN-(1-((4aR,6R,7S,7aS)-7-fluoro-2-hydroxy-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-6-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide(467 mg) as a pale yellow solid.

MS(ESI m/z): 428(M+H)

RT(min): 0.74

Third Step

A mixture ofN-(1-((4aR,6R,7S,7aS)-7-fluoro-2-hydroxy-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-6-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide(350 mg) and 7.0 mol/L ammonia/methanol solution (4.0 mL) was stirred at40° C. for 4 hours. The solvent was distilled off under reducedpressure. Ethyl acetate was added to the resulting residue, and theprecipitated solid was collected by filtration to give4-amino-1-((4aR,6R,7S,7aS)-7-fluoro-2-hydroxy-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-6-yl)pyrimidin-2(1H)-one(265 mg) as a pale yellow solid.

¹H-NMR (CD₃OD) δ: 8.05 (d, 1H, J=7.9 Hz), 6.72-6.60 (m, 1H), 5.98 (d,1H, J=7.9 Hz), 5.33-5.04 (m, 1H), 4.83-4.65 (m, 1H), 4.41-4.21 (m, 2H),3.57-3.39 (m, 1H).

MS(ESI m/z): 324(M+H)

RT(min): 0.21, 0.26

Example 28

Oxalyl chloride (20 μL) was added under ice-cooling to a mixture of4-amino-1-((4aR,6R,7S,7aS)-7-fluoro-2-hydroxy-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-6-yl)pyrimidin-2(1H)-one(20.0 mg), trimethyl phosphate (1.0 mL), N,N-dimethylformamide (10 μL)and methylene chloride (1.0 mL) which was then stirred for 40 minutes.Isopropyl alcohol (2.0 mL) was added to the reaction liquid which wasthen stirred at room temperature for 3 hours and 40 minutes and allowedto stand for 12 hours. The solvent was distilled off under reducedpressure. Methylene chloride was added to the resulting residue, and theinsoluble matter was separated by filtration. The solvent was distilledoff under reduced pressure. Water was added to the resulting residuewhich was then extracted with methylene chloride and dried overanhydrous sodium sulfate. The solvent was distilled off under reducedpressure. Diisopropyl ether was added to the resulting residue, and theprecipitated solid was collected by filtration to give4-amino-1-((2RS,4aR,6R,7S,7aS)-7-fluoro-2-isopropoxy-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-6-yl)pyrimidin-2(1H)-one(3.4 mg) as a pale yellow solid.

¹H-NMR (CD₃OD) δ: 8.08-8.02 (m, 1H), 6.75-6.68 (m, 1H), 5.97 (d, 1H,J=7.3 Hz), 5.47-5.19 (m, 1H), 5.14-4.99 (m, 1H), 4.82-4.70 (m, 1H),4.70-4.56 (m, 2H), 3.84-3.71 (m, 1H), 1.37 (d, 6H, J=5.9 Hz).

MS(ESI m/z): 366(M+H)

RT(min): 0.71

Example 29-1

Oxalyl chloride (40 μL) was added under ice-cooling to a mixture of4-amino-1-((4aR,6R,7S,7aS)-7-fluoro-2-hydroxy-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-6-yl)pyrimidin-2(1H)-one(20.0 mg), trimethyl phosphate (1.0 mL), N,N-dimethylformamide (10 μL)and methylene chloride (1.0 mL) which was then stirred at roomtemperature for 1 hour and 20 minutes. The reaction liquid was addedunder ice-cooling to a mixture of L-alanine benzyl ester hydrochloride(20.0 mg), N,N-diisopropylethylamine (200 μL) and methylene chloride(2.0 mL), followed by stirring at room temperature for 2 hours and 40minutes. Water was added to the reaction liquid which was then extractedwith methylene chloride and dried over anhydrous sodium sulfate. Thesolvent was distilled off under reduced pressure. Diisopropyl ether wasadded to the resulting residue, and the precipitated solid was collectedby filtration to give (2S)-benzyl2-(((2RS,4aR,6R,7S,7aS)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-7-fluoro-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-2-yl)amino)propanoate(6.7 mg) as a pale brown solid.

¹H-NMR (CD₃OD) δ: 8.07-8.01 (m, 1H), 7.41-7.30 (m, 5H), 6.73-6.66 (m,1H), 5.97 (d, 1H, J=7.3 Hz), 5.40-5.11 (m, 3H), 5.02-4.91 (m, 1H),4.63-4.47 (m, 2H), 4.04-3.89 (m, 1H), 3.65-3.50 (m, 1H), 1.39 (d, 3H,J=5.9 Hz).

MS(ESI m/z): 485(M+H)

RT(min): 1.00

Example 29-2

The following compound was obtained in the same manner as in Example29-1.

(2S)-isopropyl2-(((2RS,4aR,6R,7S,7aS)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-7-fluoro-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-2-yl)amino)propanoate

¹H-NMR(CD₃OD) δ: 8.05 (d, 1H, J=7.6 Hz), 6.74-6.67 (m, 1H), 5.97 (d, 1H,J=7.6 Hz), 5.42-5.15 (m, 1H), 5.06-4.91 (m, 2H), 4.65-4.52 (m, 2H),3.95-3.81 (m, 1H), 3.70-3.56 (m, 1H), 1.41-1.32 (m, 3H), 1.32-1.20 (m,6H).

MS(ESI m/z): 437(M+H)

RT(min): 0.81

Comparative Example 1

The following compound was obtained in accordance with the methoddescribed in Journal of Medicinal Chemistry, Vol. 52, pp 1531 to 1542,2014.

(2S)-benzyl2-(((RS)-(((2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate

¹H-NMR (CD₃OD) δ: 7.57-7.45 (m, 1H), 7.39-7.26 (m, 6H), 7.26-7.14 (m,3H), 6.28-6.17 (m, 1H), 5.89-5.78 (m, 1H), 5.19-5.07 (m, 2H), 4.50-4.38(m, 1H), 4.38-4.26 (m, 1H), 4.26-4.10 (m, 1H), 4.10-3.94 (m, 2H),1.39-1.32 (m, 3H).

MS(ESI m/z): 581(M+H)

RT(min): 1.14

Comparative Example 2

The following compound was obtained in accordance with the methoddescribed in Nucleosides, Nucleotides & Nucleic Acids, Vol. 24, Nos. 10to 12, pp 1635 to 1649, 2005.

((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methylbis(S-pivaloyl-2-mercaptoethan-1-yl) phosphate

¹H-NMR(CD₃OD) δ: 7.81 (d, 1H, J=7.3 Hz), 6.26-6.20 (m, 1H), 5.88 (d, 1H,J=7.3 Hz), 4.46-4.23 (m, 2H), 4.21-4.07 (m, 6H), 4.04-3.99 (m, 1H),3.22-3.09 (m, 4H), 1.26-1.18 (m, 18H).

MS(ESI m/z): 612(M+H)

RT(min): 1.31

Comparative Example 3

The following compound was obtained in accordance with the methoddescribed in Bioorganic & Medicinal Chemistry, Vol. 17, No. 17, pp 6340to 6347, 2009.

S-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate

¹H-NMR (CD₃OD) δ: 7.82-7.68 (m, 1H), 7.45-7.32 (m, 2H), 7.28-7.18 (m,3H), 6.27-6.19 (m, 1H), 5.84-5.73 (m, 1H), 4.58-4.30 (m, 2H), 4.29-4.08(m, 4H), 4.06-3.99 (m, 1H), 3.23-3.12 (m, 2H), 1.23-1.18 (m, 9H).

MS(ESI m/z): 544(M+H)

RT(min): 1.16

Comparative Example 4

First Step

The following compound was obtained in the same manner as in ReferenceExample 1.

tert-Butyltert-butoxycarbonyl(1-((2R,4S,5R)-4-((tert-butoxycarbonyl)oxy)-3,3-difluoro-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate

MS(ESI m/z): 564(M+H)

RT(min): 1.72

Second Step

The following compound was obtained in the same manner as in the secondstep of Example 11.

((2R,3S,5R)-5-(4-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)-3-((tert-butoxycarbonyl)oxy)-4,4-difluorotetrahydrofuran-2-yl)methyldihydrogen phosphate

MS(ESI m/z): 644(M+H)

RT(min): 1.35

Third Step

The following compound was obtained in the same manner as in the firststep of Example 11.

((2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methyl bis(pivaloyloxymethyl) phosphate

¹H-NMR (CD₃OD) δ: 7.61 (d, 1H, J=7.9 Hz), 6.31-6.21 (m, 1H), 5.95 (d,1H, J=7.9 Hz), 5.73-5.63 (m, 4H), 4.53-4.32 (m, 1H), 4.30-4.14 (m, 1H),4.13-4.03 (m, 1H), 1.26-1.18 (m, 18H).

MS(ESI m/z): 572(M+H)

RT(min): 1.20

Test Example

Gemcitabine-Resistant Cell Growth Inhibition Test

The gemcitabine-resistant strain of pancreatic cancer cell line Capan-1(ATCC Number: HTB-79) was constructed in accordance with the methoddescribed in Neoplasia, Vol. 12, pp 807-817, 2010 and subjected to acell growth inhibition test of the present invention compounds and theComparative Example compounds. The cell growth inhibition test wascarried out in accordance with the method described below.

For the purpose of measuring compound-induced growth inhibition, thetotal cell count was quantified based on the total cellular ATPconcentration using a CellTiter Glo (Promega Corporation) reagent usinga firefly luciferase. The Capan-1 was suspended in an IMDM medium (LifeTechnologies, Inc.) containing penicillin/streptomycin (penn/strep) and20% FBS and adjusted to a cell density of 33333 cells/mL. 90 μL (3000cells)/well of the cell suspension was seeded onto a 96-well plate(Corning, Inc.).

The cells were subjected to whole culture under standard cell growthconditions (37° C., 5% CO₂) for 24 hours. 10 μL of a serial dilution ofcompounds or 0.1% DMSO (solvent control) was added to the cells whichwere then cultured to proliferate under standard cell growth conditions(37° C., 5% CO₂) for 72 hours. For the purpose of measuring the totalcell growth, in accordance with the instructions of the CellTiter Glo,an equal volume of the CellTiter Glo reaction liquid was added to eachwell and then luminescence counts (relative light unit, RLU) werequantified. An IC₅₀ value for growth inhibition corresponds to acompound liquid concentration causing 50% inhibition of total cellgrowth in a DMSO solvent control when an RLU signal exhibited by theDMSO solvent control after 72 hours of culture is defined as 0%inhibition. Each data point was obtained from duplicate samples.

The IC₅₀ was calculated by the following method.

The results of the test substance-treated group was plotted by taking alogarithm of a cell treatment concentration (nmol/L) on the X-axis andtaking a cell growth inhibition rate (%) on the Y-axis. A straight lineconnecting the nearest two points with the cell growth inhibition rateY=50(%) being therebetween was obtained, and a 50% cell growthinhibitory concentration (IC₅₀ value) as defined by the above straightline was calculated.

Also with respect to the results of a control substance group, the IC₅₀value was determined by the same method.

IC₅₀ values were calculated for the triplicate test results, and anaverage value and a standard deviation thereof were determined. Theresults are shown in the following table.

Evaluation standards

-   -   +++2 μmol/L>IC₅₀    -   ++5 μmol/L>IC₅₀≧2 μmol/L    -   +15 μmol/L>IC₅₀≧5 μmol/L    -   −IC₅₀≧15 μmol/L

TABLE 23 Growth Growth Growth inhibitory inhibitory inhibitory activityactivity activity Example IC₅₀ Example IC₅₀ Comparative IC₅₀ No.(μmol/L) No. (μmol/L) Example No. (μmol/L) 1-1 +++ 7-1 + 1 − 1-2-5 +++7-3-1 + 2 − 2-2 + 7-3-2 + 3 − 3-1 + 7-3-3 + 4 − 3-2 + 8 +++ 4-1 ++ 9-1++ 4-2 + 9-2-1 ++ 5-2-1 + 10-1 ++ 5-2-2 + 10-2 ++ 5-2-3 + 11-1-2 + 5-2-4++ 11-2-2 ++ 5-2-5 ++ 12-1 + 5-2-6 + 12-2-4 +++ 5-2-7 + 13-1 ++ 5-2-8 +13-2-1 ++ 5-2-9 + 13-2-2 + 6-1 + 14-1 ++ 6-2-1 + 14-2 + 6-2-2 + 26-2-3++ 6-2-3 + 26-2-4 + 6-2-4 + 29-1 ++ 29-2 ++

The compounds of the present invention had an excellent cell growthinhibitory activity against gemcitabine-resistant strains of tumorcells.

INDUSTRIAL APPLICABILITY

The thionucleoside derivative or the salt thereof of the presentinvention has an excellent growth inhibitory activity against tumorcells and is useful as a tumor treatment agent. Further, thethionucleoside derivative or the salt thereof of the present inventionhas an excellent growth inhibitory activity against a tumor cell whichhas acquired resistance to gemcitabine and is useful as a tumortreatment agent against a tumor which has acquired resistance togemcitabine.

What is claimed is:
 1. A thionucleoside derivative represented byGeneral Formula [1]:

in the formula, R¹ represents a hydroxyl group which may be protected, aC₁₋₂₀ alkoxy group which may be substituted, a C₃₋₈ cycloalkoxy groupwhich may be substituted, an aryloxy group which may be substituted, aheterocyclic oxy group which may be substituted, or an amino group whichmay be substituted; R² represents a C₁₋₂₀ alkoxy group which may besubstituted, a C₃₄ cycloalkoxy group which may be substituted, anaryloxy group which may be substituted, a heterocyclic oxy group whichmay be substituted, or an amino group which may be substituted; or R¹and R², together with the phosphorus atom to which they are bonded, mayform a 5- to 10-membered nitrogen.phosphorus-containing heterocyclicring which may be substituted, a 5- to 10-memberedoxygen.phosphorus-containing heterocyclic ring which may be substituted,or a 5- to 10-membered nitrogen.oxygen.phosphorus-containingheterocyclic ring; and R³ represents a hydrogen atom; or R² and R³,together with the phosphorus atom to which R² is bonded, an oxygen atom,methylene, two carbon atoms constituting the tetrahydrothiophene ringand the oxygen atom to which R³ is bonded, may form a 6 to 10-memberedoxygen.phosphorus-containing heterocyclic ring which may be substituted;or a salt thereof.
 2. The thionucleoside derivative according to claim1, wherein R¹ is a hydroxyl group which may be protected, a C₁₋₆ alkoxygroup which may be substituted with one or more substituents selectedfrom Substituent group A, an aryloxy group which may be substituted withone or more substituents selected from Substituent group A, aheterocyclic oxy group which may be substituted with one or moresubstituents selected from Substituent group A, or an amino group whichmay be substituted with one or more substituents selected fromSubstituent group A; or the salt thereof. Substituent group A: A halogenatom; a hydroxyl group which may be protected; a cyano group; a nitrogroup; a carbamoyl group; an oxo group; a C₁₋₆ alkyl group which may besubstituted with one or more substituents selected from Substituentgroup B; a C₁₋₆ alkyldisulfanyl group which may be substituted with oneor more substituents selected from Substituent group B; a C₂₋₆ alkenylgroup which may be substituted with one or more substituents selectedfrom Substituent group B; a C₂₋₆ alkynyl group which may be substitutedwith one or more substituents selected from Substituent group B; a C₃₋₈cycloalkyl group which may be substituted with one or more substituentsselected from Substituent group B; a C₃₋₈ cycloalkyldisulfanyl groupwhich may be substituted with one or more substituents selected fromSubstituent group B; a C₁₋₆ alkoxy group which may be substituted withone or more substituents selected from Substituent group B; a C₁₋₆alkoxycarbonyloxy group which may be substituted with one or moresubstituents selected from Substituent group B; a C₃₋₈cycloalkoxycarbonyl group which may be substituted with one or moresubstituents selected from Substituent group B; an aryl group which maybe substituted with one or more substituents selected from Substituentgroup B; an aryldisulfanyl group which may be substituted with one ormore substituents selected from Substituent group B; a heterocyclicgroup which may be substituted with one or more substituents selectedfrom Substituent group B; a heterocyclic oxy group which may besubstituted with one or more substituents selected from Substituentgroup B; an acyloxy group which may be substituted with one or moresubstituents selected from Substituent group B; an acylthio group whichmay be substituted with one or more substituents selected fromSubstituent group B; an aminocarbonyloxy group which may be substitutedwith one or more substituents selected from Substituent group B; and anaminocarbonylthio group which may be substituted with one or moresubstituents selected from Substituent group B. Substituent group B: Ahalogen atom; a hydroxyl group; a cyano group; a nitro group; a carboxylgroup; a carbamoyl group; a hydroxymethyl group; a C₁₋₆ alkyl group; aC₂₋₆ alkenyl group; a C₂₋₆ alkynyl group; a C₃₋₈ cycloalkyl group; aC₁₋₆ alkoxy group; a C₁₋₆ alkoxycarbonyl group; a C₃₋₈cycloalkoxycarbonyl group; an ar-C₁₋₆ alkoxycarbonyl group; an arylgroup; an aryloxy group; a heterocyclic oxy group which may besubstituted with one or more substituents selected from a hydroxyl groupand a hydroxymethyl group; an ar-C₁₋₆ alkoxy group; and an acyloxygroup.
 3. The thionucleoside derivative according to claim 1, wherein R²is a C₁₋₆ alkoxy group which may be substituted with one or moresubstituents selected from Substituent group A, an aryloxy group whichmay be substituted with one or more substituents selected fromSubstituent group A, or an amino group which may be substituted with oneor more substituents selected from Substituent group A; or the saltthereof.
 4. The thionucleoside derivative according to claim 2, whereinR² is a C₁₋₆ alkoxy group which may be substituted with one or moresubstituents selected from Substituent group A, an aryloxy group whichmay be substituted with one or more substituents selected fromSubstituent group A, or an amino group which may be substituted with oneor more substituents selected from Substituent group A; or the saltthereof.
 5. The thionucleoside derivative according to claim 1, whereinR¹ is a hydroxyl group which may be protected, a C₁₋₆ alkoxy group whichmay be substituted with one or more substituents selected fromSubstituent group A, an aryloxy group which may be substituted with oneor more substituents selected from Substituent group A, a heterocyclicoxy group which may be substituted with one or more substituentsselected from Substituent group A, or an amino group which may besubstituted with one or more substituents selected from Substituentgroup A; and R² is a C₁₋₆ alkoxy group which may be substituted with oneor more substituents selected from Substituent group A, an aryloxy groupwhich may be substituted with one or more substituents selected fromSubstituent group A, or an amino group which may be substituted with oneor more substituents selected from Substituent group A; or the saltthereof.
 6. The thionucleoside derivative according to claim 3, whereinR¹ is a hydroxyl group which may be protected, a C₁₋₆ alkoxy group whichmay be substituted with one or more substituents selected fromSubstituent group A, an aryloxy group which may be substituted with oneor more substituents selected from Substituent group A, a heterocyclicoxy group which may be substituted with one or more substituentsselected from Substituent group A, or an amino group which may besubstituted with one or more substituents selected from Substituentgroup A; and R² is a C₁₋₆ alkoxy group which may be substituted with oneor more substituents selected from Substituent group A, an aryloxy groupwhich may be substituted with one or more substituents selected fromSubstituent group A, or an amino group which may be substituted with oneor more substituents selected from Substituent group A; or the saltthereof.
 7. The thionucleoside derivative according to claim 1, whereinR¹ is an aryloxy group which may be substituted with one or moresubstituents selected from Substituent group A, and R² is an amino groupwhich may be substituted with one or more substituents selected fromSubstituent group A, or R¹ is a C₁₋₆ alkoxy group which may besubstituted with one or more substituents selected from Substituentgroup A, and R² is a C₁₋₆ alkoxy group which may be substituted with oneor more substituents selected from Substituent group A; or the saltthereof.
 8. The thionucleoside derivative according to claim 3, whereinR¹ is an aryloxy group which may be substituted with one or moresubstituents selected from Substituent group A, and R² is an amino groupwhich may be substituted with one or more substituents selected fromSubstituent group A, or R¹ is a C₁₋₆ alkoxy group which may besubstituted with one or more substituents selected from Substituentgroup A, and R² is a C₁₋₆ alkoxy group which may be substituted with oneor more substituents selected from Substituent group A; or the saltthereof.
 9. The thionucleoside derivative according to claim 1, whereinthe thionucleoside derivative is a compound selected from: (2S)-benzyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate,(2S)-methyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(4-chlorophenoxy)phosphoryl)amino)propanoate,(2S)-cyclobutyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate,(2S)-methyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(4-bromophenoxy)phosphoryl)amino)propanoate,(2S)-methyl2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(4-iodophenoxy)phosphoryl)amino)propanoate,((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(S-pivaloyl-2-mercaptoethan-1-yl) phosphate,((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(S-isobutyryl-2-mercaptoethan-1-yl) phosphate,((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(S-propionyl-2-mercaptoethan-1-yl) phosphate,(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(2-(pivaloylthio)ethoxy)phosphoryl)oxy)methylpivalate,S-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(((isopropoxycarbonyl)oxy)methoxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate,((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(pivaloyloxymethyl) phosphate,((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(2-((2-(benzyloxy)ethyl)disulfanyl)ethyl) phosphate,((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(2-((2-pivaloyloxyethyl)disulfanyl)ethyl) phosphate,((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methylbis(2-((2-isobutyroyloxyethyl)disulfanyl)ethyl) phosphate,S-(2-(((RS)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(phenoxy)phosphoryl)oxy)ethyl)2,2-dimethylpropanethioate,4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-((((RS)-2-oxido-4H-benzo[d][1,3,2]dioxaphosphinin-2-yl)oxy)methyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one,(2S)-benzyl2-(((2RS,4aR,6R,7S,7aS)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-7-fluoro-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-2-yl)amino)propanoate,and (2S)-isopropyl2-(((2RS,4aR,6R,7S,7aS)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-7-fluoro-2-oxidotetrahydro-4H-thieno[3,2-d][1,3,2]dioxaphosphinin-2-yl)amino)propanoate;or the salt thereof.
 10. A pharmaceutical composition comprising thethionucleoside derivative or the salt thereof according to claim
 1. 11.A pharmaceutical composition comprising the thionucleoside derivative orthe salt thereof according to claim
 9. 12. The pharmaceuticalcomposition according to claim 10, for use in the treatment of a tumor.13. The pharmaceutical composition according to claim 11, for use in thetreatment of a tumor.
 14. The pharmaceutical composition according toclaim 10, for use in the treatment of lung cancer, esophageal cancer,stomach cancer, colon cancer, rectal cancer, pancreatic cancer, breastcancer, renal cancer, bladder cancer, uterine cancer, osteosarcoma,melanoma, leukemia, multiple myeloma, or malignant lymphoma.
 15. Thepharmaceutical composition according to claim 11, for use in thetreatment of lung cancer, esophageal cancer, stomach cancer, coloncancer, rectal cancer, pancreatic cancer, breast cancer, renal cancer,bladder cancer, uterine cancer, osteosarcoma, melanoma, leukemia,multiple myeloma, or malignant lymphoma.
 16. The pharmaceuticalcomposition according to claim 10 which comprises a pharmacologicallyacceptable additive in conjunction with the thionucleoside derivativerepresented by the General Formula [1] or a salt thereof.
 17. Thepharmaceutical composition according to claim 11 which comprises apharmacologically acceptable additive in conjunction with thethionucleoside derivative represented by the General Formula [1] or asalt thereof.
 18. A method for the treatment of a tumor, comprising astep of administering a therapeutically effective amount of thethionucleoside derivative or a salt thereof according to claim 1 to asubject in need of such a treatment.